INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS

Abstract: This invention relates to new indole derivatives of formula (I), wherein R<1> is hydrogen, halogen, nitro, carboxy, protected carboxy, acyl, etc., R<2> is hydrogen, halogen, lower alkenyl, acyl, etc., R<3> is lower alkenyl or lower alkyl, both of which are optionally substituted with aryl optionally substituted with one or more substituent(s) selected from the group consisting of halogen, aryl, lower alkoxy, etc., and R<4> is carboxy, protected carboxy, acyl, etc., in addition to their significances above, R<1> and R<2>, together with the carbon atoms to which they are attached, represent a 4- to 7-membered carboxylic ring optionally substituted with oxo, or its pharmaceutically acceptable salt, which is useful as a medicament; and to new use of cyclic nucleotide-PDE inhibitors.

Description: DESCRIPTION INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS This invention relates to novel compounds having pharmacological activity, to a process for their production and to a pharmaceutical composition containing the same. More particularly, it relates to novel indole compounds, which have pharmaceutical activity such as inhibiting activity of cyclic guanosine 3' , 5'-monophosphate phosphodiesterase (hereinafter described as cGMP-PDE) , to a process for their production, to a pharmaceutical composition containing the same and to a use thereof. Accordingly, one object of this invention is to provide the novel indole compounds, which have an inhibiting activity of cGMP-PDE. Another object of this invention is to provide a process for production of the indole compounds. A further object of this invention is to provide a pharmaceutical composition containing, as active ingredients, the indole compounds. Still further object of this invention is to provide a use of the indole compounds for treating or preventing various diseases. Further, this invention also relates to a new use of inhibitors of cyclic nucleotide phosphodiesterases. (hereinafter described as cyclic nucleotide-PDEs) In more detail, this invention relates to a new use of cyclic nucleotide-PDEs inhibitors for preventing or treating glo erular diseases, tubulo-interstitial diseases or renal failure, or diabetic complications. Accordingly, this invention provides a new use of cyclic nucleotide-PDE inhibitors for preventing or treating glomerular diseases, tubulo-interstitial diseases or renal failure, or diabetic complications. Further, this invention provides an agent and a pharmaceutical composition for preventing or treating glomerular diseases, tubulo-interstitial diseases or renal failure, or diabetic complications, which comprises cyclic nucleotide-PDE inhibitors. Still further, this invention provides a method for preventing or treating glomerular diseases, tubulo- interstitial diseases or renal failure, or diabetic complications, which comprises administering cyclic nucleotide-PDE inhibitors. The new indole compounds of this invention can be represented by the following general formula : wherein R 1 is hydrogen, halogen, nitro, carboxy, protected carboxy, acyl, cyano, hydroxyimino (lower)alkyl, lower alkenyl optionally substituted with oxo, or lower alkyl optionally substituted with protected carboxy, carboxy or hydroxy; R^ is hydrogen, halogen, lower alkenyl, acyl, or lower alkyl optionally substituted with protected carboxy, carboxy, lower alkoxy or hydroxy; R^ is lower alkenyl or lower alkyl, both of which are optionally substituted with one or more substituent(s) selected from the group consisting of (1) oxo. (2) aryl optionally substituted with one or more substituent (s) selected from the group consisting of halogen, aryl, lower alkoxy, lower alkylenedioxy, cyano, nitro, carboxy, protected carboxy, acyl, and amino optionally substituted with acyl or protected carboxy, and (3) a heterocyclic group optionally substituted with halogen; and R^ is carboxy, protected carboxy, acyl, cyano, halogen, a heterocyclic group, amino optionally substituted with acyl or protected carboxy, or lower alkyl optionally substituted with protected carboxy, carboxy or acyl; in addition to their significances above, R 1 and R , together with the carbon atoms to which they are attached, represent a 4 - to 7-membered carbocyclic ring optionally substituted with oxo, or its pharmaceutically acceptable salt. The compounds of formula (I) may contain one or more asymmetric centers and thus they can exist as enantiomers or diastereoisomers . Furthermore certain compounds of formula (I) which contain alkenyl groups may exist as cis- or trans- isomers. In each instance, the invention includes both mixtures and separate individual isomers. The compounds of formula (I) may also exist in tautomeric forms and the invention includes both mixtures and separate individual tautomers. The compound of the formula (I) and its salt can be in the form of a solvate, which is included within the scope of the present invention. The solvate preferably include a hydrate and an ethanolate. Also included in the scope of invention are radiolabelled derivatives of compounds of formula (I) which are suitable fcr biological studies. A preferred group of compounds of formula (I) is that wherein R 1 is cyano, acyl, or lower alkyl optionally substituted with hydroxy; R 2 is hydrogen, acyl, lower alkenyl, or lower alkyl optionally substituted with lower alkoxy or hydroxy; R 3 is methyl substituted with aryl or a heterocyclic group, wherein aryl is optionally substituted with one or more substituent(s) selected from the group consisting of halogen, lower alkylenedioxy, protected carboxy and carboxy; and R 4 is acyl, cyano, or a heterocyclic group; in addition to their significances above, R 1 and R , together with the carbon atoms to which they are attached, represent a 4- to 7-membered carbocyclic ring optionally substituted with oxo. A more preferred group of compounds of formula (I) is that wherein R 1 is lower alkyl, or lower alkanoyl optionally substituted with hydroxy, lower alkoxy or aryl; R 2 is hydrogen, lower alkenyl, or lower alkyl optionally substituted with lower alkoxy; R 3 is benzyl optionally substituted with one or more substituent (s) selected from the group consisting of halogen and lower alkylenedioxy; and R^ is acyl, cyano, or a heterocyclic group. A particularly preferred group of compounds of formula (I) is that wherein R^ is lower alkyl, or lower alkanoyl optionally substituted with hydroxy, lower alkoxy or aryl; R 2 is hydrogen, lower alkenyl, or lower alkyl optionally substituted with lower alkoxy; R 3 is benzyl optionally substituted with one or more substituent (s) selected from the group consisting of halogen and lower alkylenedioxy; R^ is hydrogen or lower alkyl, and R 6 is hydrogen, hydroxy, lower alkoxy, arylsulfonyl, a heterocyclic group, or lower alkyl optionally substituted with lower cycloalkyl or a heterocyclic group; in addition to their significances above, R 5 and R , together with the nitrogen atom to which they are attached, may represent a heterocyclic group. An especially preferred group of compounds of formula (I) is that wherein R 1 is lower alkanoyl optionally substituted with alkoxy, R 2 is lower alkyl, R 3 is benzyl optionally substituted with one or more substituent (s) selected from the group consisting of halogen and lower alkylenedioxy, and R 4 is carbamoyl. According to this invention, the object compounds (I) or its salt can be prepared by the following processes. Process 1 (ID (I) or its salt or its salt Process 2 Process 3 or its reactive or its salt derivative at the carboxy group, or its salt Process 4 Process 5 or its reactive or its salt derivative at the carboxy group, or its salt Process ■? Reduction (1-7) (1-8) or its salt or its salt Proress 7 (1-9) (1-10) or its salt or its salt Process 8 Dehydration (1-11) (1-12) or its salt or its salt Process 9 (1-12) (1-13) or its salt or its salt Process 10 Deesterif ication (1-14) (1-15) or its salt or its salt Process 11 (1-15) (1-16) or its reactive or its salt derivative at the carboxy group, or its salt Process 12 (1-17) (1-18) or its salt or its salt Process 13 Formylation (1-9) (1-19) or its salt or its salt Process 14 (1-19) (1-20) or its salt or its salt Process 15 (1-21) (1-22) or its salt or its salt Proπess 16 Process 17 Process 18 Process 19 (1-29) {I _ 30) or its salt or its salt Process 20 (1-9) (I _ 31) or its salt or its salt Process 21 (1-9) or its salt Process 22 Reduction (1-7) (1-33) or its salt or its salt Process 23 (1-34) (1-35) or its salt or its salt Process 24 wherein R! to R are each as defined above, R^ is lower alkanoyl optionally substituted with protected carboxy or carboxy, R^ is lower alkyl optionally substituted with protected carboxy or carboxy, R* is lower alkenoyl, aroyl, or lower alkanoyl optionally substituted with protected carboxy, carboxy or aryl, R^ is chloroacetyl, R^ is lower alkanoyl substituted with lower alkoxy, R g is lower alkanoyl substituted with hydroxy, R^ is halogen, R! is lower alkyl optionally substituted with protected carboxy or carboxy, RΪ is lower alkanoyl, RJ is hydroxyimino(lower)alkyl, R| is lower alkyl substituted with protected carboxy, R^ is lower alkyl substituted with carboxy, R^ is 1-hydroxy(lower)alkyl, R^ is lower alkanoyl, R 3 is lower alkenyl or lower alkyl, both of which are optionally substituted with oxo and both of which are substituted with aryl which is substituted with protected carboxy, R^ is lower alkenyl or lower alkyl, both of which are optionally substituted with oxo and both of which are substituted with aryl which is substituted with carboxy, R 3 is lower alkenyl or lower alkyl, both of which are optionally substituted with oxo and both of which are substituted with aryl which is substituted with R 5 "C0 < R 6 ' R^ is lower alkenyl or lower alkyl, both of which are optionally substituted with oxo and both of which are substituted with aryl which is substituted with nitro, R 3 is lower alkenyl or lower alkyl, both of which are optionally substituted with oxo and both of which are substituted with aryl which is substituted with amino, R j is lower alkenyl or lower alkyl, both of which are optionally substituted with oxo and both of which are substituted with aryl which is substituted with amino, R 3 is lower alkenyl or lower alkyl, both of which are optionally substituted with oxo and both of which are substituted with aryl which is substituted with amino substituted with acyl, R^ is protected carboxy or lower alkyl substituted with protected carboxy, Rj!* is carboxy or lower alkyl substituted with carboxy, Rc is --,-, M / R or lower alkyl substituted with -.^ M / R " C ° C ^ R6 * - C0N \R6 ' R' is hydrogen, protected carboxy, or -CON: R 8 is acyl, R^ is lower alkyl, X 1 is leaving group, X 2 and X are each as the same as X , and n is 1, 2, 3 or 4. In the above and subsequent description of the present specification, suitable examples of the various definitions to be included within the scope of the invention are explained in detail in the following. The term "lower" is intended to mean a group having 1 to 6 carbon atom(s), unless otherwise provided. Suitable "lower alkyl" and lower alkyl moiety in the terms "lower alkoxy" and "hydroxyi ino (lower) alkyl", may be a straight or branched C-^-Cg alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl or the like, in which preferable one is C^-C^ lower alkyl such as methyl, ethyl, propyl, butyl, isobutyl or tert-butyl. Suitable "lower alkenyl" may be a straight or branched c 2~ c 6 al k en yl such as ethenyl, propenyl (i.e. allyl or 1-propenyl) , butenyl, isobutenyl, or the like. Suitable "lower cycloalkyl" may include one having 3 to 6 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, or the like. Suitable "aryl" and aryl moiety in the term of "arylsulfonyl", "aroyl" and "ar (lower)alkanoyl" may include phenyl, naphthyl, tolyl, mesityl, xyly ' l, or the like. Suitable "halogen" may be fluoro, chloro, bromo or iodo. Suitable "lower alkylenedioxy" may include methylenedioxy, ethylenedioxy, or the like. Suitable "protected carboxy" may be a pharmaceutically acceptable and a common protected carboxy, such as an esterified carboxy, _or the like, and concrete examples of the ester moiety in said esterified carboxy may be lower alkyl optionally substituted with aryl (e.g. methyl, ethyl, propyl, tert-butyl, benzyl, and so on) . Suitable "heterocyclic group" may be one containing at least one hetero atom selected from nitrogen, sulfur and oxygen atom, and may include saturated br unsaturated, monocyclic or polycyclic heterocyclic group such as (1) unsaturated 3 to 7-membered, preferably 5 or 6-membered heteromonocyclic group containing 1 to 4 nitrogen atoms, for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl [e.g. 4H-1,2, -triazolyl, 1H-1, 2, 3-triazolyl, 2H-1,2, 3-triazolyl, etc.], tetrazolyl [e.g. lH-tetrazolyl, 2H-tetrazolyl, etc.], etc. ; (2) saturated 3 to 7-membered, preferably 5 or 6-membered heteromonocyclic group containing 1 to 4 nitrogen atoms [e.g. pyrrolidinyl, imidazolidinyl, piperidino, piperazinyl, etc.]; (3) unsaturated condensed heterocyclic group containing 1 to 5 nitrogen atoms, for example, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl [e.g. tetrazolo [1, 5-b]pyridazinyl, etc.], etc.; (4) unsaturated 3 to 7-membered, preferably 5 or 6-membered heteromonocyclic group containing an oxygen atom, for example, pyranyl, furyl, etc.; (5) unsaturated, 3 to 7-membered, preferably 5 or 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms, for example, thienyl, etc.; (6) unsaturated 3 to 7-membered, preferably 5 or 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, oxazolyl, isoxazolyl, oxadiazolyl [e.g. 1,2, 4-oxadiazolyl, 1, 3, 4-oxadiazolyl, 1, 2, 5-oxadiazolyl, etc.], etc.; (7) saturated 3 to 7-membered, preferably 5 or 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g. morpholinyl, etc.];- (8) unsaturated condensed heterocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g. benzoxazolyl, benzoxadiazolyl, etc.]; (9) unsaturated 3 to 7-membered, preferably 5 or 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example, thiazolyl, thiadiazolyl [e.g., 1, 2, 4-thiadiazolyl, 1, 3, 4-thiadiazolyl, 1, 2, 5-thiadiazolyl, etc.], etc. (10) saturated 3 to 7-membered, preferably 5 or 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e.g., thiazolidinyl, etc.]; ( 11) unsaturated condensed heterocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e.g., benzothiazolyl, benzothiadiazolyl, etc.]; (12) unsaturated condensed heterocyclic group containing 1 to 2 sulfur atoms or 1 to 2 oxygen atoms [e.g., benzothiophen, benzofuran, etc.]; or the like. "Heterocyclic group" defined above may be substituted with suitable substituent (s) such as lower alkyl, hydroxy, halogen, a heterocyclic group, or the like (e.g., 3- hydroxypyrrolidine, 4-methylpiperadine, 4-hydroxypiperidine, 1-methylimidazole, 4- (pyrimidin-2-yl)piperazin, and so on) . Suitable "acyl" may be aliphatic acyl, aromatic acyl or aliphatic acyl optionally substituted aryl, which are derived from carboxylic acid or carbamic acid. The aliphatic acyl may include (1) lower alkanoyl optionally substituted with one or more suitable substituent (s) such as hydroxy, lower alkoxy, carboxy, protected carboxy, halogen, lower alkylthio, heterocyclicthio, oxo, cyclo (lower) alkyl or a heterocyclic group (e.g. formyl, acetyl, propionyl, butyryl, isobutyryl, pentanoyl, hexanoyl, 3, 3-dimethylbutanoyl, 3-hydroxy-3- methylbutanoyl, 3-oxo-butanoyl, 3-methoxycarbonylpropanoyl, 3-carboxypropanoyl, 4-methoxycarbonylbutanoyl, 4-carboxybutanoyl, methylthioacetyl, (l-methylimidazol-2- yl) thioacetyl, hydroxyacetyl, methoxyacetyl, ethoxyacetyl, 3-methoxybutanoyl, chloroacetyl, morpholinoacetyl, piperidinylacetyl, 4-methylpiperidin-l-ylacetyl, 4-hydroxypiperidinyl, pyrolidinylacetyl, 4- (pyrimidin-2- yDpiperidinylacetyl, 3-hydroxypyrrolidinylacetyl, oxolan-4-ylacetyl, and so on) ; (2) cyclo (lower) alkanecarbonyl (e.g. cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, and so on) ; (3) lower alkenoyl (e.g. acryloyl, ethacryloyl, crotonoyl, 3-methylbutanoyl, and so on) ; (4) - is hydrogen, hydroxy, lower alkoxy, arylsulfonyl, a heterocyclic group, lower alkyl optionally substituted with lower cycloalkyl or a heterocyclic group, or the like, in addition to their significances above, R 5 and R 6 , together with the nitrogen atom to which they are attached, may represent a heterocyclic group) , such as carbamoyl, N- methylcarbamoyl, N,N-dimethylcarbamoyl, N-ethylcarbamoyl, N,N-diethylcarbamoyl, N-propylcarbamoyl, N-phenylsulfonylcarbamoyl, N-methoxycarbamoyl, N- (tetrazol-5- yl) carbamoyl, 1-pyrolidinylcarbonyl, piperidinocarbonyl, 4-methyl-1-piperazinylcarbonyl, 4-cyclohexyl-l- piperazinylcarbonyl, morpholinocarbonyl, 4-thiomorpholinylcarbonyl, or the like. The aromatic acyl may include aroyl optionally substituted with one or more suitable substituent (s) such as nitro (e.g. benzoyl, naphthoyl, nitrobenzoyl, and so on), or the like. The aliphatic acyl substituted with aryl, may include ar(lower)alkanoyl which may have one or more suitable substituent(s) such as lower alkoxy (e.g. phenylacetyl, 4-methoxyphenylacetyl, and so on) or the like. Suitable "arylsulfonyl" may include phenylsulfonyl, tosyl, methoxyphenylsulfonyl, or the like. Suitable "leaving group" may include hydroxy, halogen, acyloxy, in which the halogen and the acyl moiety may be those as exemplified above, or the like. The starting compound (II) is prepared in similar manners to those of the below-mentioned Preparations. Suitable salts of the compounds (I), (I-l) to (1-36) and (II) to (VII) may include pharmaceutically acceptable salts such as basic salts, for example, alkali metal salt (e.g. sodium salt, potassium salt, etc.), alkaline earth metal salt (e.g. calcium salt, magnesium salt, etc.), ammonium salt, amine salt (e.g. triethylamine salt, N-benzyl-N-methylamine salt, etc.) and other conventional organic salts, or acid addition salts, for example, hydrochloride, hydrobromide, sulfate or bisulfate, phosphate or hydrogen phosphate, acetate, benzoate, succinate, fumarate, maleate, lactate, citrate, tartrate, gluconate, methanesulfonate, benzenesulfonate, p-toluenesulfonate, or the like. The processes for preparing the object compound (I) are explained in detail in the following. Process 1 The compound (I) or its salt can be prepared by reacting the compound (II) or its salt with the compound (III) or its salt. This reaction is usually carried out in the presence % of an inorganic or an organic base. Suitable inorganic base may include an alkali metal [e.g., sodium, potassium, etc.], an alkali metal hydroxide [e.g., sodium hydroxide, potassium hydroxide, etc.], alkali metal hydrogen carbonate [e.g., sodium hydrogen carbonate, potassium hydrogen carbonate, etc.], alkali metal carbonate [e.g., sodium carbonate, etc.], alkali earth metal carbonate [calcium carbonate, etc.], or the like. Suitable organic base may include tri (lower)alkylamine [e.g. triethylamine, N,N-diisopropylethylamine, etc.], alkyl lithium [e.g. methyl lithium, butyl lithium, etc.], lithium diisopropylamide, lithium hexamethyldisirazido, alkali metal hydride [e.g., sodium hydride, potassium hydride, etc.] or the like. The reaction is usually carried out in a conventional solvent such as water, alcohol [e.g., methanol, ethanol, isopropyl alcohol, etc.], tetrahydrofuran, dioxane, toluene, methylene chloride, chloroform, N,N-dimethylformamide or any other organic solvents which do not adversely affect the reaction, or the mixture thereof. The reaction temperature is not critical and the reaction is usually carried out under cooling to warming. Process 2 The object compound (1-2) or its salt can be prepared by subjecting a compound (I-l) to deesterification. The reaction is carried out in accordance with a conventional method such as hydrolysis, reduction or the like. The hydrolysis is preferably carried out in the presence of a base, an acid, or the combination of Lewis acids and Lewis bases. Suitable base may include an inorganic base and an organic base. Suitable inorganic base may be the same as those exemplified in Process 1. Suitable organic base may include tri (lower) alkylamine [e.g. trimethylamine, triethylamine, etc.], picoline, 1, 5-diazabicyclo[4.3.0]non-5-ene, 1, 4-diazabicyclo[2.2.2]octane, 1, 8-diazabicyclo[5.4.0]undec-7-ene, or the like. Suitable acid may include an organic acid [e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.], an inorganic acid [e.g. hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, etc.]. The hydrolysis is also carried out in the presence of the combination of Lewis acids and Lewis bases. Suitable Lewis acid may include metal halide [e.g., aluminum chloride, aluminum bromide, titaniu (IV) chloride, tin(IV) chloride, etc.], metal alkoxide [e.g., titanium(IV) isopropoxide, etc.] or the like. Suitable Lewis base may include lower alkyl thiol [e.g., ethanethiol, ethanedithiol, etc.], di (lower)alkyl sulfide [dimethylsulfide, etc.], or the like. The reaction is usually carried out in a solvent such as water, an alcohol [e.g. methanol, ethanol, etc.], xylene, diethylene glycol monomethyl ether, methylene chloride, tetrahydrofuran, a mixture thereof or any other solvent which does not adversely influence the reaction. A liquid baεe or acid can be also used as the solvent. The reaction temperature is not critical and the reaction is usually carried out under cooling to warming. The reduction can be applied preferably for elimination of the ester moiety such as 4-nitrobenzyl, 2-iodoethyl, 2,2,2-trichloroethyl, or the like. The reduction method applicable for the elimination reaction may include chemical reduction and catalytic reduction. Suitable reducing agents to be used in chemical reduction are a combination of metal [e.g. tin, zinc, iron, etc.] or metallic compound [e.g. chromium chloride, chromium acetate, etc.] and an organic or inorganic acid exemplified above. Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalyst [e.g. platinum on carbon, platinum oxide, etc.], palladium catalyst [e.g. palladium black, palladium oxide, palladium on carbon, etc.] or any other catalyst ordinary employed in the field of organic synthetic chemistry. The catalytic reduction may be carried out in the presence of hydrogen or hydrogen doner such as formic acid, ammonium formate, cyclohexene, or the like. The reduction is usually carried out in a conventional solvent which does not adversely influence the reaction such as water, an alcohol [e.g. methanol, ethanol, propanol, etc.], N,N-dimethylformamide, or a mixture thereof. Additionally, in case that the above-mentioned acids to be used in chemical reduction are in liquid, they can also be used as a solvent. Further, a suitable solvent to be used in catalytic reduction may be the above-mentioned solvent, and other conventional solvent such as diethyl ether, dioxane, tetrahydrofuran, etc., or a mixture thereof. The reaction temperature of this reduction is not critical and the reaction is usually carried out under cooling to warming. Process 3 The compound (1-3) or its salt can be prepared by reacting the compound (1-2) or its reactive derivative at the carboxy group, . or its salt, with the compound (IV) or its reactive derivative at the amino group, or its salt, according to any well known procedure. Suitable reactive derivative at the amino group of the compound (IV) may include Schiff's base type i ino or its tautomeric enamine type isomer formed by the reaction of the compound (IV) with a carbonyl compound such as aldehyde, ketone or the like; -a silyl derivative formed by the reaction of the compound (IV) with a silylating reagent such as trimethylsilyl chloride, N,O-bis (trimethylsilyl)acetamide, N-trimethylsilylacetamide, or the like. Suitable reactive derivative of the compound (1-2) may include an acid chloride, acid azide, an acid anhydride, an activated amide, an activated ester, or the like. The suitable acid anhydride may include a mixed acid anhydride with an acid such as substituted phosphoric acid (e.g., dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc.), dialkylphosphorous acid, sulfuric acid, thiosulfuric acid, alkanesulfonic acid (e.g., methanesulfonic acid, ethanesulfonic acid, etc.), sulfuric acid, alkanoic acid (e.g., pivalic acid, pentanoic acid, isopentanoic acid, etc.), aromatic carboxylic acid (e.g., benzoic acid, chlorobenzoic acid, fluorobenzoic acid, nitrobenzoic acid, etc.),or the like. Suitable activated amide may be imidazoylamide, 4-substituted imidazoylamide, dimethylpyrazolylamide, triazolylamide tetrazolylamide, or the like. Suitable activated ester may be dimethyliminomethy1 + [ (CH 3 ) 2 N=CH-] ester, vinyl ester, propargyl ester, 4-nitrophenyl ester, 2, 4-dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, pentafluorophenyl ester, methanesulfoήylphenyl ester, phenyl thioester, p-nitrophenyl thioester, carboxymethyl thioester, pyranyl ester, pyridyl ester, 8-quinolyl thioester, an ester with a N-hydroxy compound (e.g., N,N-dimethylhydroxylamine, l-hydroxy-2H- pyridone, N-hydroxysucciήimido, N-hyd oxybenzotriazole, N-hydroxyphthalimide, etc.), or the like. These reactive derivatives can optionally be selected from them according to the kind of compound (1-2) to be used. When the compound (1-2) is used in free acid form or its salt form in the reaction, the reaction is preferably carried out in the presence .of condensing agent. Suitable condensing agent may include a carbodiimide (e.g., N, -dicyclohexylcarbodiimide, N-cyclohexyl-N'- (4- diethylaminocyclohexyl)carbodiimide, N-ethyl-N'- (3- dimethylaminopropyl)carbodiimide or its hydrochloride, etc.) diphenylphosphinic azido, diphenylphosphinic chloride, diethylphosphoryl cyanide, bis (2-oxo-3- ' oxazolidinyl) - phosphinic chloride, N,N'-carbonyldiimidazole, 2-ethoxy-l- ethoxycarbonyl-1,2-dihydroquinoline, cyanuric chloride, or the like. The reaction may be also carried out in the presence of organic or inorganic base such as alkali metal carbonate, tri (lower)alkylamine, pyridine, N- (lower) alkylmorphorine, or the like . The reaction is usually carried out in a conventional solvent such as water, acetone, alcohol [e.g., methanol, ethanol, isopropyl alcohol, etc.], tetrahydrofuran, dioxane, toluene, methylene chloride, chloroform, N,N-dimethylformamide or any other organic solvents which do not adversely affect the reaction, or the mixture thereof. The reaction temperature is not critical and the reaction is usually carried out under cooling to warming. Process 4 The compound (1-5) or its salt can be prepared by subjecting the compound (1-4) or its salt to deesterification. This deesterification can be carried out in a similar manner to that of the Process 2. and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process 2. Process 5 The compound (1-6) or its salt can be prepared by reacting the compound (1-5) or its reactive derivative at the carboxy group, or its salt, with the compound- (IV) or its reactive derivative at the amino group, or its salt. This reaction can be carried out in a similar manner to that of the Process 3, and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process 3. Process 6 The compound (1-8) or its salt can be prepared by reacting a compound (1-7) or its salt with a reducing agent. Suitable reducing agent may be diborane, sodium borohydride, lithium aluminum hydride or the like. The reaction is usually carried out in a conventional solvent such as diethyl ether, tetrahydrofuran or any other organic solvent which dose not adversely influence the reaction. The reaction temperature is not critical, and the reaction can be carried out under cooling to heating. Process i The compound (1-10) or its salt can be prepared by reacting the compound (1-9) or its salt with an acylatir.g agent (V) . Suitable acylating agent (V) may be a conventional one used in the Friedel-Crafts acylation reaction such as an acid halide [e.g. acid chloride, acid bromide, etc.], an acid anhydride or the like. This reaction is preferably carried out in the presence of a Lewis acid such as aluminum halide [e.g. aluminum chloride, aluminum bromide, etc.], titanium halide [e.g. titanium tetrachloride, etc.], zinc halide (e.g. zinc chloride), boron trifluoride or the like. The reaction is usually carried out in a conventional solvent such as carbon disulfide, dichloroethane, tetrachloromethane, benzene or any other organic solvent which does not adversely influence the reaction. The reaction temperature is not critical, and the reaction is usually carried out under cooling to heating. Process 8 The compound (1-12) or its salt can be prepared by subjecting the compound (I-ll) or its salt to dehydration at the carbamoyl group. Dehydration is carried out in the conventional manner, which is capable dehydrating a carbamoyl group to cyano group, and suitable dehydrating agent may be phosphorus compound (e.g. phosphorous pentoxide, phosphorus pentachloride, phosphorous oxychloride, pyrocatechyl phosphorus trichloride, and so on) ; thionyl chloride; or a combination of triaryl phosphine (e.g. triphenyl phosphine, and so on) and chloroform or carbon tetrachloride. The reaction is usually carried out in a conventional solvent such as water, alcohol [e.g., methanol, ethanol, isopropyl alcohol, etc.], tetrahydrofuran, dioxane, toluene, methylene chloride, chloroform, carbon tetrachloride, N,N- dimethylformamide or any other organic solvents which do not adversely affect the reaction, or the mixture thereof. The reaction temperature is not critical and the reaction is usually carried out under cooling to warming. Process 9 The object compound (1-13) or its salt can be prepared by reacting a compound (1-12) or its salt with an azide compound. Suitable azide compound may be alkali metal azide [e.g. sodium azide, potassium azide, etc.], alkaline earth metal azide [e.g. calcium azide, etc.], aluminum azide, hydrogen azide, trimethyltin azide, or the like. The reaction is preferably carried out in the presence of ammonium halide -[e.g. ammonium chloride, ammonium bromide, etc.], lower alkylammonium halide [e.g. trimethylammonium chloride, triethylammonium chloride, etc.] or the like. The reaction is usually carried out in a conventional solvent such as tetrahydrofuran, dioxane, N,N-dimethylformamide or any other organic solvent which does not adversely influence the reaction. The reaction temperature is not critical, and the reaction can be carried out under warming to heating. Proress 10 The compound (1-15) or its salt can be prepared by subjecting the compound (1-14) or its salt to deesterification. This deesterification can be carried out in a similar manner to that of the Process 2. and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process 2. Process 11 The compound (1-16) or its salt can be prepared by subjecting the acid chloride or acid anhydride derived from the compound (1-15) or its salt to intramolecular acylation reaction. This intramolecular acylation reaction can be carried out in a similar manner to that of the Process 1. and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process 7. Process 12 The compound (1-18) or its salt can be prepared by reacting the compound (1-17) or its salt with compound (IV) . This reaction is preferably carried out in the presence of organic or inorganic base exemplified in Process 1, and/or alkali metal iodide (e.g. sodium iodide, potassium iodide, etc.) . The reaction is usually carried out in a solvent such as water, tetrahydrofuran, dioxane, N,N-dimethylformamide or any other solvent which does not adversely influence the reaction. The reaction temperature is not critical, and the reaction is usually carried out at ambient temperature of under warming to heating. Process 13 The compound (1-19) or its salt can be prepared by reacting a compound (1-9) or its salt with a formylating agent. Suitable formylating agent may be N,N-dimethylformamide; (CH 3 ) (so-called Vilsmeier reagent prepared by the reaction of N,N-dimethylformamide with phosphorus oxychloride, phosgene, etc.); or the like. When a formylating agent is N,N-dimethylformamide, the reaction is preferably carried out in the presence of a base such as lower alkyl alkali metal [e.g. n-butyl lithium, ethyl magnesium bromide, etc.], or the like. The reaction is usually carried out in a solvent such as dioxane, tetrahydrofuran, N,N-dimethylformamide, methylene chloride, chloroform, or any other organic solvent which does not adversely influence the reaction. The reaction temperature is not critical, and the reaction is usually carried out under cooling to heating. Process 14 The compound (1-20) or its salt can be prepared by subjecting the compound (1-19) or its salt to oxidation reaction. Oxidation is carried out in a conventional manner, which is capable of oxidizing formyl group to carboxy group, and suitable oxidizing reagent may be oxygen acid- such as periodate (e.g. sodium periodate, potassium periodate, etc.), peroxy acid such as peroxybenzoic acid (e.g., peroxybenzoic acid, m-chloroperoxybenzoic acid, etc.), potassium permanganate, cromic acid, sodium hypochlorite, or the like. The reaction is usually carried out in a conventional solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, dichloromethane, ethylene dichloride, chloroform, N,N-dimethylformamide, N,N-dimethylacetamide, or any other organic solvent which does not adversely affect the reaction. Among these solvents, hydrophilic solvents may be used in a mixture with water. The reaction temperature is not critical and the reaction is usually carried out under cooling to heating. Process 15 The compound (1-22) or its salt can be prepared by subjecting the compound (1-21) or its salt to a rearrangement reaction. The rearrangement reaction, which is capable of converting the carboxy group into amino group optionall y substituted with protected carboxy or acyl (e.g. carbamoyl substituted with lower alkyl, etc.), may be the condition such as Curtius Rearrangement, Hoffmann reaction, Schmidt reaction, or the modification thereof. For example, the Curtius rearrangement consists of the formation of acid azide, the decomposition of acid azide to isocyanate and nitrogen, and the reaction of isocyanate with water, alcohol or amine to afford amine, urethane or urea, respectively. Acid azide can be prepared by treating corresponding acid hydrazide with nitrous acid, treating corresponding acid chloride with alkali metal azide, treating carboxylic acid with diphenylphosphoryl azide, or the like. Acid azide can be rearranged in inert solvent (e.g., toluene, dichloromethane, etc.), from which the isocyanate can be isolated, or in the presence of reagents like alcohol or amine which will react with the intermediate isocyanate to form urethan or urea. Amine or its salt can be obtained by hydrolysis of isocyanate, urethan, or urea. The reaction temperature is not critical and the reaction is usually carried out under cooling to warming. Process 1$ The compound (1-24) or its salt can be prepared by reacting the compound (1-23) or its reactive derivative at the amino group, or its salt, with the compound (VI) or its salt, or the compound (VII) or its salt. When free acid is used as the compound (VI), the reaction is preferably carried out in the presence of condensing agent exemplified in Process 3. The reaction is usually carried out in a conventional solvent such as water, alcohol [e.g., methanol, ethanol, isopropyl alcohol, etc.], tetrahydrofuran, dioxane, toluene, methylene chloride, chloroform, N,N-dimethylformamide or any other organic solvents which do not adversely affect the reaction, or the mixture thereof. The reaction temperature is not critical and the reaction is usually carried out under cooling to warming. Process The compound (1-26) or its salt can be prepared by subjecting a compound (1-25) or its salt to reduction. The present reduction is carried out by chemical reduction, catalytic reduction, or the like. Suitable reducing agents to be used in chemical reduction are a combination of metal [e.g. tin, zinc, iron, etc.] or metallic compound [e.g. chromium chloride, chromium acetate, etc.] and an organic or inorganic acid [e.g. formic acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc. ] . Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalyst [e.g. platinum, platinum black, platinum oxide, etc.], palladium catalyst [e.g. palladium black, palladium oxide, palladium on carbon, etc.], nickel catalyst [e.g. reduced nickel, nickel oxide, Raney nickel, etc.], cobalt catalyst [e.g. reduced cobalt, Raney cobalt, etc.], iron catalyst [e.g. reduced iron, Raney iron, etc.], copper catalyst [e.g. reduced copper, Raney copper, Ullnar. copper, etc.] or the like. The reduction is usually carried out in a conventional solvent which does not adversely influence the reaction such as water, an alcohol [e.g. methanol, ethanol, propanol, etc.], N,N-dimethylformamide, or a mixture thereof. Additionally, in case that the above-mentioned acids to be used in chemical reduction are in liquid, they can also be used as a solvent. Further, a suitable solvent to be used in catalytic reduction may be the above-mentioned solvent and other conventional solvent such as diethyl ether, methylene chloride, dioxane, tetrahydrofuran, etc., or a mixture thereof. The reaction temperature of this reduction is not critical and the reaction is usually carried out under cooling to warming. Process 18 The compound (1-28) or its salt can be prepared by subjecting a compound (1-27) or its salt to cleavage of ether bond. The cleavage of ether bond is carried out in the presence of an acid including Lewis acid [e.g. hydrochloric acid, hydrobromic acid, hydroiodic acid, boron tribro ide, boron trichloride, etc.], tri (lower)alkylsilyliodide [e.g. trimethylsilyliodide, etc.], or any other method ordinary employed in the field of organic synthesis. The reaction is usually carried out in a solvent such as water, acetic acid, methylene chloride, tetrahydrofuran, a mixture thereof or any other solvent which does not adversely influence the reaction. The reaction temperature is not critical and the reaction is usually carried out under cooling to heating. Process 19 The compound (1-30) or its salt can be prepared by subjecting the compound (1-29) or its salt to oxidation. This oxidation can be performed according to the general procedures ordinarily employed in the field of organic chemistry, which is capable of oxidizing a secondary alcohol to ketone, and suitable oxidizing agent is, for example, derivatives of hexavalent chromiu (Cr VI ) (e.g. chromium trioxide, sodium dichromate, chromium trioxide-dipyridine complex, etc.) or heptavalent manganese(Mn VI1 ) (e.g. potassium permanganate, manganese dioxide, etc.). The reaction is usually carried out in a conventional solvent such as water, tetrahydrofuran, dioxane, toluene, methylene chloride, chloroform, N,N-dimethylformamide, acetone, or any other organic solvents which do not adversely affect the reaction, or the mixture thereof. The reaction temperature is not critical and the reaction is usually carried out under cooling to warming. Process 20 The compound (1-31) or its salt can be prepared by subjecting the compound (1-9) or its salt to halogenation. This halogenation is usually carried out by using a conventional halogenating agent such as halogen (e.g., chlorine, bromine, etc,), phosphorus trihalide (e.g., phosphorus tribromide, phosphorus tichloride, etc.), phosphorus pentahalide (e.g., phosphorus pentachloride, phosphorus pentabromide, etc.), phosphorus oxychlroide (e.g., phosphoryl trichloride, phosphoryl monochloride, etc.), thionyl halide (e.g., thionyl chloride, thionyl bromide, etc.), oxalyl halide (e.g., oxalyl chloride, oxalyl bromide, etc.), sulfuryl halide (e.g. sulfuryl chloride, etc.), pyridinium hydrobromide perbromide, or the like. This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl alcohol, etc.), benzene, dioxane, N,N-dimethylformamide, tetrahydrofuran, methylene chloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which dose not adversely affect the reaction. The reaction temperature is not critical and the reaction is usually carried out under cooling to warming. Process 21 The compound (1-32) or its salt can be prepared by reacting a compound (1-9) or its salt with a nitrating agent. Suitable nitrating agent may be nitric acid, fuming nitric acid, potassium nitrate, nitronium tetrafluoroborate or the like. The reaction is usually carried out in an acid or an acid anhydride such as sulfuric acid, acetic acid, acetic anhydride or the like. The reaction temperature is not critical, and the reaction is usually carried out under cooling to heating. Process 22 The compound (1-33) or its salt can be prepared by subjecting the compound (1-7) or its salt to reduction. This reduction can be performed according to the general procedures ordinarily employed in the field of organic chemistry, which is capable of reducing a ketone to a secondary alcohol, and suitable reducing agent is, for example, metal hydride such as aluminum hydrides (e.g. lithium aluminum hydride, lithium di (lower)alkylaluminum hydride, _, , _ , _© , etc.), boron hydrides (e.g. sodium Reα-Al^^ borohydride, sodium borocyanohydride, etc.), or the like. The reaction is usually carried out in a conventional solvent such as water, tetrahydrofuran, dioxane, toluene, methylene chloride, chloroform, N,N-dimethylformamide, acetone, or any other organic solvents which do not adversely affect the reaction, or the mixture thereof. The reaction temperature is not critical and the reaction is usually carried out under cooling to warming. Process 23 The compound (1-35) or its salt can be prepared by reacting a compound (1-34) or its salt with hydroxylamine or its salt. The reaction is usually carried out in a conventional solvent such as water, an alcohol [e.g. methanol, ethanol, etc.], acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, dioxane or any other organic solvent which does not adversely influence the reaction. These conventional solvents may also be used in a mixture with water. The reaction is preferably carried out in the presence of an inorganic or organic base exemplified in Process 1. The reaction temperature is not critical, and the reaction is usually carried out under cooling to heating. Process 24 The compound (1-37) or its salt can be prepared by reacting the compound (1-36) or its reactive derivative at the amino group, or its salt with the compound (VI) or compound (VII) . This reaction can be carried out in a similar manner to that of Process 16 and therefore the regents -to be used and the reaction conditions (e.g. reaction temperature, etc.) can be referred to those of the Process 16. The compounds (I) and pharmaceutically acceptable salts thereof of the present invention possess inhibitory activity of cGMP-PDE (especially PDE-V) , relaxant activity of smooth muscle, bronchodilator activity, vasodilative activity, inhibitory activity of smooth muscle cells proliferation, inhibitory activity of allergy, and so on. The compounds (I) and pharmaceutically acceptable salts thereof, therefore, have utility in the treatment and prevention of various diseases, such as angina, hypertension, pulmonary hypertension, congestive heart failure, glomerular diseases (e.g. diabetic glomerulosclerosis, etc.), renal tubulo-intestinal diseases (e.g. nephropathy induced by FK506, cyclosporins, or the like) , renal failure, atherosclerosis, conditions of reduced blood vessel patency (e.g., post-percutaneous transluminal coronary angioplasty) , peripheral vascular disease, stroke, chronic reversible obstructive lung diseases (e.g. bronchitis, asthma (chronic asthma, allergic asthma) ) , allergic rhinitis, urticaria, glaucoma, diseases characterized by disorders of gut motility (e.g., irritable bowel syndrome), impotence (e.g. organic impotence, psychic impotence, etc.), or diabetic complications (e.g. diabetic gangrene, diabetic arthropathy, diabetic glomerulosclerosis, diabetic dermopathy, diabetic neuropathy, diabetic cataract, diabetic retinopathy, etc.) . Besides the compounds of the formula (I) , many compounds, disclosed in various prior publications, are known to have a cyclic nucleotide-PDE inhibitory activity. Particularly, a compound having the following formula : and its analogous compound, and a compound having the following formula : and its analogous compounds, which have an inhibiting activity of cyclic nucleotide-PDE (especially cGMP-PDE) , were known and disclosed in International Patent Publication No. WO 93/07124 and European Patent Publication No. EP 0 526 004. And, various cyclic nucleotide-PDE inhibitors (e.g. papaverine, dipyridamole, etc.) were known and disclosed in Biochemical Pharmacology, vol 46 No. 5, P 833-839. And further, until now cGMP-PDE inhibitors as exemplified above have been also known to be useful for treating or preventing of various diseases, for example, according to the International Publication No. WO93/07124, angina pectoris, cardiac infarction, ischemic heart disease, for example, chronic and acute cardiac failure, lung hypertension which may be complicated with cor pulmonale, hypertension caused by various factors, peripheral circulatory failure, brain dysfunction, bronchitic asthma and allergic disorder, for example, atopic dermatitis, allergic rhinitis, or the like. The inventors of this invention have surprisingly found that the cyclic nucleotide-PDE inhibitors are useful for treating or preventing glomerular diseases, renal tubulo- interstitial diseases and chronic renal failure. According to "International Statistical Classification of Diseases and Related Health Problems (tenth revision) " (W. H. 0., 1992), diseases of genitourinary system are divided into several groups, such as glomerular diseases, renal tubulo-interstitial diseases, renal failure and so on. Glomerular Diseases are divided into several subgroups, such as rapidly progressive nephritis syndrome, recurrent and persistent haematuria, chronic nephritic syndrome, nephrotic syndrome, glomerular disorders in other diseases, and so on. The diseases, to which glomerular disorder is ascribed, are for example infectious and parasitic diseases; neoplastic diseases; blood diseases and disorders involving the immune mechanism; diabetes mellitus; other endocrine, nutritional and metabolic diseases; systemic connective tissue disorders (e.g. Goodpasture's syndrome, systemic lupus erythematosus, Wegener's granulomatosis, etc.); and so on. Renal tubulo-interstitial diseases are also divided into several subgroups, one of which is drug- and heavy-metal- induced tubulo-interstitial and tubular conditions, and another one of which is renal tubulo-interstitial disorders in other diseases. The former subgroup includes analgesic nephropathy; nephropathy induced by drugs (e.g. FK506, cyclosporins, and so on) , medicaments and biological substances; nephropathy induced by unspecified drug, medicament and biological substance; nephropathy induced by heavy metals; and toxic nephropathy. In the latter subgroup, the diseases, to which renal tubulo-interstitial disorder is ascribed, are for example infectious and parasitic diseases, neoplastic diseases, blood diseases and disorders involving the immune mechanism, metabolic diseases, systematic connective tissue disorders (e.g. sicca syndrome, systematic lupus erythematosus) , transplant rejection, and so on. Renal failure is divided into three subgroups, one of which is chronic renal failure. The cyclic nucleotide-PDE inhibitors are useful for treating or preventing glomerular diseases, particularly glomerular disorders in other diseases, more particularly glomerular disorders in diabetes mellitus and glomerular disorders in systemic lupus erythematosus; renal tubulo- interstitial diseases, particularly drug- and heavy-metal- induced tubulo-interstitial and tubular conditions, and renal tubulo-interstitial disorders in other disease, more particularly nephropathy induced by drugs (e.g. FK506, cyclospolins, and so on) , medicaments and biological substances, and renal tubulo-interstitial disorders in systemic connective tissue disorder; and chronic renal failure. The cyclic nucleotide-PDEs include cyclic adenosine 3' , 5'-monophosphate phosphodiesterase (hereinafter described as cAMP-PDE) and cGMP-PDE. cAMP-PDE and cGMP-PDE play a major role in the regulation of intracellular concentrations of cAMP and cGMP, respectively. The cyclic nucleotide-PDEs are classified into five isozyme families, based largely on primary protein and cDNA sequence information, as follows : Ca ++ -calmodulin (CaM) -dependent family (Type I); cGMP- stimulated family (Type II) ; cGMP-inhibited by a large number of positive inotropic agents such as milrinone (Type III) ; cAMP-specific family, selectively inhibited by rolipram (Type IV) ; cGMP-specific family, selectively inhibited by zaprinast (Type V) . The term "immunophilin" is intended to mean a macromolecular protein or glycoprotein, which is capable of recognizing and selectively binding with immunosuppressive agent such as FK506, cyclosporins, rapamycins and so on, and have a peptidyi-propyl cis-trans isomerase activity; for example, FK506 binding protein (hereinafter indicated as FKBP) and intracellular receptor to the cyclosporins, preferably, FKΞP-12 and cyclophilin produced by mammal, for example, cattle or man. Immunophilin is known and is obtained by substantially the same method of J. Am. Chem. Soc, 113, 1409-1411 (1991), Proc. Natl. Acad. Sci. U.S.A., 88, 6229-6233 (1991), Nature 346, 671-674 (1991) and 337, 473-475, 476-478 (1989), International Patent Application Nos. 91/17493, 92/01052, Japanese Patent Application No. 2-209897 and so on. The compound designated as FK506 (or FR-900506) and its analogous compounds are well known to have a potent immunosuppressive activity and are produced by fermentation of the genus Streptomyces, especially Streptomyces tukubaensis No. 9993 (FERM BP-927) or Streptomyces hygroscopicus subsp. yakU S iπiaensi S No. 7238 (FERM BP-928) (European Patent No. 0184162-B1) . The cyclosporins, for example, cyclosporin A, B, C, D, E, F and G, and its derivatives, are disclosed in United State Patent Nos. 4,117,118, 4,215,199, 4,288,431, 4,388,307, Helv. Chem. Acta 60, 1568 (1977) and 65, 1655 (1982), Transplant. Proc, 17, 1362 (1985) and so on, and are well known to have an immunosuppressive activity. However, FK506 and cyclosporins are also known to induce a renal tubulo-interstitial disease. The cyclic nucleotide-PDE inhibitors can be administered in a pure or impure form and in a single compound or a mixture thereof, preferably, in a pharmaceutical vehicle or carrier. The pharmaceutical composition of this invention can be used in the form of a pharmaceutical preparation, for example, in solid, semisolid or liquid form, which contains the cyclic nucleotide PDE inhibitors, as an active ingredient, in admixture with an organic or inorganic carrier or excipient suitable for external, enteral, intravenous, intramuscular, or parenteral applications. The active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable, carriers for ointment, cream, plaster, tablets, pellets, capsules, suppositories, solutions (saline, for example) , emulsion, suspensions (olive oil, for example) , and any other form suitable for use. The carriers which can be used are water, wax, glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, paraffin, colloidal silica, potato starch, urea and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form, and in addition auxiliary, stabilizing, thickening and coloring agents and perfumes may be used. The active compound is included in the pharmaceutical composition in an effective amount sufficient to produce the desired effect upon the process or condition of the diseases. Mammals which may be treated by the present invention include livestock mammals such as cows, horses, etc., domestic animals such as dogs, cats, rats, etc. and humans, preferably humans. For applying this , composition to a human, it is preferable to apply- it by external (topical), oral, parenteral, enteral, intravenous, or intramuscular administration. While the dosage of therapeutically effective amount of the macrolide compounds varies from and also depends upon the age and condition of each individual patient to be treated, in case of the systemic administration, a daily dose of about 0.01-1000 mg, preferably 0.1-500 mg and more preferably 0.5- 100 mg of the active ingredient is generally given for treating the diseases, and an average single dose of about 0.2-0.5 mg, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg, 250 mg and 500 mg is generally administered. Daily doses for chronic administration in humans will be in the range of about 0.3 mg/kg/day. And further, it is considered that the compounds, which have a cyclic nucleotide-PDE inhibitory activity, described in the European Patent Publication Nos. 579,496, 534,443, 526,004, 636,626; United State Patent Nos. 3,819,631, 5,294,612, 5,488,055; International Patent Application Nos. 93/07,124, 94/19,351; Japan Patent Publication No. 07-330,777; and so on, are useful for treating or preventing glomerular diseases, tubulo-interstitial diseases and renal failure. In order to exhibit the usefulness of the present invention, the activity of compound (I) and the activity of the compound of (VIII) or (IX), papaverine, or dipyridamole, the representative compound of the cyclic nucleotide-PDE inhibitors, is shown in the following. Test 1 cGMP-Phosphodiesterase (PDE) assay cGMP-PDE was separated from other isozymes in human platelets by a modification of the method of Thompson et. al. (Cyclic Nucleotide Phosphodiesterase (PDE) , in Methods of Enzymatic analysis, Vol 4, pl27-234, 1984) . In enzyme inhibition assays, the test compounds were dissolved in 10% DMSO and then diluted with assay buffer (50 mM Tris-HCl, pH 8.0, 0.1 mM dithiothreitol, 2 mM EGTA and 10 u/ml snake venom) , at final concentrations ranging from 10 ~10 to 10 ~6 M. Assays were performed at 0.1 μM substrate ([ 3 H]-cGMP) concentration, at 30°C for 10 minutes using enzyme dilutions which gave 10-20 a _ hydrolysis of substrate. Each assay was initiated by addition of substrate and terminated by addition of anion exchange resin (Dowex 1-X8, 25 μg/mg) followed by centrifugation for 10 minutes (3000 rpm, at 4°C) . Radioactivity of supernatant ( 3 H-GMP) was assayed by liquid scintillation counting. The compounds prepared in the present Examples 3, 4, 6, 9, 12, 15, 18, 21, 22-(2) to 22-(4), 22-(6), 23, 24-(l), 25-(2), 26, 27-(2), 27-(5), 27-(8), 37-(3), 37-(4), 37-(6), 37-(7), 37-(9), 37-(ll), 37-(12), 37-(14), 37-(17), 38-(2), 39, 42, 43, 58, 60, 63, 67-(2), 69, 70, 72, 73-(33), 73-(36) 73-(40), 75-(4), 75-(8), 75-(10), 75-(15), 75-(21), 75-(23), 75-(27), 75-(29), 75-(30), 75-(35), 75-(38) and 75-(39), which were selected as the representative compounds of the present invention, had IC^ Q values below 100 nM. Test 2 Smooth muscle relaxant The aorta were carefully removed from male Wistar rats, cleaned of fat and extraneous tissue. Spirally cut strips of the aorta were placed in a 25 ml organ bath containing Tyrode solution of the following composition (mM) ; NaCl, 137; KC1, 2.7; CaCl 2 , 1-8; NaH 2 P0 4 , 0.4; NaHC0 3 , 12.0; MgS0 4 , 1.1; glucose, 5.6. The bath was maintained at 37°C and bubbled with 95% 0 2 and 5% C0 2 . The spirally cut strip was stretched to a resting force of 1.0 g, and the isometric contraction was recorded via a force development transducer on an ink writing recorder. Tissues were equilibrated for 60 minutes before contraction was induced by noradrenaline (NA, 1 μM) . The test compounds were cumulatively added to organ bath in increasing concentrations ranging from 10 —R to 10— J R M, after maximum stable constriction to NA had been achieved. For example, the compounds prepared in the present Examples 6, 12, 27-(8), 37-(4), 37-(7), 37-(9), 37-(12), 43, 72, 73- (33), 73- (36) and 75- (8), which were selected as the representative compounds of the present invention, had IC50 values below 100 nM. Test 3. vSMC proliferation Vascular smooth muscle cells (vSMCs) were prepared from explants of the thoracic aorta of 10 week old male Wistar rats by a modification of the method of Ross (J. Cell Biol., 50: 172, 1971). They were cultured in DMEM containing 10% fetal calf serum, 1% penicillin G and 1% streptomycin at 37°C in a 95% air, 5% C0 2 humidified atmosphere. vSMCs were seeded in 24 well plates and cultured in the presence of 10% fetal calf serum for 3 days. Cell growth then was arrested by transfer to serum free DMEA. After 24 hours, each test compound or vehicle was added to medium for 1 hour, and then cells were stimulated by PDGF (10 ng/ml) . After 24 hours of additional incubation, [ 3 H]-thymidine (1 μCi/ml) was added during the final 4 hours of incubation time, and trichloracetic acid insoluble radioactivity was assayed by liquid scintillation counting. For example, the compounds prepared in the present Examples 3, 9, 15, 22-(6), 23, 24-(l), 27-(5), 27-(8), 37- (14), 38-(2), 60, 67-(2), 75- (29) and 75- (30), which were selected as representative compounds of the present invention, had IC50 below 100 nM. Test 4. Vasopressin induced-vasospasm model Male Donryu rats, weighing 160-200 g, were anesthetized intraperitoneally with sodium pentobarbital (60 mg/kg) 15 minutes before intravenous administration of vasopressin, and the femoral vein was cannulated with polyethylene tubing (diameter 0.8 mm). Coronary vasospasm was induced with vasopressin (0.2 iu/kg) dissolved in saline through the cannula in the femoral vein. The each test compound (10 mg/kg) was administered orally 30 minutes before the administration of vasopressin. The standard limb lead II of the electrocardiogram was recorded with an electrocardiograph. The depression of ST segment was measured as the difference in the amplitudes of the ST segment after and just before the administration of vasopressin. The amplitudes of ST segment were measured at intervals of 0.5 minutes for 5 minutes after administration of vasopressin. For example, the compounds prepared in the present Examples 3, 6, 12, 37- (12), 38- (1), 42 and 43 of the present invention, showed more than 50% inhibiting activity, respectively. Test 5. Cyclosporin nephritis model Spontaneously hypertensive rats weighing 250-300 g were used. Cyclosporin dissolved in olive-oil containing 5% ethanol was given orally to the animals in a daily dose 50 mg/kg for 2 weeks. After the last dosing of cyclosporin, 24-hours urine was collected for urinalysis. Blood was withdrawn from the abdominal aorta under ether anesthesia 24 hours after the last dosing of cyclosporin, and plasma was separated by centrifugation for biochemical analysis. The animal were bled to death and kidneys were removed for histopathological examination. The each test compound (3.2 mg/kg) was dissolved in PEG 400 and given orally by the volume of 1 ml/kg twice a day for two weeks. Biochemistry and urinalysis : Urine volume, plasma creatinine, urine creatinine, blood urea nitrogen, plasma sodium, urine sodium, plasma potassium and urine potassium, were measured with an autoanalyzer (TBA-20R Toshiba, OM-6020 Daiichi Kagaku) . Histopathology : The kidneys were fixed in phosphate- buffered 10% formalin and its paraffin specimens were prepared and these sections were stained with hematoxylin. The compound (VIII), the compound (IX), and the compounds prepared in the present Examples 3 and 6, which were selected as representative compounds of the present invention, showed more than 50% recovery in a measure cf blood urea nitrogen, and more than 40% recovery in a measure of creatinine clearance (ml/kg/min) , respectively. Test 6. FK506 nephritis model (a) Spontaneously hypertensive rats weighing 250-300 g were used. FK506 dissolved in olive-oil containing 5% ethanol was given orally to the animals in a daily dose 18 mg/kg for 1 week. After the last dosing of FK506, 24-hours urine was collected for urinalysis. Blood was withdrawn from the abdominal aorta under ether anesthesia 24 hours after the last dosing of FK506, and plasma was separated by centrifugation for biochemical analysis. The each test compound was dissolved in PEG 400 and given orally by the volume of 1 ml/kg twice a day for two weeks. Biochemistry and urinalysis : Urine volume, plasma creatinine, urine creatinine, blood urea nitrogen, plasma sodium, urine sodium, plasma potassium and urine potassium, were measured with an autoanalyzer (TBA-20R Toshiba, OM-6020 Daiichi Kagaku) . The compound (VIII) and the compound prepared in Example 6, which was selected as representative compounds of this invention, showed more than 50% recovery in urinary sodium excretion, and more than 45% recovery in a measure of creatinine clearance (ml/kg/min) , respectively. (b) Prevention of experimental FK506-induced nephritis by cyclic nucleotide regulating drugs FK506 was administered orally to male Sprague-Dawley rats (body weights; 292-329 g) fed with low sodium diet (0.05% Sodium) in a daily dose of 10 mg/kg/day for 14 days. FK506 was provided in a solid dispersion formulation and dissolved in distilled water to a final concentration of 2 mg/ml. Papaverine was dissolved in saline to 5 mg/ml. Dipyridamole (i.v. formulation; 5 mg/ml) was purchased from Dainippon Pharmaceutical Co., Ltd. Papaverine (20 mg/kg) or dipyridamole (20 mg/kg) was administered intramuscularly 30 minutes before FK506 dosing. After the final dosing of FK506, 24-hours urine was collected for urinalysis. Blood was withdrawn from the abdominal aorta under ether anesthesia 24 hours after final dosing of FK506, and plasma was separated for biochemical analysis and plasma renin activity measurements. The kidney was removed from each animal and was fixed with in 10% formalin solution for histological analysis. Papaverine and dipyridamole significantly improved renofunction of FK506 dosed rats. Both compounds showed more than 50% recovery in a measure of blood urea nitrogen, and more than 50% recovery in a serum creatinine. Test 7. Diabetic glomerulosclerosis model 6 weeks old Male SD rats were treated with streptozotocin (60 mg/kg i.v.) to induce diabetes mellitus. One week after streptozotocin treatment, test compound, 3.2, 10 mg/kg was started to be orally administered twice a day for 16 weeks. The compound prepared in Example 6, which was selected as representative compound of this invention, retarded the onset of diabetic cataract and improved the parameters reflecting the abnormalities of peripheral circulation (improved the decreased blood flow in ears and raised the decreased skin temperature on foot pad) . Said compound, 10 mg/kg, perfectly recovered the reduced valiance of RR intervals in cardioelectrography, reduced on average by 37% the elimination of protein in urine, and perfectly inhibited the increased 4-hydroxyproline contents in renal cortex. Test 8. Impotence model (a) Effect of test compound on nitroprusside or Ach-induced relaxation in isolated rat corpora cavernosa Male SD rats were anesthetized with sodium pentobarbital 50 mg/kg intraperitoneally, and the corpora cavernosa was excised. The tunica albuginea was dissected according to the methods described by Italiano et al. (Pharmacological Research, 30, No.4, 1994) and used for in vitro pharmacological study. The erectile tissue strip was placed in a 25 ml organ bath containing Krebs-Ringer solution. The bath was maintained at 37 β C and bubbled with 95% 0 2 and 5% C0 2 . The strip was stretched with a resting force of 0.25 g, and isometric contraction were recorded via force development transducer on a recorder. The strip was equilibrated in the Krebs-Ringer solution for about 60 minutes, and preconstructed by 0.1 mM norepinephrine to ascertain the responsibility of each preparation. The strip was washed several times, and then constricted by 0.1 mM norepinephrine. After getting stable constrictile response to norepinephrine, the first dose- response curve for sodium nitroprusside or Ach was obtained. After washing a few times for 60 minutes, the strip was constricted by norepinephrine again, and the second dose- response curve for sodium nitroprusside or Ach was obtained. The test compound was added 30 minutes before adding norepinephrine. The compound prepared in Example 6, which was selected as representative compound of this invention, at 10 -7 M potentiated nitroprusside-induced relaxation of corpora cavernosa, and ED^ Q value of dose-response curve to nitroprusside was about 50 μM. Said compound at 10 -7 M also potentiated Ach-induced relaxation of corpora cavernosa. 100 μM Ach-induced relaxant response to the contractile response induced by 10 -4 M norepinephrine was only 11.0% in control preparation, but this relaxant response to Ach increased to 18.7% in the presence of 10 -7 M said compound. (b) Effect of test compound on the relaxation elicited by electrical field stimulation in rat corpora cavernosa. The rat erectile tissue strip prepared according to the method described by Italiano et al. (Pharmacological Research, 30, No4, 1994) was placed 25 ml organ bath containing Krebs-Ringer solution. The bath was maintained at 37°c and bubbled with 95% 0 2 and 5% C0 2 . The solution also contained atropine (1 μM) and guanethidine (50 μM) . The erectile tissue strip was stretched with a resting force of 0.25 g, and isometric contraction were recorded via force development transducer on a recorder. The bipolar platinum electrode connected to the electric stimulator was placed around the strip. The strip was equilibrated in the Krebs-Ringer solution for about 60 minutes and preconstructed by 0.1 mM norepinephrine to ascertain the responsibility of each preparation. The strip was washed several times, and then constricted by 0.1 mM norepinephrine. After getting stable contractile response to norepinephrine, the first electrical field stimulation (1 to 45Hz, 20V, 0.5 msec duration, 90 sec interval) was delivered. 30 minutes after adding the tested compound, the second electrical field stimulation was delivered. The compound prepared in Example 6, which was selected as representative compound of this invention, at 10 -7 M potentiated relaxation of corpora cavernosa elicited by electrical field stimulation in rat corpora cavernosa. Relaxant response elicited by 30Hz was only 14.3% in control preparation, but this relaxant response increased to 17.1% in the presence of 10 -7 M said compound. (c) Male beagle weighing 8.0 - 12.0 kg were anesthetized with pentobarbital sodium (35 mg/kg, i.v.). After tracheotomy, the animal was artificially ventilated using a volume-cycled ventilator. The femoral artery was cannulated for continuous blood pressure and heart rate monitoring. The femoral vein was cannulated for maintenance of anesthesia and administration of tested compound. Two laser-dopper probes were placed in the corpus spongiosum penis and corpus cavernosum penis for recording blood flow. After a period of stabilization of all parameters, tested compound was injected intravenously at a various concentration. The administration of the compound prepared in Example 6, which was selected as representative compound of this invention, increased in the blood flow of both corpus spongiosum penis and corpus cavernosum penis without hemodynamic change. The increase in blood flow reached a peak value of 55% of baseline and continued for longer than 15 minutes after the administration of said compound 1.0 mg/kg. (d) Effect of tested compound on genital grooming and penile erection in male mice. Eight weeks old male ICR mice were housed under standard conditions of temperature, lighting and water supply before the experiment. The test compound was dissolved in PEG400. After oral administration of the test compound, each mouse was transferred to an individual cage. The genital grooming and penile erection were observed for one hour. The compound prepared in Example 27- (8), which were selected as representative compound of this invention markedly increased the frequencies of genital grooming by average of 266% and lengthened the duration of penile erection by average of 171% (n=10) . Test 9. Toxities of Compound (I) Test on the toxicity by repetitive oral administration of the compounds prepared in Example 6 and 27- (8), which were selected as representative compound of this invention, in SD rat was conducted and the dead at dose of 32mg/kg once a day for 14 consecutive days could not be observed. The following preparations and examples are given for the purpose of illustrating the present invention. (to be continued on the next page) Preparation 1 (1) To a solution of 2-amino-4-methoxycarbonylphenyl trifluoromethanesulfonate (2.6 g) in a mixture of pyridine (5.6 ml) and dichloromethane (20 ml) was added benzyl chlorofor ate (2.08 ml) at 0 β C, and the mixture was stirred at 20 β C for 4.5 hours. The mixture was diluted with dichloromethane and washed successively with diluted hydrochloric acid, aqueous sodium bicarbonate and brine. The organic layer was dried over sodium sulfate and evaporated in vacuo. The residue was chromatographed on silica gel eluting with dichloromethane to give 2-benzyloxycarbonylamino-4- methoxycarbonylphenyl trifluoromethanesulfonate (2.61 g) as colorless crystals. NMR (CDC1 3 , δ) : 3.92 (3H, s) , 5.23 (2H, s) , 6.89 (IH, br s), 7.3-7.45 (6H, ) , 7.83 (IH, dd, J=l, 8Hz) , 8.81 (IH, s) (2) A mixture of 2-benzyloxycarbonylamino-4- methoxycarbonylphenyl trifluoromethanesulfonate (1.01 g) , 1-pentynyl (tributyl) stannane (1.02 g) , lithium chloride (0.29 g) and tetrakis (triphenylphosphine)palladium (80 mg) in dioxane (24 ml) was heated at 100°C for 2 hours. The solvent was evaporated in vacuo and the residue was chromatographed on silica gel eluting with a mixture of hexane and ethyl acetate (4:1) to give methyl 3-benzyloxycarbonylamino-4- (1- pentynyDbenzoate (536 mg) as colorless crystals. NMR (CDC1 3 , δ) : 1.03 (3H, t, J=7Hz) , 1.67 (2H, m) , 2.44 (2H, t, J=7Hz), 3.87 (3H, s) , 5.23 (2H, s), 7.25-7.7 (7H, m) , 8.78 (IH, s) (3) To a solution of methyl 3-benzyloxycarbonylamino-4- (1- pentynyDbenzoate (949 mg) in tetrahydrofuran (24 ml) was added gold(III) sodium chloride (24 mg) under argon atmosphere, and the mixture was heated under reflux for 100 minutes. The solvent was evaporated in vacuo and the residue was chromatographed on silica gel eluting with a mixture of hexane, dichloromethane, and ethyl acetate (6:3:2) to give methyl l-benzyloxycarbonyl-2-propylindole-6-carboxylate (852 mg) as colorless crystals. NMR (CDC1 3 , δ) : 0.98 (3H, t, J=7Hz), 1.71 (2H, m) , 2.97 (2H, t, J=7Hz), 3.90 (3H, s) , 5.49 (2H, s) , 6.39 (IH, s), 7.3-7.6 (6H, m) , 7.91 (IH, dd, J=l, 8Hz), 8.80 (IH, s) (4) To a solution of methyl l-benzyloxycarbonyl-2- propylindole-6-carboxyiate (200 mg) in a mixture of methanol and ethyl acetate (1:1, 8 ml) was added 10 r c palladium o carbon (30 mg) , and the mixture was stirred under hydrogen atmosphere for 20 minutes. The catalyst was removed by filtration through celite and washed with methanol. The filtrate was evaporated in vacuo to give methyl 2- propylindole-6-carboxylate (112 mg) as colorless crystals. NMR (CDC1 3 , δ) : 1.02 (3H, t, J=7Hz), 1.78 (2H, m) , 2.76 (2H, t, J=7Hz), 3.93 (3H, s), 6.29 (IH, s), 7.51 (IH, d, J=8Hz), 7.77 (IH, d, J=8Kz), 8.04 (IH, s) , 8.15 (IH, br s) (5) To a stirring suspension of aluminum chloride (294 mg) and acetyl chloride (0.08 ml) in dichloromethane (10 ml) was added methyl 2-propylindole-6-carboxylate (20C mg) , and the mixture was stirred at 20°C for 1 hour. The resulting mixture was poured onto ice and extracted with ethyl acetate. The combined organic phase was washed with aqueous sodium bicarbonate and brine, then dried over sodium sulfate and evaporated in vacuo. The residue was triturated with isopropyl ether to give methyl 3-acetyl-2-propyiindole-6- carboxylate (78 mg) as colorless crystals. NMR (CDC1 3 , δ) : 1.02 (3H, t, J=7Hz), 1.81 (2H, m) , 2.69 (3H, s), 3.18 (2H, t, J=7Hz) , 3.96 (3H, s), 7.93 (IH, ad, J=l, 8Hz), 8.01 (IH, d, J=8Hz), 8.12 ( IH, d, J=lHz ) , 8 . 88 ( IH, br s ) Prpoaration 2 Methyl 3-isobutyryl-2-propylindole-6-carboxylate (474 mg) was prepared from methyl 2-propylindole-6-carboxylate (700 mg) and isobutyryl chloride (1.01 ml) in a similar manner to that of Preparation 1 (5) . NMR (CDC1 3 , δ) : 1.04 (3H, t, J=8Hz) , 1.28 (6H, d, J=8Hz), 1.83 (2H, sextet, J=8Hz) , 3.18 (2H, t, J=8Hz), 3.52 (2H, septet, J=8Hz) , 3.96 (3H, s) , 7.92 (2H, s), 8.16 (IH, s) , 9.13 (IH, br s) Preparation 3 Methyl 3-propionyl-2-propylindole-6-carboxylate (298 mg) was prepared from methyl 2-propylindole-6-carboxylate (500 mg) and propionyl chloride (0.40 ml) in a similar manner to that of Preparation 1 (5) . NMR (CDC1 3 , δ) : 1.04 (3H, t, J=8Hz) , 1.29 (3H, t, J=8Hz), 1.83 (2H, sextet, J=8Hz) , 3.06 (2H, q, J=8Hz), 3.20 (2H, t, J=8Hz) , 3.96 (3H, s) , 7.93 (IH, dd, J=l, 8Hz), 8.00 (IH, d, J=8Hz) , 8.15 (IH, d, J=lHz), 9.22 (IH, s) , Preparation 4 (1) Methyl 3-benzyloxycarbonylamino-4-(4-methyl-l- pentynyDbenzoate (2.25 g) was prepared from 2- benzyloxycarbonylamino-4-methoxycarbonylphenyl trifluoromethanesulfonate (3.0 g) and (4-methyl-l- pentynyl) (tributyl) stannane (2.7 g) in a similar manner to that of Preparation 1 (2) . NMR (CDC1 3 , δ) : 1.05 (6H, d, J=8Hz) , 1.88-2.02 (IH, m) , 2.40 (2H, d, J=8Hz) , 3.90 (3H, s) , 5.25 (2H, s), 7.32-7.45 (6H, m) , 7.52 (IH, s), 7.66 (IH, d, J=8Hz), 8.78 (IH, s) (2) Methyl l-benzyloxycarbonyl-2-isobutylindole-6- carboxylate (1.67 g) was prepared from methyl 3- benzyloxycarbonylamino-4- (4-methyl-l-pentynyl)benzoate (2.15 g) in a similar manner to that of Preparation 1 (3) . NMR (CDC1 3 , δ) : 0.90 (6H, d, J=8Hz) , 1.90-2.04 (IH, m) , 2.86 (2H, d, J=8Hz) , 3.90 (3H, s) , 5.48 (2H, s), 6.38 (IH, s), 7.40-7.56 (6H, m) , 7.91 (IH, d, J=8Hz), 8.82 (IH, s) (3) Methyl 2-isobutylindole-6-carboxylate (752 mg) was prepared from methyl l-benzyloxycarbonyl-2-isobutylindole-6- carboxylate (1.5 g) in a similar manner to that of Preparation 1 (4) . NMR (CDC1 3 , δ) : 0.98 (6H, d, J=8Hz), 1.95-2.08 (IH, m) , 2.66 (2H, d, J=8Hz) , 3.92 (3H, s) , 6.28 (IH, s), 7.53 (IH, d, J=8Hz), 7.76 (IH, d, J=8Hz) , 8.08 (IH, s) , 8.23 (IH, br s) (4) Methyl 2-isobutyl-3-isobutyrylindole-6-carboxylate (246 mg) was prepared from methyl 2-isobutylindole-6-carboxylate (300 mg) and isobutyryl chloride (0.41 ml) in a similar manner to that of Preparation 1 (5) . NMR (CDC1 3 , δ) : 0.98 (6H, d, J=8Hz), 1.27 (IH, d, J=8Hz), 2.10-2.23 (IH, m) , 3.06 (2H, d, J=8Hz) , 3.52 (2H, septet, J=8Hz) , 3.96 (3H, s) , 7.92 (2H, s), 8.16 (IH, s), 9.02 (IH, s) Preparation 5 (1) Methyl 3-benzyloxycarbonylamino-4- (1-butynyl)benzoate (646 mg) was prepared from 2-benzyloxycarbonylamino-4- methoxycarbonylphenyl trifluoromethanesulfonate (1.82 g) and 1-butynyl (tributyl) stannane (1.51 g) in a similar manner to that of Preparation 1 (2) . NMR (CDC1 3 - δ) : 1.26 (3H- t, J=7Hz) , 2.50 (2H, q, J=7Hz), 3.91 (3H, s) , 5.24 (2H, s) , 7.3-7.5 (7H, m) , 7 . 65 ( IH, dd, J=l , 8Hz ) , 8 . 79 ( IH, br s ) (2) Methyl l-benzyloxycarbonyl-2-ethylindole-6-carboxylate (551 mg) was prepared from methyl 3-benzyloxycarbonylamino-4- (l-butynyl)benzoate (640 mg) in a similar manner to that of Preparation 1 (3) . NMR (CDC1 3 , δ) : 1.30 (3H, t, J=7Hz) , 3.05 (2H, q, J=7Hz), 3.88 (3H, s) , 4.98 (2H, s) , 6.92 (IH, s), 7.35-7.60 (6H, m) , 7.89 (IH, dd, J=l, 8Hz) , 8.79 (IH, s) (3) Methyl 2-ethylindole-6-carboxylate (306 mg) was prepared from methyl l-benzyloxycarbonyl-2-ethylindole-6-carboxylate (546 mg) in a similar manner to that of Preparation 1 (4) . NMR (CDC1 3 , δ) : 1.38 (3H, t, J=7Hz) , 2.82 (2H, q, J=7Hz), 3.91 (3H, s), 6.30 (IH, s) , 7.50 (IH, d, J=8Hz), 7.75 (IH, d, J=8Hz) , 8.03 (IH, s), 8.14 (IH, br s) (4) Methyl 2-ethyl-3-propionylindole-6-carboxylate (435 mg) was prepared from methyl 2-ethylindole-6-carboxylate (660 mg) and propionyl chloride (0.62 ml) in a similar manner to that of Preparation 1 (5) . NMR (CDC1 3 , δ) : 1.29 (3H, t, J=7Hz) , 1.39 (3H, t, J=7Hz) , 3.06 (2H, t, J=7Hz) , 3.26 (2H, t, J=7Hz) , 3.94 (3H, s), 7.24 (IH, s) , 7.92 (IH, d, J=8Hz) , 7.98 (IH, d, J=8Hz), 8.14 (IH, s) , 8.92 (IH, br s) Preparation 6 (1) Methyl 3-isobutyrylindole-6-carboxylate (618 mg) was prepared from methyl indole-6-carboxylate (500 mg) and isobutyryl chloride (0.84 ml) in a similar manner to that of Preparation 1 (5) . NMR (CDC1 3 , δ) : 1.28 (6H, d, J=7Hz) , 3.35 (IH, m) , 3.96 (3H, s), 7.93-8.06 (2H, m) , 8.19 (IH, s), 8.46 ( IH, d, J=8Hz ) , 8 . 96 ( IH, br s ) (2) To a solution of methyl 3-isobutyrylindole-6-carboxylate (146 mg) in tetrahydrofuran (5 ml) was added 1M solution of brane-tetrahydrofuran complex in tetrahydrofuran (1.8 ml), and the mixture was stirred at 50 β C for 1 hour. The resulting mixture was evaporated in vacuo, and the residue was quenched with aqueous ammonium chloride and extracted with ethyl acetate. The organic phase was washed with brine, and dried over sodium sulfate. After evaporation of solvent, the residue was chromatographed on silica gel eluting with a mixture of hexane and ethyl acetate (2:1) to give methyl 3- isobutylindole-6-carboxylate (105 mg) as colorless crystals. NMR (CDC1 3 , δ) : 0.94 (6H, d, J=7Hz) , 1.98 (IH, m) , 2.62 (2H, d, J=7Hz) , 3.93 (3H, s) , 7.12 (IH, s) , 7.61 (IH, d, J=8Hz), 7.78 (IH, d, J=8Hz) , 8.08 (IH, s) , 8.16 (IH, br s) (3) Methyl 2-acetyl-3-isobutylindole-6-carboxylate (43 mg) was prepared from methyl 3-isobutylindole-6-carboxylate (99 mg) and acetyl chloride (0.073 ml) in a similar manner to that of Preparation 1 (5) . NMR (CDC1 3 , δ) : 1.01 (6H, d, J=7Hz) , 2.02 (IH, m) , 2.69 (3H, s), 2.98 (2H, d, J=7Hz), .3.96 (3H, s) , 7.73 (IH, d, J=8Hz) , 7.79 (IH, d, J=8Hz) , 8.11 (IH, s) , 9.09 (IH, br s) Preparation 7 (1) Methyl 3-acetylindole-6-carboxylate (470 mg) was prepared from methyl indole-6-carboxylate (655 mg) and acetyl chloride (0.27 ml) in a similar manner to that of Preparation 1 (5) . NMR (DMS0-d 6 , δ) : 2.46 (3H, s), 3.88 (3H, s), 7.79 (IH, d, J=8Hz), 8.10 (IH, s) , 8.24 (IH, d, J=8Hz) , 8.52 (IH, s) (2) Methyl 3-ethylindole-6-carboxylate (327 mg) was prepared from methyl 3-acetylindole-6-carboxylate (470 mg) in a similar manner to that of Preparation 6 (2) . NMR (CDC1 3 , δ) : 1.33 (3H, t, J=7Hz) , 2.78 (2H, q, J=7Hz), 3.93 (3H, s) , 7.15 (IK, s), 7.63 (IH, d, J=8Hz), 7.79 (IH, d, J=8Hz) , 8.12 (IH, s) , 8.14 (IK, br s) (3) Methyl 3-ethyl-2-propionylindole-6-carboxylate (65.7 mg) was prepared from methyl 3-ethyiindole-6-carboxylate (184 mg) and propionyl chloride (0.17 mi) in a similar manner to that of Preparation 1 (5) . NMR (CDCi 3 , δ) : 1.29 (3H, t, J=7Hz) , 1.34 (3H, t, J=7Hz), 3.03 (2H, q, J=7Hz) , 3.14 (2K, q, J=7Hz) , 3.94 (3K, s), 7.73 (IH, d, J=8Hz) , 7.79 (IH, d, J=8Hz), 8.13 (IH, ε), 9.10 (IH, br s) Preparation 8 (1) 3-Isob tyryl-2-propylindole-6-carboxylic acid (853 mg) was prepared from methyl 3-isobutyryl-2-propylinαole-6- carboxylate (935 mg) in a similar manner to that of Example 2. NMR (DM50-d 6 , δ) : 0.95 (3H, t, J=8Hz), 1.14 (6H, d, J=8Hz), 1.72 (2H, sextet, J=8Hz) , .3.08 (2H, t, J=8Hz), 3.46 (IH, septet, J=8Hz) , 7.76 (IH, d, J=9Hz), 7.92 (IH, dd, J=l, 9Hz) , 8.00 (IH, d, J=lHz) (2) 3-Isobutyryl-2-propyIindole-6-carboxamide (853 mg) was prepared from 3-isobutyryl-2-propylindole-6-carboxylic acid (935 mg) in a similar manner to that of Example 6. NMR (DMS0-d 5 , δ) : 0.95 (3H, t, J=8Hz) , 1.15 (6H, d, J=8Hz) , 1.70 (2H, sextet, J=8Hz) , 3.07 (2H, t, J=8HzI , 3.46 (IH, septet, J=8Hz) , 7.26 (IH, br s) , 7. "2 1 IK, d, J=9Hz) , 7.87 (IK, dd, J=l, 9Hz) , BAD ORIGINAL 7 . 94 ( IH, d, J=lHz ) P pnaratinn 9 Methyl 3-benzoyl-2-propylindole-6-carboxylate (289 mg) was prepared from methyl 2-propylindole-6-carboxylate (500 mg) and benzoyl chloride (970 mg) in a similar manner to that of Preparation 1 (5) . NMR (CDCi 3 , δ) : 0.82 (3H, t, J=8Hz), 1.66 (2H, sextet, J=8Hz), 2.78 (2H, t, J=8Hz) , 3.85 (3H, s), 7.29 (IH, d, J=8Hz), 7.49-7.54 (2H, ) , 7.60-7.64 (4H, ) , 8.02 (IH, s) Preparation 10 To a stirred solution of methyl 2-propylindole-6- carboxylate (911 mg) in acetonitrile (15 ml) was added chlorosuifonylisocyanate (0.6 g) in acetonitrile (1.5 ml) at 0°C. The mixture was stirred at 0°C for 30 minutes, then N,N-dimethylformamide (0.35 g in acetonitrile (15 ml) was added at 0°C. The resultant mixture was stirred at 20°C for 40 minutes, and then poured into water. The mixture was extracted with methylene chloride three times, and the combined organic phase was dried over sodium sulfate and evaporated in vacuo. The residue was chromatographed or. silica gel eluting with a mixture of ethyl acetate and hexane (1:3) tc give the crystals which were recrystallized from a mixture of ethyl acetate and hexane tc give methyl 3-cyano-2- propylindoie-6-carboxylate (535 g) as colorless crystals. mp : 148.5-150°C IR (KBr) : 3251, 2218, 1710, 1284, 1218 cm -1 NMR (CDC1 3 , δ) : 1.07 (3K, t, J=7Hz), 1.89 (2H, sextet, J=7Hz), 3.00 (2H, , J= " ?Hz) , 3.99 (3H, s), ^.70 (IH, d, J=7.5Hz), 7.95 (IH, d, J=7.5Hz), 8.19 (IK, s) , 9.05 (IK, br s} MASS (m/z: 243 (M + +l) 76 (bo) ORIGINAL Preparation 11 Methyl 3-acetyl-2-ethylindole-6-carboxylate (106 mg) was prepared from methyl 2-ethylindole-6-carboxylate (237 mg) and acetyl chloride (0.19 ml) in a similar manner to that of Preparation 1 (5) . NMR (CDC1 3 , δ) : 1.42 (3H, t, J=7Hz) , 2.69 (3H, s), 3.27 (2H, q, J=7Hz) , 3.96 (3H, s) , 7.93 (IH, d , J=8Hz), 8.01 (IH, d, J=8Hz), 8.12 (IH, s), 8.93 (IH, br s) Preparation 12 Methyl 2-ethyl-3-isobutyryiindoie-6-carboxylate (200 mg) was prepared from methyl 2-ethylindole-6-carboxylate (317 mg) and isobutyryl chloride (0.36 ml) in a similar manner tc t hat of Preparation 1 (5) . NMR (CDC1 3 , δ) : 1.28 (6K, d, J=7Hz) , 1.38 (3H, t, J=7Hz), 3.25 (2H, q, J=7Hz), 3.51 (IH, m) , 3.94 (3H, s), 7.92 (2H, s) , 8.13 (IH, s), 8.92 (IH, br s) Preparation 13 ( 1 > Methyl 3-benzyloxycarbonyiamino-4- (1-propynyl)benzoate (1.34 g) was prepared from 2-benzyioxycarbonylamino-4- methoxycarbonylphenyl trifluoromethanesulfonate (2.1 g) and tributyl (1-propynyl) stannane (2.49 g) in a similar manner to that of Preparation 1 (2) . NMR (CDC1 3 , δ) : 2.14 (3H, ε), 3.91 (3H, s), 5.24 (2H, s), 7.35-7.50 (6K, ) , 7.65 (IH, d, J=8Hz) , 8.82 (IH, s) !2^ Methyl l-benzyloxycarbonyl-2-methylindole-6-carboxylate (1.2 g) was prepared from methyl 3-benzyloxycarbonylamino-4- (1-propynyl)benzoate (1.32 g) in a similar manner to that of Preparation 1 (3) . NMR (CDCI3, δ) : 2.63 (3H, s), 3.89 (3H, s), 5.50 (2H, s ) , 6 . 38 ( IH, s ) , 7 . 35-7 . 56 ( 6H, m) , 7 . 91 ( IH, d, J=8Hz ) , 8 . 81 ( IH, s ) (3) Methyl 2-methylindole-6-carboxylate (562 mg) was prepared from methyl l-benzyloxycarbonyl-2-methylindole-6- carboxylate (1.18 g) in a similar manner to that of Preparation 1 (4) . NMR (CDC1 3 , δ) : 2.49 (3H, s), 3.92 (3H, s) , 6.28 (IH, s), 7.51 (IH, d, J=8Hz), 7.77 (IH, d, J=8Hz) , 8.03 (IH, s) , 8.12 (IH, br s) (4) Methyl 3-isobutyryl-2-methylindole-6-carboxylate (142 mg) was prepared from methyl 2-methylindole-6-carboxylate (305 mg) and isobutyryl chloride (0.47 ml) in a similar manner to that of Preparation 1 (5) . NMR (CDCI3, δ) : 1.26 (6H, d, J=7Hz), 2.81 (3H, s) , 3.47 (IH, ) , 3.93 (3H, s), 7.92 (IH, d, J=8Hz) , 8.09 (IH, s) , 8.85 (IH, br s) Preparation 14 (1) Methyl 3-benzyIoxycarbonyiamino-4- (3-methoxy-l- propynyl) benzoate (4.23 g) was prepared from 2- benzyloxycarbonylamino-4-methoxycarbonylphenyl trifluoromethanesuifonate (7.73 g) and (3-methoxy-l- propynyl) tributylstannane (6.67 g) in a similar manner to that of Preparation 1 (2) . NMR (CDCI3, δ) : 3.44 (3H, s) , 3.91 (3H- s), 4.38 (2H, s), 5.23 (2K, s) , 7.3-7.5 (7H, m) , 7.69 (IK, c, J=8Hz), 8.82 (IH, s) (2) Methyl l-benzyloxycarbonyi-2-methoxymethylmdole-6- carboxylate (2.14 g) was prepared from methyl 3- benzyloxycarbonyi mino-4- (3-methoxy-1-propynyl ) enzoate (4.23 g) in a similar manner to that of Preparation 1 (3) . NMR (CDC1 3 , δ) : 3.44 (3H, s), 3.88 (3H, s), 4.80 (2H, BAD OHI I.-..- ^ s ) , 5 . 49 ( 2H, s ) , 6 . 70 ( IH, s ) , 7 . 38-7 . 58 ( 6H, m) , 7 . 92 ( IH, d, J=8Hz ) , 8 . 80 ( IK, s ) (3) Methyl 2-methoxymethylindoie-6-carboxylate (0.42 g) was prepared from methyl i-benzyioxycarbonyl-2- methoxymethylindole-6-carboxylate (2.12 g) in a similar manner to that of Preparation I (4) . NMR (CDC1 3 , δ) : 3.41 (3H, s), 3.94 (3H, s), 4.64 (2K, s), 6.47 (IH, s), 7.59 (IH, d, J=8Hz), 7.80 (IK, d, J=8Kz) , 8.11 (IH, s) , 8.59 (IH, br s) (4) Methyl 3-isobutyryl-2-methoxymethyiindoie-6-carboxylate (146 mg) was prepared from methyl 2-mεthoxymethyiindole-6- carboxylate (396 mg) and isobutyryl chloride (0.53 ml) in a similar manner to that of Preparation I (5) . NMR (CDCI3, δ) : 1.26 (6H, d, J=7Hz) , 3.48 (IH, m) , 3.58 (3H, s), 3.94 (3H, s), 5.03 (2H, s) , 7.88 (IH, d, J=8Hz), 7.96 (IK, d, J=8Hz) , 8.18 (IH, s), 9.45 (IH, br s) Preparation 15 (1) To a solution of methyl 2-propylindole-6-carboxylate (300 mg) in dichloromethane (10 mi) was added a 1M solution of tin(IV) chloride in dichloromethane (2.76. l) at 20°C. The mixture was stirred at 2C°C for 30 minutes, then methoxyacetyl chloride (0.25 ml) was added. After stirred at 20°C for 30 minutes, the mixture was partitioned between ethyl acetate and water. The organic layer was washed with water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was chromatographed on silica gel eluting with a mixture of ethyl acetate and hexane (1:10-1:1) to give methyl 3-methoxyacetyl-2-propylindole-6-carboxylate (135 mg) as pale yellow crystals, mp : 12-7-:29°C NMR (CDCl-., δ) : 1.05 (3K, t, J=8Kz) , 1.83 (2H, 1 BAD ORIGINA g sextet, J=8Hz), 3.02 (2H, t, J=8Hz) , 3.57 (3H, s), 3.97 (3H, s), 4.72 (2H, s) , 7.83 (IH, d, J=8Kz) , 7.95 (IH, d, J=8Hz), 8.18 (IH, s), 9.38 (IH, br s) (2) 3-Methoxyacetyl-2-propylindole-6-carboxylic acid (108 mg) was prepared from methyl 3-methoxyacetyl-2-propylindole- 6-carboxyiate (120 mg) in a similar manner to that of Example 2. ? : >250°C NMR (DMS0-d 6 , δ) : 0.97 (3K, t, J=8Hz) , 1.74 (2H, sextet, J=8Hz), 3.09 (2K, t, J=8Hz) , 3.38 (3H, s), 4.61 (2H, s), 7.75 (IK, d, J=8Hz), 7.91 (IH, d, J=8Hz), 8.00 (IH, s) (3) 3-Metr.oxyacetyl-2- p ropylindole-o-carboxamide (89 mg) was prepared from 3-methoxyacetyl-2-propylindole-6-carboxylic acid (95 mg) in a similar manner to that of Example 6. mp : 165-167 °C NMR OMSO-d 6 , δ) : 0.95 (3K, t, J=8Hz) , 1.74 (2H, sextet, J=8Hz) , 3.06 (2H, t, J=8Hz) , 3.38 (3H, s), ^.60 (2H, s), 7.25 (IK, br s) , 7.70 (IK, d, J=8Hz), -.84 (IH, d, J=8Hz), 7.94 (IK, s), 7.97 (IK, br s) Preparation 16 Tc a solution of methyl 2-aminc-3-hydroxybenzoate (882 mg) in pyridine (2 ml) was added acetic anhydride (1.2 ml) and the mixture was stirred at 2C°C for 18 hours. The reaction mixture was diluted with diisopropyl ether, and the resulting solid was collected and washed with diisopropyl ether. The solid was triturated with diisopropyl ether to give methyl 2-acetamido-3-acetoxybenzoate (1.25 g) as solid. NMR (CDC1 3 , δ) : 2.18 (3H, s), 2.26 (3H, s), 3.90 (3H, s\ 7.27 (IH, t, J=8Hz), 7.39 (IH, d, J=8Hz), 7.83 .IK, d, J=8Hz), 9.09 (IK, br s) BAD Om nM/u- vM preparation 17 The following compounds described in (1) to (4) were prepared in a similar manner to that of Preparation 16. (1) Methyl 3-acetamido-4-acetoxybenzoate NMR (CDC1 3 , δ) : 2.21 (3K, s), 2.37 (3H, s), 3.93 (3H, s), 7.22 (IH, d, J=8Hz), 7.83 (IH, d, J=8Kz), 8.22 (IH, s) (2) Methyl 4-acetamido-3-acetoxybenzoate NMR (DMSO-d 6 , δ) : 2.12 (3K, s), 2.33 (3H, s), 3.84 (3K, s), 7.73 (IH, d, J=2Hz), 7.82 (IK, dd, J=2, 8Hz), 8.22 (IH, d, J=8Hz), 9.64 (IH, s) (3) Methyl 3-acetamido-2-acetoxybenzoate NMR (CDCI3, δ) : 2.20 (3H, s) , 2.43 (3H, s), 3.91 (3H, s), 7.29 (IH, t, J=8Hz), 7.74 (IH, d, J=8Hz), 8.51 (IH, d, J=8Hz) (4) Methyl 3-acetamido-4-trifluoro ethanesulfonyloxyphenyl- acetate mp : 68.5-70°C IR (KBr) : 3341, 1727, 1699, 1437, 1425 cm -1 NMR (CDCI3, δ) : 2.24 (3K, s), 3.68 (3H, s), 3.73 (3H, s), 7.11 (IH, dd, J=8, IHz), 7.24-7.30 (2K, ) , 8.19 (IH, s) MASS (m/z) : 354 (M + -I), 149 (bp) Preparation 18 To a solution of methyl 2-acetamido-3-acetoxybenzoate (1.72 g) in methanol (9 ml) was added powdered potassium carbonate (1.4 g) , and the mixture was stirred for 20 minutes. The resulting solid was removed by filtration and washed with methanol. The filtrate was evaporated in vacuo, and the residue was acidified with IN hydrochloric acid and extracted with ethyl acetate. The organic phase was washed with brine, dried over sodium, sulfate and evaporated in vacuo. The residue was triturated with a mixture of isopropyl ether and hexane to give methyl 2-acetamido-3- hydroxybenzoate (1.21 g) as solid. NMR (CDC1 3 , δ) : 2.33 (3K, s), 3.93 (3H, s), 7.14 (IK, t, J=8Hz), 7.23 (IH, d, J=8Hz), 7.61 (IH, d, J=8Hz) , 9.88 (IH, s) Preparation 19 The following compounds described in (1) to (3) were prepared in a similar manner tc that of Preparation 18. (1) Methyl 3-acetamido-4-hydroxybenzoate NMR (DMSO-d 6 , δ) : 2.11 (3H, s) , 3.80 (3H, s), 6.93 (IH, d, J=8Hz), 7.56 (IK, d, J=2Hz) , 8.47 (IH, s), 9.20 (IH, s) (2) Methyl 4-acetamido-3-hydroxybenzoate NMR (DMSO-d 6 , δ) : 2.14 (3H, s) , 3.78 (3H, s), 7.37 (IH, dd, J=2, 8Hz), 7.45 (IH, d, J=2Hz), 8.08 (IH, d, J=8Hz), 9.32 (IH, s) (3) Methyl 3-acetamido-2-hydroxybenzoate NMR (CDC1 3 , δ) : 2.33 (3K, s) , 4.97 (3H, s), 6.90 (IH, t, J=8Hz), 7.56 (IH, d, J=8Hz) , 7.81 (IH, br s), 8.57 (IH, d, J=8Hz) Preparation 20 To a solution of methyl 2-acetamido-3-hydroxybenzoate (1.2 g) in a mixture of pyridine (1.4 ml) and dichloromethane (2 ml) was added slowly trifluoromethanesulfonic anhydride (1.1 ml) at 0°C. When addition was completed, the mixture was stirred at 20°C for 20 minutes. The resulting mixture was poured into ice and extracted with ethyl acetate. The organic phase was washed with IN hydrochloric acid, aqueous sodium bicarbonate and brine, dried over sodium sulfate and evaporated in vacuo. The residue was triturated with a mixture of dichloromethane and hexane to give methyl 2- acetamido-3-trifluoromethanesulfonyloxybenzoate (1.78 g) as solid. NMR (CDC1 3 , δ) : 2.24 (3K, ε), 3.93 (3K, s) , 7.34 (IH, t, J=8Hz), 7.49 (IH, d, J=8Hz) , 7.99 (IH, d, J=8Hz) , 8.90 (IH, br s) Preparation 21 The following compounds described in (1) to (4) were prepared in a similar manner to that of Preparation 20. (1) Methyl 3-acetamido-4-trifluoromethanesulfonyloxybenzoate NMR (CDCI3, δ) : 2.25 (3H, s), 3.93 (3H, s), 7.37 (IH, d, J=8Hz), 7.92 (IK, m) , 8.86 (IH, br s) (2) Methyl 4-acetamido-3-trifiuoromethanesulfonyloxybenzoate NMR (CDCI3, δ) : 2.27 (3K, s) , 3.94 (3H, s) , 7.51 (IH, br s), 7.94 (IH, d, J=2Hz) , 8.05 (IH, dd, J=2, 8Hz), 8.47 (IH, d, J=8Hz) (3) Methyl 3-acetamido-2-trifiuoromethanesulfonyloxybenzoate NMR (CDCi 3 , δ) : 2.23 (3H, s), 3.93 (3H, s), 7.40 (IH, br s), 7.43 (IH, t, J=8Hz), 7.76 (IK, d, J=8Hz), S.39 (IH, d, J=8Hz) (4) Methyl 3-nitro-4-trifIuoromethanesulfonyloxyphenyl- acetate p : 44-45°C IR (KBr) : 1736, 1544, 1434, 1340 cm -1 NMR (CDCI3, δ) : 3.75 (2K, s), 3.76 (3H, s), 7.41 (IH, d, J=6Hz), 7.68 (IH, dd, J=8, IHz), 8.10 (IH, d, BAD ORIGINAL MASS (m/ z ) : 343 (M + ) , 135 (bp ) Preparation 22 The following compounds described in (1) to (3) were prepared from a similar manner to that of Preparation 1 (2) . (1) Methyl 2-acetamido-3- (1-pentynyl)benzoate NMR (CDC1 3 , δ) : 1.06 (3H, t, J=7Hz), 1.64 (2H, m) , 2.20 (3H, s), 2.43 (2H, t, J=7Hz), 3.88 (3H, s), 7.16 (IK, t, J=8Hz), 7.57 (IH, d, J=8Hz) , 7.76 (IH, d, J=8Hz) , 8.42 (IH, br s) (2) Methyl 4-acetamido-3- (1-pentynyl)benzoate NMR (CDC1 3 , δ) : 1.11 (3K, t, J=8Hz), 1.68 (2H, sextet, J=8Hz) , 2.24 (3H, s), 2.52 (2H, t, J=8Hz) , 3.89 (3H, s), 7.94 (IK, dd, J=l, 8Hz) , 8.07 (IH, d, J=lHz), 8.12 (IH, br s), 8.48 (IH, d, J=8Hz) (3) Methyl 3-acetamido-2- (1-pentynyl)benzoate NMR (CDC1 3 , δ) : 1.12 (3H, t, J=7Hz), 1.73 (2H, m) , 2.22 (3H, s), 2.59 (2K, t, J=7Kz), 3.91 (3H, s), 7 .32 (IK, t, J=8Hz), 7.63 (IK, d, J=8Hz), 8.29 (IK, or s) , 8.62 (IK, d, J=8Kz) Preparation 23 A mixture of methyl 3-acetam do-4-trifluoromethane- sulfonyioxybenzoate (1.43 g) , methyl 5-hexynoate (582 mg) , palladiu (ID chloride (14.9 mg) , triphenylphosphine (43.8 mg) and copper (I) chloride (32 mg) in diethylamine (18 ml) was stirred at 20°C for 14 hours. The solvent was evaporated in vacuo and the residue was chromatographed on silica gel eluting w th a mixture of hexane and ethyl acetate (1:2) to give methyl 3-acetamιdo-4- (5-methoxycarbon-yl-l-pentynyl) - benzoate (1.15 g) as colorless crystals. NMR !CDCi 3 , δ) : 2.02 (2K, _r. » , 2.27 (3H, s), 2.53 (2H, t, J=7Hz), 2.63 (2H, t, J=7Hz), 3.68 (3H, s), 3.90 (3H, s), 7.41 (IH, d, J=8Hz) , 7.70 (IH, d, J=8Hz) , 8.00 (IH, br s) , 8.98 (IH, br s) Reparation 24 The following compounds described in (1) to (3) were prepared in a similar manner to that of Preparation 23. (1) Methyl 3-acetamido-4- (1-pentynyl) benzoate NMR (CDC1 3 , δ) : 1.12 (3H, t, J=7Hz) , 1.65 (2H, m) , 2.23 (3K, s), 2.54 (2K, t, J=7Hz), 3.90 (3H, s), 7.43 (IH, dd, J=l, 8Hz) , 7.7C (IH, ) , 7.95 (IK, br s), 8.98 (IH, br s) (2) Methyl 3-acetamido-4- (4-methoxycarbonyl-l- butynyl)benzoate NMR (CDC1 3 , δ) : 2.32 (3H, s), 2.68 (2H, m) , 2.80 (2H, m) , 3.73 (3H, ε) , 3.89 (3H, s), 7.38 (IH, d, J=8Hz), 7.67 (IH, m) , 8.28 (IH, br s), 9.04 (IH, br s) (3) Methyl 3-acetamido-4- (1-pentynyl) henylacetate mp : 77-78°C IR (K3r) : 3293, 1739, 1699, 1665, 1428 cm -1 NMR (CDC1 3 , δ) : 1.09 (3H, t, J=7Hz) , 1.69 (2H, sextet, J=7Hz), 2.22 (3K, s) , 2.49 (2H, t, J=7Hz), 3.64 (2K, ε), 3.70 (3K, s), 6.94 (IH, d, J=7.5Hz), 7.31 (IH, d, J=7.5Hz), 7.93 (IK, br ε), 8.33 (IH, s) MASS (m/z) : 274 (M + +l, bp) Preparation 25 The following compoundε deεcribed in (1) to (7) were prepared in a similar manner to that of Preparation 1 (3 ) . BAD ORIGINAL g (1) Methyl l-acetyl-2- (3-methoxycarbonylpropyl) indole-6- carboxylate NMR (CDC1 3 , δ) : 2.08 (2K, m) , 2.43 (2H, t, J=7Hz) , 2.86 (3H, ε), 3.12 (2H, t, J=7Hz) , 3.67 (3H, ε) , 3.94 (3H, ε), 6.49 (IK, s) , 7.52 (IH, d, J=8Hz) , 7.93 (IH, d, J=8Hz) , 8.47 (IH, s) (2) Methyl l-acetyl-2-propyiindole-7-carboxylate NMR (CDCI3, δ) : 1.04 (3H, t, J=7Hz) , 1.78 (2K, m) , 2.39 (3H, s), 2.79 (2K, m) , 3.91 (3H, s), 6.38 (IH, m) , 7.23 (IH, t, J=8Hz) , 7.68 (IH, d, J=8Hz) , 7.79 (IH, d, J=8Hz) (3) Methyl l-acetyl-2-propyIindole-6-carboxylate NMR (CDC1 3 , δ) : 1.06 (3K, t, J=7Hz), 1.77 ( 2H, m) , 2.82 (3K, s), 3.03 (2H, t, J=8Hz) , 3.94 (3H, ε), 6.47 (IH, ε), 7.49 (IK, d, J=8Hz) , 7.94 (IH, d, J=8Hz), 8.53 (IH, s) (4) Methyl l-acetyl-2-propyIindole-5-carboxylate NMR {CDCI3, δ) : 1.05 (3K, t, J=8Hz) , 1.75 (2H, sextet, J=8Hz), 2.76 (3K, s), 2.98 (2K, t, J=8Hz) , 3.94 (3H, s), 6.48 (IK, d, J=lHz), 7.87 (IH, d, J=8Hz) , 7.95 (IH, d, J=8Hz), 8.18 .(IK, s) (5) Methyl I-acetyl-2-propyiindole-4-carboxylate NMR (CDCI3, δ) : 1.07 (3H, t, J=7Hz) , 1.80 (2H, m) , 2.76 (3K, ε), 3.01 (2K, t, J=7Hz), 3.97 (3H, ε) , 7.18 (IK, ε), 7.28 (IK, t, J=8Hz), 8.06 (IH, d, J=8Hz) , 8.15 (IK, d, J=8Hz) (6) Methyl l-acetyl-2- (2-methoxycarbonylethyl) indole-6- carboxylate NMR (CDCI3, δ) : 2.78 (2K, t, J=7Hz), 2.87 (3H, ε) , 3.39 (2H, t, J=7Hz) , 3.68 (3H, s), 3.94 (3K, ε) , BADOh._.... 6 . 49 ( IH, s ) , 7 . 52 ( IH, d, J=8Hz ) , 7 . 93 ( IH, d, J=8Hz ) , 8 . 46 ( IH, s ) (7) Methyl l-acetyl-2-propylindol-6-ylacetate mp : 85-87°C IR (KBr) : 1736, 1700, 1376, 1320, 1303 cm "1 NMR (CDCI 3 , δ) : 1.04 (3H, t, J=7Hz) , 1.74 (2H, sextet, J=7Hz), 2.75 (3H, s) , 2.96 (2H, t, J=7Hz) , 3.70 (2H, ε), 3.75 (3H, ε) , 6.40 (IH, s) , 7.14 (IH, d, J=8Hz), 7.43 (IH, d, J=8Hz) , 7.81 (IH, s) MASS (m/z) : 274 (M + +l), 74 (bp) Preparation 26 To a εolution of methyl l-acetyl-2- (3- methoxycarbonyipropyl) indole-6-carboxylate (2.34 g) in methanol (20 ml) waε added powdered potaεεium carbonate (1.04 g) , and the mixture waε εtirred under reflux for 10 minuteε. The resulting mixture was evaporated in vacuo and the residue was acidified with IN hydrochloric acid and extracted with chloroform. The organic phase was washed with aqueous sodium bicarbonate and brine, dried over sodium sulfate and then evaporated in vacuo. The residue was triturated with ether to give methyl 2- (3-methoxycarbonylpropyl) indole-6- carboxylate (1.23 g) as solid. NMR (CDC1 3 , δ) : 2.07 (2H, m) , 2.42 (2H, t, J=7Hz) , 2.84 (2H, t, J=7Hz), 3.68 (3H, s) , 3.92 (3H, s), 6.31 (IH, ε), 7.52 (IH, d, J=8Hz) , 7.78 (IK, d, J=8Hz), 8.07 (IH, s), 8.39 (IH, br s) Preparation 27 The following compounds described in (1) to (5) were prepared in a similar manner to that of Preparation 26. (1) Methyl 2-propylindole-7-carboxylate NMR (CDC!-,, δ) : 1.02 (3H, t, J=7Hz), 1.78 (2H, m) , BAD ORIGINAL 2.78 (2K, t, J=7Hz) , 3.98 (3H, s), 6.28 (IH, m) , 7.09 (IH, t, J=8Hz) , 7.72 (IH, d, J=8Hz) , 7.79 (IH, d, J=8Hz) , 9.58 (IK, br s) (2) Methyl 2-propyIindole-c-carboxylate (3) Methyl 2-propyIindole-5-carboxylate NMR !CDCi 3 , δ) : 1.02 (3H, t, J=8Hz), 1.76 (2H, sextet, J=8Hz), 2.74 (2H, t, J=8Hz) , 3.92 (3H, s), 6.33 (IH, d, J=lHz), 7.28 (IH, d, J=8Hz), 7.73 (IK, d, J=8Hz), 8.10 (IH, br s), 8.28 (IH, s) (4) Methyl 2-propylindole-4-carboxylate NMR (CDC1 3 , δ) : 1.03 (3H, t, J=7Kz), 1.80 (2H, m) , 2.78 (2H, ) , 3.98 (3K, ε), 6.89 (IH, s), 7.14 (IK, t, J=8Hz), 7.48 (IH, d, J=8Hz) , 7.84 (IH, d, J=8Hz) , 8.08 (IH, br sS (5) Methyl 2- (2-methoxycarbonylethyl) indole-6-carboxyiate NMR {CDCI3, δ) : 2.78 (2H, ) , 3.10 (2H, m) , 3.73 (3K, ε), 3.93 (3H, s) , 6.3C (IK, s), 7.53 (IH, d, J=8Hz), 7.76 (IK, d, J=SKz), 8.08 (IK, ε), 8.88 (IK, br ε) Preparation 28 The following compounds described in (I) tc (19) were prepared in a similar manner to that of Preparation 1 (5) . (1; Methyl 3-isobutyryl-2-propylmdole-7-carboxylate NMR ;CDC1 3 , δ) : 1.04 (3H, t, J=7Hz) , 1.27 (6H, d, -=7Hz), 1.82 (2H, ) , 3.26 (2H, m) , 3.47 (IH, ) , 3.99 (3H, ε), 7.28 (IK, t, J=8Hz), 7.85 (IH, d, J=8Hz), 8.18 (IH, s) (2) Methyl 3-iεobutyryl-2-propylir.doie-5-carboxylate r NMR (CDCI3, δ) : 1.04 (3H, t, J=8Hz) , 1.28 (6H, d, J=8Hz), 1.78 (2H, sextet, J=8Hz) , 3.15 (2H, t, J=8Hz), 3.56 (IH, septet, J=8Hz) , 3.96 (3H, s) , 7.37 (IH, d, J=lHz), 7.93 (IH, dd, J=l, 8Hz) , 8.66 (IH, d, J=8Hz), 8.75 (IH, br s) (3) Methyl 3- (3-methoxycarbonylpronanoyl) indole-6- carboxylate NMR (DMSO-d 6 , δ) : 2.65 (2H, t, J=7Hz) , 3.22 (2H, t, J=7Hz), 3.59 (3H, s) , 3.87 (3H, s) , 7.80 (IH, d, J=8Hz), 8.10 (IH, s), 8.23 (IH, d, J=8Hz) , 8.59 (IH, s) (4) Methyl 3-acetyl-2-methylindole-6-carboxylate NMR (CDC1 3 , δ) : 2.54 (3H, s) , 2.73 (3H, s) , 3.86 (3H, s), 7.76 (IH, d, J=8Hz), 7.97 (IH, s) , 8.12 (IH, d, J=8Hz) (5) Methyl 2-methyl-3-propionylindole-6-carboxylate NMR (CDC1 3 , δ) : 1.12 (3H, t, J=7Hz) , 2.72 (3H, s) , 2.92 (2H, q, J=7Hz) , 3.86 (3H, s) , 7.75 (IH, d, J=8Hz), 7.96 (IH, s) , 8.11 (IH, d, J=8Hz) (6) Methyl 3- (3, 3-dimethylbutanoyl) indole-6rcarboxylate NMR (CDC1 3 , δ) : 1.11 (9H, m) , 2.33 (2H, s) , 3.94 (3H, s), 7.92-8.0 (2H, m) , 8.19 (IH, s) , 8.52 (IH, d, J=8Hz) , 8.90 (IH, br s) (7) Ethyl 3-isobutyryl-2-propylindol-6-ylacetate IR (Neat) : 3300, 1740, 1625 cm -1 NMR (CDC1 3 , δ) : 1.04 (3H, t, J=7Hz) , 1.25 (6H, d, J=7Hz), 1.26 (3H, t, J=7Hz) , 1.77 (2H, sextet, J=7Hz), 3.12 (2H, t, J=7Hz) , 3.41-3.55 (IH, m) , 3.72 (2H, s), 4.16 (2H, q, J=7Hz) , 7.17 (IH, d, J=7.5Hz), 7.30 (IH, ε), 7.82 (IH, d, J=7.5Hz), 8.40 (IH, br ε) MASS (m/z) : 316 (M + +l), 74 (bp) (8) Methyl 3-isobutyryl-2-propylindol-6-ylacetate IR (Neat) : 3290, ' 1730, 1625 cm -1 NMR (CDC1 3 , δ) : 1.03 (3H, t, J=7Hz) , 1.26 (6H, d, J=7Hz), 1.76 (2H, sextet, J=7Hz) , 3.12 (2H, t, J=7Hz), 3.41-3.54 (IH, ) , 3.71 (2H, ε), 3.75 (3H, ε), 7.16 (IH, d, J=7.5Hz), 7.30 (IH, ε), 7.83 (IH, d, J=7.5Hz), 8.40 (IH, br s) MASS (m/z) : 302 (M + +l, bp) (9) Methyl 2-acetyl-3-methylindole-6-carboxylate NMR (CDC1 3 , δ) : 2.66 (3H, ε), 2.67 (3H, ε), 3.94 (3H, ε), 7.72 (IH, d, J=8Hz) , 7.81 (IH, d, J=8Hz) , 8.11 (IH, s) , 9.09 (IH, br s) (10) Methyl 3-propionylindole-6-carboxylate NMR (CDC1 3 , δ) : 1.12 (3H, t, J=7Hz) , 2.89 (2H, q, J=7Hz), 3.87 (3H, s) , 7.79 (IH, d, J=8Hz) , 8.11 (IH, s), 8.28 (IH, d, J=8Hz) , 8.53 (IH, ε) (11) Methyl 2-propionyl-3-propylindole-6-carboxylate NMR (CDC1 3 , δ) : 1.06 (3H, t, J=7Hz), .1.29 (3H, t, J=7Hz), 1.74 (2H, m) , 2.95-3.13 (4H, m) , 3.94 (3H, s), 7.72 (IH, d, J=8Hz), 7.79 (IH, d, J=8Hz), 8.12 (IK, s) , 9.11 (IH, br ε) (12) Methyl 2-iεobutyryl-3-propylindole-6-carboxylate NMR (CDC1 3 , δ) : 1.04 (3H, t, J=7Hz) , 1.29 (6H, t, J=7Hz), 1.76 (2H, m) , 3.09 (2H, ) , 3.44 (IH, m) , 3.94 (3H, ε), 7.71 (IH, d, J=8Hz) , 7.79 (IH, d, J=8Hz), 8.12 (IH, ε), 9.12 (IH, br s) (13) Methyl 3-cyclopropanecarbonyl-2-propylindole-6- 'BAD ORIGIN £ carboxylate mp : 152.5-l54 β C IR (KBr) : 3371, 1687, 1623, 1458 cm -1 NMR (CDC1 3 , δ) : 1.00-1.09 (2H, m) , 1.02 (3H, t, J=7Hz), 1.28-1.32 (2H, m) , 1.82 (2H, sextet, J=7Hz), 2.56-2.65 (IH, m) , 3.15 (2H, t, J=7Hz), 3.96 (3K, s), 8.00 (2K, AB, J=8, 8Hz) , 8.15 (IH, s) , 8.89 (IK, br s) MASS (m/z) : 286 (M + ÷l, bp) (14) Methyl 3-cyclobutanecarbonyl-2-propylindole-6- carboxylate mp : 159-160 β C IR (KBr) : 1692, 1645, 1623 cm -1 NMR (CDC1 3 , δ) : 1.06 (3K, t, J=7Hz) , 1.83 (2H, sextet, J=7Hz), 1.93-2.13 (2H, m) , 2.30-2.51 (4H, m) , 3.20 (2H, t, J=7Hz) , 3.95 (3H, s), 3.99 (IH, quintet, J=7Hz), 7.93 (2K, ε), 8.15 (IH, ε) , 9.08 (IH, br s) MASS (m/z) : 300 (M + +l), 74 (bp) (15) Methyl 3-cycIopentanecarbonyl-2-propylindole-6- carboxylate mp : 137-139°C IR (KBr) : 1692, 1647, 1624 cm -1 NMR (CDC1 3 , δ) : 1.02 (3H, t, J=7Hz) , 1.64-1.82 (6H, m) , 1.94-2.05 (4H, m) , 3.17 (2H, t, J=7Hz) , 3.72 (IK, quintet, J=7Kz) , 3.95 (3H, s) , 7.93 (2H, ABX, J=8, 8, 1Hz), 8.15 (IH, d, J=lHz) , 9.19 (IH, ε) MASS (m/z) : 314 (M + +l, bp) (16) Methyl 3-cyclohexanecarbonyl-2-propylindole-6- carboxylate mp : 136-137°C IR (KBr) : 1691, 1651, 1487, 1435 cm -1 BAD OORRI.SAN : fi NMR (CDCI3, δ) : 1.03 (3H, t, J=7Hz), 1.25-2.04 (12H, ) , 3.14-3.25 (IH, m) , 3.18 (2H, t, J=7Hz) , 3.97 (3H, s), 7.90 (2H, q, J=7.5Hz), 8.17 (IH, s) , 9.16 (IH, br s) MASS (m/z) : 328 (M + +l), 74 (bp) (17) Methyl 3- (3-methyl-2-butenoyl) -2-propylindole-6- carboxylate mp : 146-147°C IR (KBr) : 1715, 1464, 1433, 1220 cm -1 NMR {CDCI3, δ) : 1.05 (3H, t, J=7Hz), 1.82 (2H, sextet, J=7Hz), 2.05 (3K, s), 2.20 (3H, s) , 3.18 (2H, t, J=7Hz), 3.94 (3H, s) , 6.63 (IH, ε) , 7.95 (2H, AB, J=7.5, 7.5Hz), 8.11 (IK, s), 8.88 (IH, br s) MASS (m/z) : 300 (M + +I), 74 (bp) (18) Methyl 3-crotonoyl-2-propylindole-6-carboxylate mp : 153-154 β C IR (KBr) : 1715, 1650, 1583, 1567, 1459, 1432 cm -1 NMR {CDCI3, δ) : 1.05 (3H, t, J=7Hz) , 1.83 (2H, εextet, J=7Hz) , 2.04 (3H, dd, J=7, 1Hz) , 3.15 (2K, t, J=7Hz), 3.96 (3H, s), 6.89 (IH, dd, J=15, 1Hz) , 7.04 (IH, dd, J=15, 7Hz), 7.94 (2H, dq, J=7, 1Hz) , 8.12 (IH, s), 8.99 (IH, br s) MASS (m/z) : 286 (M + +l) (19) 3-Acetyl-6-chloroindole NMR (CDCi 3 , δ) : 2.44 (3H, s), 7.19 (IH, d, J=8Hz) , 7.51 (IH, s), 8.14 (IH, d, J=8Hz) , 8.35 (IH, s) Preparation 29 The following compounds described in (1) to (3) were prepared in a εimilar manner to that of Preparation 6 (2) . BAD ORIGINAL ; '' ( 1 ) Methyl 3- ( 3-methoxycarbonylpropyl) indole-6-carboxylate NMR (CDC1 3 - δ) : 2.04 (2H, m) , 2.37 (2H, t, J=7Hz) , 2.81 (2H, t, J=7Hz), 3.64 (3H, s), 3.93 (3H, s), 7.16 (IH, s), 7.61 (IH, d, J=8Hz , 7.79 (IH, d, J=8Hz), 8.10 (IH, s), 8.22 (IH, br s) (2) Methyl 3-methylindole-6-carboxylate NMR (CDCI3, δ) : 2.33 (3K, s), 3.93 (3H, s) , 7.12 (IH, s), 7.59 (IH, d, J=8Hz), 7.80 (IH, d, J=8Hz) , 8.09 (IH, s) , 8.10 (IH, br s) (3) Methyl 3-propylindole-€-carboxylate NMR {CDCI3, δ) : 1.00 (3H, t, J=7Hz), 1.74 (2H, m) , 2.73 (2H, t, J=7Hz), 3.93 (3H, ε), 7.14 (IH, d, J=lKz), 7.60 (IH, d, J=8Hz) , 7.79 (IH, d, J=8Hz) , 8.10 (IH, s) , 8.18 (IH, br s) Preparation 30 To a solution of methyl 3- (3-methoxycarbonylpropyl) - indole-6-carboxylate (656 mg) in methanol (24 ml) was added IN aqueous sodium hydroxide (2.46 ml), and the mixture was stirred at 20°C for 2 days. The resulting mixture was evaporated in vacuo, and the residue was acidified with IN hydrochloric acid (2.-5 ml) and extracted with ethyl acetate. The organic phase was washed with brine, dried over εodium sulfate and evaporated in vacuo. The residue was triturated with ether to give methyl 3- (3-carboxypropyl) indole-6- carboxylate (486 mg) as solid. NMR (CDC1 3 , δ) : 2.03 (2H, m) , 2.37 (2H, m) , 2.80 (2H, ) , 3.93 (3H, s) , 7.17 (IH, ε), 7.59 (IH, d, J=8Hz), 7.74 (IH, d, J=8Hz) , 8.09 (IH, s) Preparation 31 A mixture of methyl 3- (3-carboxypropyi) indole-6- carboxylate (173 mg) , triphenylphosphine (191 mg) and carbon tetrachloride (1.0 ml) in 1,2-dichloroethane (10 ml) was heated at 80°C for 2 hours. The resulting mixture was diluted with chloroform and washed with water, aqueous sodium bicarbonate and brine. The organic phase waε dried over sodium sulfate and evaporated in vacuo. The residue was purified by silica gel thin layer chromatography with a mixture of hexane and ethyl acetate (4:1) and recrystallized from a mixture of hexane and ethyl acetate to give methyl 8- oxo-5, 6, 7, 8-tetrahydrocarbazole-2-carboxylate (72.2 mg) aε colorleεε crystals. NMR (CDC1 3 - δ) : 2.29 (2H, m) , 2.69 (2H, t, J=7Hz) , 3.03 (2H, t, J=7Hz), 3.94 (3H, s), 7.69 (IH, d, J=8Hz), 7.82 (IH, d, J=8Hz), 8.16 (IH, ε), 8.95 (IH, br ε) Preparation 32 To a stirred mixture of methyl (E)-4-[2- (dimethylamino)vinyl]-3-nitrobenzoate (500 mg) , which was prepared by the method of Brown et al. described in Journal of Medicinal Chemistry, vol. 35, page 2419 (1992), and pyridine (0.16 ml) in tetrahydrofuran (3 ml) was added butyryl chloride (0.21 ml) at 20°C. The reaction mixture was stirred at 40°C for 24 hours and 50°C for 4 hours. After cooled to 20°C the reaction mixture was diluted with water and extracted with ethyl acetate. The organic phase was washed with water and brine, dried over magnesium εulfate and evaporated in vacuo. The residue was chromatographed on silica gel eluting with a mixture of ethyl acetate and hexane (1:1) to give methyl 4- (l-dimethylaminomethylene-2- oxopentyl)-3-nitrobenzoate (426 mg) as colorless amorphous. NMR (CDCI3, δ) : 0.89 (3H, t, J=7Hz), 1.52-1.65 (2H, m), 2.30 (2H, t, J=7Hz) , 2.78 (6H, ε), 3.99 (3H, ε), 7.34 (IH, d, J=7.5Hz), 7.56 (IH, ε), 8.18 (IH, dd, J=7.5, 1Hz), 8.51 (IH, d, J=lHz) MASS (m/z) : 321 (M + +l) 'BAD ORIGIN*. ^ Preparation 33 A solution of methyl 4- (i-dimethyiaminomethylene-2- oxopentyl) -3-nitrobenzoate (172 g) in dioxane (9 ml) was refluxed for 4 days. The resulting mixture was evaporated in vacuo, and the residue was purified by thin layer chromatography with a mixture of hexane and ethyl acetate (2:1) to give methyl 3-nitro-4- (2-oxopentyl)benzoate (127 mg) . NMR (CDC1 3 , δ) : 0.97 (3H, t, J=7Hz) , 1.69 (2H, ) , ' 2.60 (2H, t, J=7Hz), 3.95 (3H, s) , 4.16 (2H, s), 7.36 (IH, d, J=8Hz), 8.22 (IH, d, J=8Hz) , 8.73 (IH, s) Preparation 34 To a solution of methyl 3-nitro-4- (2-oxopentyl) enzoate (114 mg) in a mixture of tetrahydrofuran (1.5 ml), ethanol (1.5 ml) and water (2.1 ml) was added sodium hydrosulfite (3.0 g) , and the mixture waε stirred under reflux for 30 minutes. The resulting mixture was evaporated in vacuo, and the residue was diluted with ethyl acetate. The organic phase was washed with water and brine, dried over sodium sulfate and evaporated in vacuo. The residue was purified by thin layer chromatography with a mixture of hexane and ethyl acetate (2:1) to give methyl 2-propylindoie-6-carboxylate (54.6 mg) . Preparation 35 To a stirred solution of 3-isobutyryl-2-propylindole-6- carboxylic acid (331 mg) in tetrahydrofuran (5 ml) were added bεnzylalcohol (1.25 ml), dicyclohexylcarbodiimide (303 mg) and 4-dimethylaminopyridine (20 mg) at 20°C. The reaction mixture waε stirred at 20°C for 8 hours. The precipitated urea waε filtered off and the filtrate was evaporated in vacuo. The residue was extracted with ethyl acetate and the extract was washed witn water two times and brine. The organic phase was dried over εodium εulfate and evaporated in vacuo. The residue was chromatographed on silica gel eluting with a mixture of ethyl acetate and hexane (1:4) to give the crystalε which were recryεtallized from a mixture of ethyl acetate and hexane to give benzyl 3-isobutyryl-2- propylindole-6-carboxylate (215 mg) as colorless crystals, p : 102-104°C IR (KBr) : 1700, 1655 cm -1 NMR (CDCI3, δ) : 1.05 (3K, t, J=7Hz), 1.28 (6K, t, J=7H∑), 1.73-1.87 (2K, m) , 3.17 (2H, t, J=7Hz) , 3.45-3.53 (IH, m) , 5.40 (2H, s), 7.32-7.50 (5K, m) , 7.95 (2K, A3, J=9, 8Kz), 8.14 (IH, ε), 8.59 (IH, br s) MASS (m/z) : 364 (M τ +1), 76 (bp) Preparation 36 The following compound was prepared in a similar manner to that of Example 32. Methyl 3-formylindoIe-6-carboxylate NMR (CDC1 3 , δ) : 3.88 (3K, s), 7.83 (IK, dd, J=l, 8Hz), 8.12 (IH, ε), 6.16 (IH, d, J=8Hz), 8.49 (IH, s) , 12.45 (IH, br s) Preparation 37 To a solution of methyl 3-isobutyryl-2-propylindole-6- carboxylate (201 mg) in carbon tetrachloride (7 ml) was added N-bromoεuccinimide (157 mg) and 2,2'-azobis (4-methoxy-2,4- dimethyivaleronitrile; (20 mg) and refluxed for 30 minutes. The resulting mixture was filtered and the filtrate was evaporated in vacuo. The residue was purified by preparative thin layer chromatography on silica gel eluting with a mixture of hexane and ethyl acetate (2:1) to give methyl 2- (1-bromopropyl) -3-iεobutyrylindole-6-carboxylate (179 mg) . Thiε compound waε used immediately without purification. Preparation 38 To a solution of methyl 2- (1-bromopropyl)-3- isobutyrylindole-6-carboxylate (179 mg) in 1,2-dichloroethane (8 ml) waε added N,N-diiεopropylethylamine (0.24 ml) and refluxed for 40 minutes. The resulting mixture waε evaporated in vacuo, then the reεidue waε diluted with ethyl acetate and waεhed with diluted hydrochloric acid, water and brine. The organic phaεe was dried over sodium sulfate and evaporated in vacuo. Trituration with diethyl ether g_.ve methyl 3-isobutyryl-2- (1-propenyl) indole-6-carboxylate (55.2 mg) . NMR (CDCI 3 , δ) : 1.27 (6H, d, J=7Hz), 2.01 (3H, d, J=7Kz), 3.47 (IH, m) , 3.93 (3H, ε), 6.44 (IH, m) , 7.32 (IH, d, J=16Hz), 7.89 (IH, d, J=8Hz), 7.94 (IH, d, J=8Hz), 8.11 (IH, s) , 8.94 (IH, br s) Preparation 39 To a solution of methyl 2- (1-bromopropyl)-3- iεobutyrylindole-6-carboxylate (323 mg) in acetic acid (3 ml) was added potasεium acetate (345 mg) and the mixture was stirred at 6C°C for 2 hours. The resulting mixture waε evaporated in vacuo, then the residue was diluted with ethyl acetate and washed with water, aσueous sodium bicarbonate and brine. The organic phaεe was dried over sodium sulfate and evaporated in vacuo. The residue was purified by preparative thin layer chromatography on silica gel eluting with a mixture of hexane and ethyl acetate (2:1) to give methyl 2- (i-acetoxypropyl)-3-isobutyrylindole-6-carboxylate (207 mg) . NMR (CDC1 3 , δ) : 0.99 (3H, t, J=7Hz) , 1.23 (3H, d, J=7Kz), 1.29 (3H, d, J=7Hz), 1.94 (IH, m) , 2.08 (IK, m) , 2.18 (3H, s), 3.52 (IH, m) , 3.94 (3H, ε), 6.6" (IH, m), 7.88 (IH, d, J=8Hz) , 7.94 (IH, d, J=8:-:z;, 8.18 (IK, ε), 9.09 (IK, br ε) * A- ,. preparation 40 To a mixture of methyl 2-propylindole-6-carboxylate (10 g) , methoxyacetic acid (4.6 ml) and carbontetrachloride (13.4 ml) in 1,2-dichloroethane (45 ml) was added slowly triphenylphosphine (16.7 g) in 1,2-dichloroethane (30 ml) over 1 hour under reflux, and the resulting mixture was heated under reflux for additional 8 hours. After evaporation of solvent, the residue was chromatographed on εilica gel eluting with a mixture of hexane and ethyl acetate (1:1) and triturated with diethyl ether to give methyl 3-methoxyacetyl-2-propylindole-6-carboxylate (8.11 g) . Preparation 41 The following compound was prepared in a similar manner to that of Preparation 15 (1) . Methyl 3-ethoxyacety1-2-propylindole-6-carboxylate NMR (CDC1 3 , δ) : 1.05 (3H, t, J=7Hz), 1.32 (3H, t, J=7Hz), 1.84 (2H, sextet, J=8Hz) , 3.22 (2H, t, J=7Hz), 3.74 (3H, q, J=7Hz), 3.97 (3H, s), 4.75 (2H, ε), 7.83 (IH, d, J=8Hz) , 7.94 (IH, d, J=8Hz) , 8.15 (IH, ε) , 9.27 (IH, br ε) Preparation 42 To a stirred mixture of methyl 4-hydroxyphenylacetate (10.0 g) in acetic acid (55 ml) was added nitric acid (22.1 ml) at 0°C. The reaction mixture was stirred at 0°C for 2 hours. After warmed to 20°C, the reaction mixture was diluted with water (200 ml) and precipitated crystalε were collected. The cryεtalε were diεεolved in chloroform, and the εolution waε washed with water, dried over magnesium sulfate and evaporated in vacuo. The residue was recrystallized from a mixture of chloroform and hexane to give methyl 4-hydroxy-3-nitrophenylacetate (9.3 g) as yellow crystalε. mp : 64-69 β C IR (KBr) : 1734, 1540, 1534, 1263, 1170 cm -1 NMR (CDC1 3 , δ) : 3.64 (2H, ε), 3.73 (3H, ε) , 7.14 (IH, d, J=8Hz), 7.52 (IH, dd, J=8, 1Hz) , 8.02 (IH, d, J=lHz) MASS (m/z) : 210 (M + -l) Iron powder (2.5 g) waε added to a εtirred mixture of methyl 3-nitro-4-trifluoromethaneεuIfonyloxyphenylacetate (2.97 g) and cone, hydrochloric acid (7.3 ml) in methanol (22 ml) at 0°C in εome εmali portion. The reaction mixture waε εtirred at 20°C for 2 hours, then poured into a mixture of ethyl acetate and saturated sodium bicarbonate. The organic phase was waεhed with saturated sodium, bicarbonate and brine, dried over sodium sulfate and evaporated in vacuo. The residue was chromatographed on silica gel eluting with a mixture of ethyl acetate and hexane (1:4) to give methyl 3-amino-4-trifluoromethanesulfonyloxyphenylacetate (2.34 g) aε colorless crystals, mp : 66-69°C NMR (CDC1-5- δ) : 3.57 (2H, s), 3.71 (3H, ε), 3.94 (2H, ε), 6.67 (IH, dd, J=7.5, lHz) , 6.79 (IH, d, J=lHz) , 7.11 (IH, d, J=7.5Hz) Preparation 44 The following compounds were prepared from methyl I-acetyl-2-propylindol-6-ylacetate in a similar manner to that of Preparation 26. Methyl 2-propylindol-6-ylacetate IR (Neat) : 3400, 1740 cm "1 NMR (CDC1 3 , δ) : 1.00 (3H, t, J=7Hz), 1.75 (2H, sextet, J=7Hz), 2.72 (2K, t, J=7Hz) , 3.70 (3H, s) , 3.72 (2H, ε), 6.22 (IK, s), 6.99 (IK, d, J=7.5Hz), 7 . 22 ( IH, ε ) , 7 . 47 ( IH, d, J=7 . 5Hz ) , 7 . 83 ( IH, br s ) MASS (m/ z ) : 232 (M τ + 1 ) , 74 (bp ) Ethyl 2-propylindol-6-yiacetate IR (Neat) : 3400, 1735 cm -1 NMR (CDC1 3 , δ) : 1.00 (3H, t, J=7Hz), 1.05 (3H, t, J=7Hz), 1.74 (2H, sextet, J=7Hz) , 2.72 (2H, t, J=7Hz), 3.69 (3H, s), 4.13 (2H, q, J=7Kz) , 6.20 (IH, ε), 6.99 (IH, d, J=7.5Hz), 7.23 (IH, s) , 7.46 (IH, d, J=7.5Hz), 7.83 (IK, br ε) MASS (m/z) : 346 (M + +l), 74 (bp) 2-Propylindol-6-ylacetic acid mp : 35-87°C IR (KBr) : 3381, 1701, 1691 cm -1 NMR (CDC1 3 , δ) : 1.00 (3H, t, J=7Hz) , 1.73 (2H, εextet, J=7Hz) , 2.72 (2H, t, J=7Hz) , 3.73 (2H, ε), 6.21 (IH, ε), 6.98 (IH, d, J=7.5Hz), 7.21 (IH, ε), 7.48 (IH, d, J=7.5Hz), 7.83 (IH, br ε) MASS (m/z) : 216 (M + -i, bp) Preparation 45 To a stirred solution of methyl 3-ethylindole-6- carboxylate (138 mg) in dichloromethane (5 ml) was added sulfuryl chloride (0.066 ml), and the mixture was stirred at 20°C for 1 hour. The resulting mixture was poured into ice and extracted with ethyl acetate. The combined organic phaεe was washed with aσueous sodium bicarbonate and brine, then dried over εodium εulfate and evaporated in vacuo. The reεidue waε chromatographed on εilica gel eluting with a mixture of hexane and ethyl acetate (4:1) to give methyl 2-chloro-3-ethylindole-6-carboxylte (58.2 mg) aε a εolid. NMR (CDC1 3 , δ) : 1.26 (3H, t, J=7Hz) , 2.76 (2H, q, J=7Hz), 3.92 (3K, ε), 7.54 (IH, d, J=8Hz) , 7.82 BAΠ ORIGINAL CL ( IH, d, J=8Hz ) 8 . 02 ( IH, s ) , 8 . 19 ( IH, br s ) Preparation 46 To a εtirred solution of methyl 3-formylindole-6- carboxylate (368 mg) in 1,4-dioxane (10 ml) was added acetylmethylene triphenylphosphorane (1.15 g) , and the mixture waε εtirred under reflux for 12 hourε. The reεulting mixture waε evaporated in vacuo, rediεsolved with ethyl acetate and washed with IN hydrochloric acid and brine. The organic phase was dried over sodium sulfate and evaporated in vacuo. The residue was chromatographed on silica gel eluting with a mixture of chloroform and ethyl acetate (1:2) to give methyl 3- (3-oxo-I-butenyl) indoie-6-carboxylate (75 mg) as a solid. NMR (CDC1 3 , δ) : 2.39 (3K, s), 3.95 (3H, s), 6.79 (IH, d, J=15Hz), 7.71 (IH, ε), 7.80 (IH, d, J=8Hz) , 7.87-7.96 (2H, m) , 8.14 (IH, ε) Preparation 47 The following compound waε prepared from in a εimilar manner to that of Preparation 46. Methyl 3- (2-methoxycarbonylethenyl) indole-6-carboxylate NMR (DMSO-d 6 , δ) : 3.72 (3H, ε), 4.87 (3H, ε), 6.44 (IK, d, J=15Hz), 7.76 (IH, d, J=8Hz) , 7.89 (IH, d, J=15Hz), 7.98 (IH, d, J=8Hz), 8.10 (IH, s), 8.20 (IH, s) Preparation 48 To a solution of methyl 3- (2-methoxycarbonylethenyl)- indole-6-carboxylate (213 mg) in a mixture of 1,4-dioxane (2 ml) and methanol (3 ml) was added 10% palladium on carbon (40 mg) and the mixture was stirred under hydrogen at 20°C for 6.5 hourε. The reεulting mixture waε filtered through celite and the filtrate was evaporated in vacuo. The residue was triturated with diiεopropyl ether to give methyl 3- (2- methoxycarbonylethyl) indole-6-carboxylate (177 mg) . NMR (CDC1 3 , δ) : 2.72 (2H, t, J=7Hz), 3.12 (2H, t, J=7Hz), 3.68 (3H, ε), 3.94 (3H, ε), 7.20 (IH, d, J=2Hz), 7.62 (IH, d, J=8Hz), 7.82 (IH, d, J=8Hz) , 8.12 (IH, ε) , 8.21 (IH, br s) Preparation 49 The following compound was prepared from a similar manner to that of Preparation 30. 3- ;6-Methoxycarbonylindol-3-yl)propionic acid NMR (CDCI3, δ) : 2.72 (2K, t, J=7Hz), 3.10 (2K, t, J=7Hz), 3.94 (3H, s), 7.19 (IH, ε) , 7.60 (IH, d, J=8Hz), 7.77 (IK, d, J=8Kz), 8.10 (IH, s) Preparation 50 The following compound was prepared in a similar manner to that of Preparation 31. Methyl 3-oxo-l, 2,3, 4-tetrahydrccyclopent [b]indole-6- carboxyiate NMR (CDCI3, δ) : 3.05 (2H, m) , 3.14 (2H, m) , 3.97 (3H, s), 7.76 (IH, d, J=8Hz), 7.85 (IH, d, J=8Hz), 8.21 (IH, s) Preparation 51 The following compoundε deεcribed in (1) to (6) were prepared in a εimilar manner to that of Preparation 8 (1) . (1) 3-Cyclopropanecarbonyl-2-propyIindole-6-carboxylic acid mp : 250.5-251.5°C (dec.) IR (KBr) : 1685, 1600, 1463, 1424, 1300 cm -1 NMR (CDCI 3 -CD 3 OD, δ) : 1.00-1.09 (2H, m) , 1.02 (3K, t, J=7Hz), 1.25-1.29 (2K, m) , 1.81 (2H, εextet, J=7Hz), 2.59-2.69 (IH, ) , 3.12 (2H, t, J=7Hz) , 7.99 (2K, AB, 0=7.5, 7.5Hz), 8.09 (IH, ε) MASS (m/z) : 270 (M + -l) (2) 3-Cyclobutanecarbonyl-2-propyiindole-6-carboxylic acid mp : 244-245°C IR (KBr) : 1688, 1419, 1292 cm -1 NMR (CDCI3-CD3OD, δ) : 1.05 (3H, t, J=7Hz) , 1.80 (2H, sextet, J=7Hz) , 1.92-2.15 (2H, ) , 2.29-2.49 (2H, m) , 4.01 (IH, quintet, J=7Hz) , 7.90 (2H, s), 8.08 (IH, s) MASS (m/z) : 286 (M + +I) , 74 (bp) (3; 3-Cyclopentanecarbonyl-2-propyIindole-6-carboxylic acid mp : 233-235°C IR (KBr) : 1673, 1611, 1463, 1453 cm -1 NMR (CDCI3-CD3OD, δ) : 0.99 (3K, t, J=7Hz) , 1.51-1.79 (6K, m) , 1.89-1.97 (4K, m) , 3.10 (2K, t, J=7Hz), 3.70 (IH, quintet, J=7Hz), 7.85-7.94 (2K, m) , 8.05 (IH, ε) MASS (m/z) : 298 (M + -l, bp) (4; 3-Cyclohexanecarbonyl-2-propylindole-6-carboxylic acid mp : 2I7-218°C IR (KBr) : 1675, 1614, 1457 cm -1 NMR (CDCI3-CD3OD, δ) : C.99 (3H, t, J=7Hz) , 1.19-1.56 (6K, ) , 1.74 (2H, εextet, J=7H∑) , 1.80-1.95 (4K, m) , 3.08 (2K, t, J=7K∑) , 3.09-3.20 (IK, m) , 7.80 (IK, d, J=8Hz) , 7.88 (IK, dd, J=8, 1Hz) , 8.03 (IH, d, J=lHz) MASS (m/z) : 312 (M -i, bp; (5) 3- !3-Methyl-2-butenoyl) -2-propyiindole-6-carboxylic acid mp : 246-248°C (dec.) 1669, 1465, 1423 cm - ' 1 IKBr 'BADORIGINA- . WO9*32379 PCT/JP«« ) 9. - 87 - NMR (DMSO-d 6 , δ) : 0.96 (3H, t, J=7Hz) , 1.75 (2H, sextet, J=7Hz), 2.00 (3H, s) , 2.09 (3H, s) , 3.08 (2H, t, J=7Kz), 6.60 (IH, s), 7.73 (IH, d, J=7.5Hz), 7.95 (IH, d, J=7.5Hz), 7.99 (IH, ε) MASS (m/z) : 284 (M ÷ -l, bp) , 82 (bp) Preparation 52 The following compoundε described in (1) to (6) were prepared in the similar manner to that of Example 6. (1) 3-Cyciopropanecarbonyl-2-prcpylindoIe-6-carboxamide mp : 120-122°C IR (KBr) : 1670, 1623, 1598, 1394 cm -1 NMR (DMSO-d 6 , δ) : 0.94 (3H, t, J=7Hz) , 0.99-1.04 (4H, m) , 1.73 (2H, sextet, J=7Hz), 2.55-2.62 (IH, m) , 3.07 (2H, t, J=7Hz), 7.22 (IH, br s), 7.69 (IH, dd, J=7.5, 1Hz), 7.93 (IK, d, J=lKz), 7.96 (IH, br ε) , 8.00 (IH, d, J=7.5Hz) MASS (m/z) : 269 (M + -l), 98 (bp) (2) 3-Cyciobutanecarbonyl-2-propyIindole-6-carboxamide mp : 253-255°C IR (KBr) : 1675, 1624, 1605, 1456, 1397 cm -1 NMR (DMSO-d 6 , δ) : 0.97 (3H, t, J=7Hz) , 1.66-1.89 (3H, m) , 1.97-2.09 (IK, m) , 2.23-2.30 (4K, m) , 3.09 (2H, t, J=7Kz), 3.99 (IK, quintet, J=7Hz), 7.24 (IH, br S), 7.69 (IH, d, J=7.5Hz), 7.86 (IK, d, J=7.5Hz) , 7.90 (IK, ε) , 7.97 (IK, br s) MASS (m/z) : 285 (M + +I), 85 (bp) (3) 3-Cyclopentanecarbonyl-2-propylindole-6-carboxamide mp : 213-215°C IR (KBr) : 1666, 1628, 1623, 1604 cm -1 NMR (CDC1 3 -CD 3 0D, δ) : 1.01 (3H, t, J=7Hz) , 1.61-1.83 (6K, m) , 1.9C-1.98 (4K, m) , 3.13 (2K, t, J=7Hz) , J 3.69 (IH, quintet, J=7Hz) , 7.52 (IH, dd, J=8, 1Hz) , 7.91 (IH, d, J=lHz), 7.96 (IH, d, J=8Hz) MASS (m/z) : 299 (M + +l), 74 (bp) (4) 3-Cyclohexanecarbonyl-2-propylindole-6-carboxamide mp : 245-247°C IR (KBr) : 1663, 1627, 1595, 1459, 1402 cm -1 NMR (DMSO-d 6 , δ) : 0.95 (3H, t, J=7Hz) , 1.16-1.30 (IH, ) , 1.35-1.46 (4H, ) , 1.70 (2H, sextet, J=7Hz) , 1.75-1.88 (5H, m) , 3.05 (2H, t, J=7Hz) , 3.10-3.17 (IH, m) , 7.25 (IH, br s), 7.70 (IH, dd, J=7.5, 1Hz), 7.81 (IH, d, J=7.5Hz), 7.93 (IH, d, J=lHz) , 7.95 (IH, br s) MASS (m/z) : 313 (M + +l), 85 (bp) (5) 3- (3-Methyl-2-butenoyl) -2-propylindole-6-carboxamide mp : 179-181 β C IR (KBr) : 1669, 1648, 1591, 1458, 1394 cm -1 NMR (DMS0-d 6 , δ) : 0.95 (3H, t, J=7Hz) , 1.72 (2H, sextet, J=7Hz) , 1.99 (3H, s) , 2.05 (3H, s) , 3.05 (2H, t, J=7Hz), 6.59 (IH, s) , 7.22 (IH, br s), 7.67 (IH, d, J=7.5Hz), 7.88 (IH, d, J=7.5Hz), 7.90 (IH, ε) , 7.92 (IH, br s) MASS (m/z) : 285 (M + +l), 85 (bp) (6) 3- (3-Methoxybutanoyl) -2-propylindole-6-carboxamide p : 140-144 β C IR (KBr) : 1644, 1623, 1604, 1460, 1394 cm -1 NMR (CDC1 3 , δ) : 1.02 (3H, t, J=7Hz) , 1.30 (3H, d, J=7Hz), 1.80 (2H, sextet, J=7Hz) , 2.98 (IH, dd, J=15, 7Hz), 3.17 (2H, t, J=7Hz) , 3.39 (IH, dd, J=15, 7Hz), 3.40 (3H, s) , 7.10 (IH, sextet, J=7Hz) , 7.55 (IH, dd, J=8, 1Hz) , 8.02 (IH, d, J=8Hz) , 8.10 (IH, d, J=lHz), 9.60 (IH, br s) MASS (m/z) : 303 (M + +l), 74 (bp) Preparation 53 The following compound was prepared from methyl 3- crotonyl-2-propylindole-6-carboxylate in a similar manner to that of Preparation 8 (1) . 3- (3-Methoxybutanoyl) -2-propylindole-6-carboxylic acid mp : 286-288°C (dec.) IR (KBr) : 3288, 1685, 1645, 1620 cm "1 NMR (DMS0-d 6 , δ) : 0.96 (3H, t, J=7Hz), 1.19 (3H, d, J=7Hz), 1.73 (2H, sextet, J=7Hz) , 2.90 (IH, dd, J=15, 7Hz), 3.08 (2H, t, J=7Hz), 3.13 (3H, s) , 3.15 (IH, dd, J=15, 7Hz), 3.91 (IH, sextet, J=7Hz) , 7.26 (IH, d, J=8Hz), 7.99 (IH, s), 8.00 (IH, d, J=8Hz) MASS (m/z) : 302 (M + -l), 98 (bp) Example 1 To a solution of methyl 3-acetyl-2-propylindole-6- carboxylate (74 mg) in dimethylformamide (1.4 ml) was added sodium hydride (601, 15.4 mg) . The mixture was stirred at 20°C for 30 minutes, then 2-chlorobenzyl bromide (0.045 ml) was added. After stirred for 1 hour, the mixture was diluted with ethyl acetate and washed with water and brine. The organic phase was dried over εodium εulfate and evaporated in vacuo tc give methyl 3-acetyl-l- (2-chlorobenzyl) -2- propylindole-6-carboxylate (125 mg) aε εolid. NMR (CDC1 3 , δ) : 1.01 (3H, t, J=7Hz), 1.63 (2H, ) , 2.74 (3K, ε), 3.05 (2H, m) , 3.89 (3H, ε), 5.49 (2H, ε), 6.22 (IH, d, J=8Hz), 7.03 (IH, t, J=8Hz) , 7.20 (IH, t, J=8Hz), 7.46 (IH, d, J=8Hz), 7.93 (IH, ε), 7.97 (IH, d, J=8Hz) , 8.04 (IH, d, J=8Hz) Example 2 To a εolution of methyl 3-acetyl-l- (2-chlorobenzyl) -2- propylindole-6-carboxylate (125 mg) in ethanol (6 ml) was added IN aσueous sodium hydroxide (0.7 ml), and the mixture was εtirred under reflux for 1 hour. The resulting mixture was evaporated in vacuo, and the residue was acidified with IN hydrochloric acid (0.75 ml) and extracted with ethyl acetate. The extract was washed with brine, dried over sodium sulfate and evaporated in vacuo. The residue was triturated with isopropyl ether to give 3-acetyl-l- (2- chlorobenzyl) -2-propylindcle-6-carboxylic acid (78 mg) as solid. NMR (CDCI3, δ) : 1.02 (3K, t, J=7Hz) , 1.61 (2H, m) , 2.76 (3H, s), 3.08 (2H, m) , 5.52 (2K, s), 6.24 (IH, d, J=8Hz), 7.04 (IH, t, J=8Hz), 7.22 (IK, t, J=8Hz), 7.46 (IH, d, J=8Hz), 7.99 (IH, ε), 8.03 (IH, d, J=8Hz), 8.06 (IH, d, J=8Hz) Example 3 BAD ORIGINAL To a εolution of 3-acetyl-l- (2-chlorobenzyl)-2- propylindole-6-carboxylic acid (74 mg) in dimethylformamide (2 ml) were added 1-hydroxybenzotriazole (38 mg) , l-(3- dimethylaminopropyl) -3-ethyicarbodiimiαe hydrochloride (98 mg) and 3N methanol εolution of ammonia (0.5 ml). After stirred at 20°C for 14 hours, the resulting mixture was diluted with ethyl acetate. The organic phase was washed succeεsively with IN hydrochloric acid, water, aqueous sodium bicarbonate and brine, dried ever sodium sulfate and evaporated in vacuo. The residue was triturated with isopropyl ether to give 3-acetyl-l- (2-chlorobenzyl) -2- propylindole-6-carboxamide (67 mg) as colorleεε cryεtalε. mp : 208-211°C NMR (CDC1 3 , δ) : 1.01 (3K, t, J=7Hz) , 1.61 (2H, m) , 2.73 (3H, ε), 3.06 (2K, m) , 5.49 (2H, s) , 6.22 (IH, dd, J=l, 8Hz), 7.02 (IH, dt, J=l, 8Hz) , 7.21 (IH, dt, J=l, 8Hz), 7.45 (IH, dd, J=l, 8Hz) , 7.63 (IH, dd, J=l, 8Hz), 7.84 (IH, d, J=8Hz) , 8.07 (IH, d, J=8Hz) Example 4 Methyl 1- (2-chiorobenzyl) -3-iεobutyryl-2-propylindole-6- carboxylate (533 mg) waε prepared from methyl 3-iεobutyryl-2- propylindole-6-carboxyiate (440 mg) and 2-chlcrobenzyl bromide (346 mg) in a εimilar manner to that of Example 1. NMR (CDCI3, δ) : 1.01 (3H, t, J=8Hz) , 1.30 (6H, d, J=8Hz), 1.55-1.66 (2H, m) , 3.02-3.07 (2K, m) , 3.58 (2K, εeptet, J=8Hz), 3.90 (3K, s) , 5.50 (2H, s), 6.24 (IH, dd, J=l, 8Kz), 7.05 (IH, dt, J=l, 8Hz) , 7.24 (IH, dt, J=l, 8Kz), 7.46 (IH, dd, J=l, 8Hz), 7.95 (IH, s), 7.97 (2K, s) Example 5 1- (2-Chlorobenzyl) -3-isobutyryl-2-propylindole-6- carboxylic acid (450 mg) was prepared from methyl l-(2- BAD ORIGINAL 0 chlorobenzyl) -3-isobutyryl-2-propylindole-6-carboxylate (510 mg) in a similar manner to that of Example 2. NMR (DMSO-d 6 , δ) : 0.92 (3H, t, J=8Hz), 1.18 (6H, d, J=8Kz), 1.38-1.52 (2K, m) , 3.02-3.08 (2H, m) , 3.55 (2K, septet, J=8Hz), 5.68 (2H, s), 6.28 (IH, dd, J=l, 8Hz), 7.18 (IH, dt, J=l, 8Hz) , 7.32 (IH, dt, J=l, 8Hz), 7.52 (IH, dd, J=l, 8Hz) , 7.84 (IH, dd, J=l, 8Hz), 7.97 (IH, d, J=lKz), 8.00 (IH, d, J=8Hz) Example 6 To a solution of 1- (2-chlorobenzyl) -3-isobutyryl-.'.- propylindole-6-carboxyiic acid (150 mg) in dimethylformamide (3 ml) were added 1-hydroxybenzotriazole (102 mg) , l-(3- dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (109 mg) . After stirred at 20°C over night, the resulting mixture was poured into 28% aqueous ammonia (5 ml) . The mixture was partitioned between ethyl acetate and water, and the organic phase was washed with IN hydrochloric acid and brine, dried over sodium, εulfate and evaporated in vacuo. The cryεtalline reεidue waε recryεtallized from a mixture of ethyl acetate and hexane to give 1- (2-chlorobenzyI) -3-isobutyryi-2- propylindole-c-carboxamide (123 mg) as colorlesε cryεtals. mp : 185-186°C NMR (CDCi 3 , δ) : 1.01 (3H, t, J=8Hz) , 1.30 (6H, d, J=8Hz), 1.55-1.66 (2H, ) , 3.00-3.06 (2K, m) , 3.56 (2K, εeptet, J=8Hz) , 5.49 (2H, ε) , 6.24 (IH, dd, J=l, 8Hz), 7.04 (IH, dt, J=l, 8Hz) , 7.23 (IH, dt, J=l, 8Hz), 7.46 (IH, dd, J=l, 8Hz) , 7.63 (IH, dd, J=l, 8Hz), 7.85 (IH, d, J=lHz) , 7.97 (IH, d, J=8Hz) Example Methyl I- (2-chlorobenzyl)-3-propionyl-2-propylindole-6- carboxylate (436 mg) waε prepared from methyl 3-propionyl-2- propyiindole-6-carboxylate (260 mg) and 2-chlorobenzyl bromide (215 mg in a similar manner tc that cf Example 1. QRKMNW-. O 96/32379 - 93 - NMR (CDCI3, δ) : 1.02 (3H, t, J=8Hz) , 1.30 (3H, t, J=8Hz), 1.55-1.68 (2H, m) , 3.00-3.16 (4H, m) , 3.90 (3H, ε), 5.49 (2H, ε), 6.22 (IH, dd, J=l, 8Hz), 7.05 (IH, dt, J=l, 8Hz), 7.23 (IH, dt, J=l, 8Hz) , 7.46 (IH, dd, J=l, 8Hz), 7.93 (IH, d, J=8Hz) , 7.96 (IK, dd, J=l, 8Hz), 8.03 (IH, d, J=8Hz) Example 8 1- (2-Chlorobenzyl) -3-propionyl-2-propylindole-6- carboxylic acid (308 mg) waε prepared from methyl 1- (2- chlorobenzyl)-3-propionyl-2-pro?ylindole-6-carboxylate (425 mg) in a εimilar manner to that cf Example 2. NMR (DMSO-d 6 , δ) : 0.94 (3K, t, J=8Hz), 1.14 (3H, t, J=8Hz), 1.49 (2H, εextet, J=8Hz), 3.00-3.10 (4H, m) , 5.67 (2H, ε), 6.27 (IH, dd, J=l, 8Hz) , 7.18 (IH, dt, J=l, 8Hz), 7.32 (IH, dt, J=l, 8Hz) , 7.56 (IH, dd, J=l, 8Hz), 7.83 (IH, dd, J=l, 8Hz) , 7.96 (IH, d, J=lHz), 8.09 (IK, d, J=8Hz) Example 9 1- (2-Chlorobenzyl) -3-propionyl-2-propylindole-6- carboxamide (81 mg) waε prepared from 1- (2-chlorobenzyl)-3- propionyl-2-propylindole-6-carboxylic acid (100 mg) in a similar manner to that of Example 6. mp : 151-152°C NMR (CDC1 3 , δ) : 1.02 (3H, t, J=8Hz), 1.30 (3H, t, J=8Hz), 1.62 (2H, sextet, J=8Hz) , 3.04-3.14 (4H, (2K, ε), 6.22 (IK, dd, J=l, 8Hz) , 7.03 (IH, dt, J=l, 8Kz), 7.22 (IK, dt, J=l, 8Hz) , 7.45 (IK, dd, J=l, 8Hz), 7.64 (IK, dd, J=l, 8Hz) , 7.84 (IK, d, J=lHz), 8.06 (IK, d, J=8Hz) Example 10 Methyl 1- (2-chlorobenzyl) -2-isobutyl-3-isobutyrylindole- 6-carboxyiate (258 mg) waε prepared from methyl 2-iεobutyl-3- isobutyrylindole-6-carboxylate (210 mg) and 2-chlorobenzyl bromide (157 mg) in a similar manner to that of Example 1. NMR (CDC1 3 , δ) : 0.97 (6K, d, J=7Hz) , 1.31 (6H, d, J=7Hz), 1.96-2.10 (IH, ) , 3.04 (2H, d, J=7Hz) , 3.60 (IK, εeptet, J=7Hz) , 3.90 (3H, ε) , 5.53 (2H, ε), 6.18 (IH, d, J=8Hz), 7.04 (IH, t, J=8Hz), 7.23 (IH, t, J=8Hz), 7.46 (IH, t, J=8Hz), 7.94 (IH, ε), 7.96 2H, ε) Example 11 1- (2-Chlorobenzyl) -2-iεobutyl-3-isobυtyrylindole-6- carboxylic acid (184 mg) was prepared from methyl I- (2- chlorobenzyl) -2-isobutyl-3-iεobutyrylindole-6-carboxylate (213 mg) in a εimilar manner to that of Example 2. NMR (DMSO-d 6 , δ) : 0.88 (6H, d, J=8Hz) , 1.17 (6H, d, J=7Hz), 1.82-1.95 (IH, m) , 3.07 (2H, d, J=8Hz) , 3.57 (IH, εeptet, J=7Hz), 5.68 (2H, ε), 6.25 (IH, d, J=8Hz), 7.18 (IH, t, J=8Hz), 7.33 (IH, t, J=8Hz), 7.57 (IK, d, J=8Hz), 7.85 (IK, d, J=8Hz), 7.95 (IH, ε), 8.00 (IH, d, J=8Hz) Example 12 1- (2-Chlorobenzyl)-2-isobutyl-3-iεobutyrylindole-6- carboxamide (143 mg) was prepared from 1- (2-chlorobenzyl)-2- isobutyi-3-isobutyrylindole-6-carboxylic acid (160 mg) in a similar manner to that of Example 6. NMR (DMSO-d 6 , δ) : 0.86 (6H, d, J=8Hz), 1.17 (6H, d, J=7Hz), 1.80-1.94 (IH, m) , 3.02 (2H, d, J=8Hz), 3.57 (IK, septet, J=7Hz), 5.62 (2H, s), 6.16 (IK, d, J=8Hz), 7.18 (IH, t, J=8Hz) , 7.30-7.35 (2H, m) , 7.57 (IH, d, J=8Kz), 7.82 (IH, d, J=8Hz), 7.94 (IH, s), 7.96 (IH, d, J=8Hz), 8.00 (IH, ε) Example 13 Methyl 1- ( 2-chlorobenzyl ) -2-ethyl-3-propιonylindcle- 6- BAD ORIGINAL t carboxylate (278 mg) was prepared from methyl 2-ethyl-3- propionylindole-6-carboxylate (215 mg) and 2-chlorobenzyl bromide (0.24 ml) in a similar manner to that of Example 1. NMR (CDC1 3 , δ) : 1.22 (3H, t, J=7Hz) , 1.30 (3H, t, J=7Hz), 3.05-3.20 (4H, m) , 3.90 (3H, s), 5.50 (2H, s), 6.22 (IH, d, J=8Hz), 7.02 (IH, t, J=8Hz) , 7.20 (IH, t, J=8Hz), 7.46 (IH, d, J=8Hz) , 7.92 (IH, s) , 7.95 (IH, d, J=8Hz), 8.04 (IH, d, J=8Hz) Example 14 1- (2-Chlorobenzyl)-2-ethyl-3-propionylindoIe-6- carboxylic acid (417 mg) was prepared from methyl 1- (2- chlorobenzyl)-2-ethyl-3-propionyiindole-6-carboxylate (453 mg) in a similar manner to that of Example 2. NMR (DMS0-d 6 , δ) : 1.09 (3H, t, J=7Hz), 1.17 (3H, t, J=7Hz), 3.08 (2H, t, J=7Hz) , 3.11 (2H, t, J=7Hz) , 5.68 (2H, s), 6.24 (IH, d, J=8Hz), 7.18 (IH, t, J=8Kz), 7.31 (IK, t, J=8Hz), 7.57 (IH, d, J=8Hz) , 7.83 (IH, d, J=8Hz), 7.95 (IH, s), 8.13 (IH, d, J=8Hz) Example 15 1- (2-Chlorobenzyl) -2-ethyl-3-propionylindole-6- carboxamide (242 mg) waε prepared from 1- (2-chlorobenzyl)-2- ethyl-3-propionyiindoie-6-carboxylic acid (252 mg) in a similar manner to that of Example 3. NMR (CDC1 3 , δ) : 1.23 (3H, t, J=7Hz) , 1.29 (3H, t, J=7Hz), 3.08-3.18 (4K, m) , 5.49 (2H, s), 6.19 (IH, d, J=8Hz), 7.02 (IH, t, J=8Hz), 7.21 (IK, t, J=8Hz), 7.46 (IK, d, J=8Hz), 7.62 (IK, d, J=8Kz) , 7.83 (IH, s), 8.09 (IK, d, J=8Hz) Example 16 Methyl 2-acetyi-l- (2-chlorobenzyl) -3-iεobutylindole-6- carboxylate (71.4 mg) waε prepared from methyl 2-acetyl-3- BAD ORIG INAL )U isobutylindole-6-carboxylate (58 mg) and 2-chlorobenzyl bromide (0.04 ml) in a similar manner to that of Example 1. NMR (CDC1 3 , δ) : 1.02 (6H, d, J=7Hz) , 2.02 (IH, m) , 2.59 (3H, s), 3.01 (2H, d, J=7Hz) , 3.90 (3H, ε) , 5.84 (2H, ε), 6.19 (IH, d, J=8Hz), 6.99 (IH, t, J=8Hz), 7.15 (IH, t, J=8Hz), 7.40 (IH, d, J=8Hz), 7.75 (IH, d, J=8Hz), 7.83 (IK, d, J=8Hz), 7.98 (IH, Example 17 2-Acetyl-l- (2-chlorobenzyl) -3-iεobutylindole-6- carboxyiic acid (45.3 mg) was prepared from methyl 2-acetyI- 1- (2-chiorobenzyl) -3-iεobutylindole-6-carboxylate (67 mg) in a similar manner to that of Example 2. NMR (C CI3, δ) : 1.02 (6H, d, J=7Hz) , 2.03 (IH, m) , 2.62 (3H, s), 3.03 (2H, d, J=7Hz),.5.76 (2K, ε), 6.19 (IK, d, J=8Hz), 7.00 (IH, t, J=8Hz), 7.14 (IH, t, J=8Hz), 7.41 (IH, d, J=8Hz) , 7.77 (IH, d, J=8Hz), 7.86 (IK, d, J=8Hz) , 8.02 (IH, s) Example 8 2-Acetyl-l- (2-chlorobenzyl) -3-iεobutylindoie-6- carboxamide (33.4 mg) waε prepared from 2-acetyl-l- (2- chiorobenzyl)-3-iεobutylindoie-6-carboxylic acid (41.7 mg) in a εimilar manner to that of Example 3. NMR (CDCi 3 , δ) : 1.01 (6H, d, J=7Hz), 2.02 (IH, m) , 2.62 (3H, ε), 3.03 (2H, d, J=7Hz) , 5.54 (2H, ε), 6.22 (IH, d, J=8Hz), 6.99 (IH, t, J=8Hz), 7.16 (IH, t, J=8Hz), 7.41 (IK, d, J=8Hz), 7.54 (IH, d, J=8Kz) , 7.78 (IH, d, J=8Hz), 7.79 (IK, s) Example 19 Methyl 1- (2-chiorobenzyl) -3-ethyl-2-propionylindole-6- carboxylate (66 mg) waε prepared from methyl 3-ethyl-2- orooionvIindcie-6-carbcxylate (89 mg) and 2-chlcrobenzyl bromide (0.051 ml) in a similar manner to that of Example 1. NMR (CDC1 3 , δ) : 1.16 (3H, t, J=7Hz) , 1.38 (3H, t, J=7Hz), 2.95 (2H, q, J=7Hz) , 3.14 (2H, q, J=7Hz) , 3.90 (3H, s), 5.72 (2H, s) , 6.23 (IH, d, J=8Hz) , 6.98 (IH, t, J=8Hz), 7.14 (IH, t, J=8Hz) , 7.39 (IH, d, J=8Hz), 7.77 (IH, d, J=8Hz) , 7.85 (IH, d, J=8Hz), 7.97 (IH, s) Example Q 1- (2-Chlorobenzyl) -3-ethyl-2-propionylindole-6- carboxylic acid (48.7 mg) was prepared from methyl l-(2- chlorobenzyl) -3-ethyl-2-propionylindole-6-carboxylate (59.4 mg) in a similar manner to that of Example 2. NMR (CDC1 3 , δ) : 1.16 (3H, t, J=7Hz) , 1.37 (3H, t, J=7Hz), 2.94 (2H, q, J=7Hz), 3.15 (2H, q, J=7Hz) , 5.72 (2H, s), 6.25 (IH, d, J=8Hz) , 6.99 (IH, t, J=8Hz), 7.15 (IH, t, J=8Hz), 7.40 (IH, d, J=8Hz), 7.78 (IH, d, J=8Hz), 7.87 (IH d, J=8Hz) , 8.01 (IH, s) Example 21 1- (2-Chlorobenzyl) -3-ethyl-2-propionylindole-6- carboxamide (40.4 mg) was prepared from 1- (2-chlorobenzyl) -3- ethyl-2-propionylindole-6-carboxylic acid (46 mg) in a similar manner to that of Example 3. NMR (CDC1 3 , δ) : 1.16 (3H, t, J=7Hz), 1.38 (3H, t, J=7Hz), 2.96 (2H, q, J=7Hz) , 3.14 (2H, q, J=7Hz) , 5.72 (2H, s), 6.25 (IH, d, J=8Hz) , 7.00 (IH, t, J=8Hz), 7.14 (IH, t, J=8Hz), 7.39 (IH, d, J=8Hz) , 7.56 (IH, d, J=8Hz) , 7.79 (IH, s), 7.80 (IH, d, J=8Hz) Example 22 The following compounds described in 1) to 6) were prepared by reacting the compound (1-2) obtained in Example 2 N or Example 34-19) , and a suitable amine (IV) in a similar manner to that of Example 3. (1) 3-Acetyl-l- (2-chlorobenzyl) -N,N-dimethyl-2-propylindole- 6-carboxamide mp : 150-153°C NMR (CDC1 3 , δ) : 1.03 (3H, t, J=7Hz) , 1.63 (2H, m) , 2.72 (3H, s), 2.98 (6H, br s) , 3.09 (2H, m) , 5.44 (2H, s), 6.26 (IH, dd, J=l, 8Hz) , 7.03 (IH, dt, J=l, 8Hz), 7.20 (IH, dt, J=l, 8Hz) , 7.29 (IH, s) , 7.35 (IH, d, J=8Hz), 7.43 (IH, dd, J=l, 8Hz) , 8.03 (IH, d, J=8Hz) (2) 3-Acetyl-l- (2-chlorobenzyl) -N-cyclopropylmethyl-2- propylindole-6-carboxamide mp : 158-162°C NMR (CDC1 3 , δ) : 0.28 (2H, m) , 0.55 (2H, m) , 1.03 (3H, t, J=7Hz), 1.05 (IH, m), 1.60 (2H, ) , 2.72 (3H, s), 3.04 (2H, m) , 3.31 (2H, m) , 5.49 (2H, s) , 6.22 (IH, d, J=8Hz), 6.28 (IH, m) , 7.03 (IH, t, J=8Hz) , 7.22 (IH, t, J=8Hz), 7.45 (IH, d, J=8Hz) , 7.61 (IH, dd, J=l, 8Hz), 7.82 (IH, d, J=lHz) , 8.05 (IH, d, J=8Hz) (3) 3-Acetyl-l- (2-chlorobenzyl) -N- (2-pyridylmethyl) -2- propylindole-6-carboxamide mp : 172-175 β C NMR (CDC1 3 , δ) : 1.02 (3H, t, J=7Hz) , 1.63 (2H, m) , 2.73 (3H, s), 3.07 (2H, ) , 4.75 (2H, d, J=5Hz) , 5.51 (2H, s), 6.22 (IH, d, J=8Hz) , 7.02 (IH, t, J=8Hz), 7.15-7.27 (2H, m) , 7.33 (IH, d, J=8Hz) , 7.44 (IH, d, J=8Hz), 7.58-7.76 (3H, s) , 7.88 (IH, S ), 8.07 (IH, d, J=8Hz), 8.56 (IH, ) (4) 3-Acetyl-l-(2-chlorobenzyl) -6- (morpholinocarbonyl) -2- propylindole NMR (CDC13 δ) : 1.03 (3H, t, J=7Hz) , 1.63 (2H, m) , 2.73 (3H, s), 3.09 (2H, m) , 3.63 (8H, br s) , 5.44 (2H, s), 6.23 (IH, d, J=8Hz) , 7.06 (IH, t, J=8Hz) , 7.2-7.4 (3H, m) , 7.46 (IH, d, J=8Hz) , 8.06 (IH, d, J=8Hz) (5) 3-Acetyl-l- (2-chlorobenzyl) -N-phenylsulfonyl-2- propylindole-6-carboxamide mp : 206-208°C NMR (CDC1 3 , δ) : 0.99 (3H, t, J=7Hz) , 1.54 (2H, m) , 2.72 (3H, s), 3.02 (2H, m) , 5.43 (2H, ε), 6.13 (IH, d, J=8Hz), 7.00 (IH, t, J=8Hz), 7.21 (IH, t, J=8Hz), 7.43 (IH, d, J=8Hz) , 7.5-7.7 (4H, m) , 7.77 (IH, s), 8.08 (IH, d, J=8Hz) , 8.13-8.18 (2H, m) , 8.81 (IH, br s) (6) 1- (2-Chlorobenzyl) -3-formyl-N-phenylsulfonyl-2- propylindole-6-carboxamide mp : 242-245°C NMR (CDC1 3 , δ) : 0.87 (3H, t, J=7Hz) , 1.49 (2H, m) , 3.07 (2H, t, J=7Hz), 5.66 (2H, s) , 6.32 (IH, d, J=8Hz), 7.18 (IH, t, J=8Hz), 7.33 (IH, t, J=8Hz), 7.55-7.75 (4H, ) , 7.88 (IH, ) , 7.96 (IH, s), 7.98 (IH, d, J=8Hz), 8.09 (IH, s), 8.23 (IH, d, J=8Hz) (7) 1- (2-Chlorobenzyl) -3-formyl-2-propyl-N- (lH-tetrazol-5- yl) indole-6-carboxamide mp : 275°C (dec.) NMR (DMSO-d 6 , δ) : 0.90 (3H, t, J=7Hz) , 1.54 (2H, m) , 3.13 (2H, t, J=7Hz), 5.69 (2H, s) , 6.38 (IH, d, J=8Hz), 7.19 (IH, t, J=8Hz), 7.33 (IH, t, J=8Hz) , 7.60 (IH, d, J=8Hz), 8.03 (IH, d, J=8Hz), 8.31 (IH, s), 8.32 (IH, d, J=8Hz), >10 (IH, s) Example 23 l-Hydroxybenzotriazole (68 mg) and l-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (72 mg) were added to a solution of 1-(2-chlorobenzyl)-3- isobutyryl-2-propylindole-6-carboxylic acid (100 mg) in dimethylformamide (3 ml) , and the mixture was stirred at 20°C overnight, then hydroxylamine hydrochloride (35 mg) and diisopropylethylamine (0.088 ml) were added. After stirred at 20°C for 2 hours, the reaction mixture was partitioned between ethyl acetate and water. The organic phase was washed with IN hydrochloric acid and brine, dried over sodium sulfate, and evaporated in vacuo. The residue was purified by preparative thin layer chromatography with 10% methanol in chloroform and recrystallization from ethyl acetate to give 1- (2-chlorobenzyl) -3-isobutyryl-2-propylindole-6- carbohydroxamic acid (67 mg) as pale red crystals, mp : 185-186°C NMR (CDC1 3 , δ) : 1.00 (3H, t, J=8Hz) , 1.28 (6H, d, J=8Hz), 1.60 (2H, sextet, J=8Hz), 3.02-3.06 (2H, m) , 3.53 (2H, septet, J=8Hz) , 5.47 (2H, s) , 6.20 (IH, dd, J=l, 8Hz), 7.03 (IH, t, J=8Hz), 7.20 (IH, t, J=8Hz), 7.46 (IH, d, J=8Hz) , 7.57 (IH, d, J=8Hz), 7.77 (IH, s), 7.97 (IH, d, J=8Hz) Example 24 The following compounds described in 1) to 2) were prepared by reacting the compound (1-2) obtained in Example 5 and a suitable amine (IV) in a similar manner to that of Example 23. (1) 1- (2-Chlorobenzyl)-3-isobutyryl-0-methyl-2-propylindole- 6-carbohydroxamic acid NMR (CDC1 3 , δ) : 1.00 (3H, t, J=8Hz) , 1.30 (6H, d, J=8Hz), 1.54-1.66 (2H, m) , 3.00-3.06 (2H, m) , 3.53 (IH, septet, J=8Hz) , 3.86 (3H, ε) , 5.49 (2H, ε) , 6.22 (IH, dd, J=l, 8Hz), 7.03 (IH, dt, J=l, 8Hz) , 7.23 (IH, dt, J=l, 8Hz), 7.46 (IH, dd, J=l, 8Hz) , 7.56 (IH, dd, J=l, 8Hz) , 7.75 (IH, d, J=lHz) , 7.96 (IH, d, J=8Hz), 8.82 (IH, s) (2) 1- (2-Chlorobenzyl) -3-isobutyl-2-propyl-N- (2- pyridylmethyl) indole-6-carboxamide NMR (CDC1 3 , δ) : 1.00 (3H, t, J=8Hz), 1.30 (6H, d, J=8Hz), 1.62 (2H, sextet, J=8Hz) , 3.03-3.07 (2H, m) , 3.57 (IH, septet, J=8Hz) , 4.66 (2H, d, J=6Hz), 5.50 (2H, s), 6.24 (IH, dd, J=l, 8Hz) , 7.02 (IH, dt, J=l, 8Hz), 7.18-7.24 (2H, m) , 7.33 (IH, d, J=8Hz), 7.45 (IH, d, J=8Hz) , 7.62-7.68 (2H, m) , 7.72 (IH, dd, J=l, 8Hz), 7.88 (IH, d, J=lHz), 7.98 (IH, d, J=8Hz), 8.56 (IH, d, J=6Hz) Example 25 The following compounds described in 1) to 2) were prepared by reacting the compound (II) obtained in Preparation 8 (2) and a suitable halide (III) in a similar manner to that of Example 1. (1) 1- (4-Chloro-2-fluorobenzyl)-3-isobutyryl-2-propylindole- 6-carboxamide mp : 200-202°C IR (KBr) : 3380, 3195, 1650, 1620 cm "1 NMR (CDC1 3 , δ) : 1.03 (3H, t, J=7Hz) , 1.30 (6H, d, J=7Hz), 1.52-1.65 (2H, m) , 3.06-3.10 (2H, ) , 3.49- 3.59 (IH, ) , 5.47 (2H, s), 6.34 (IH, ddd, J=8, 8, 1Hz), 6.94 (IH, dd, J=8, 1Hz) , 7.19 (IH, d, J=8Hz) , 7.60 (IH, d, J=8Hz), 7.89 (IH, s), 7.97 (IH, d, J=8Hz) MASS (m/z) : 415 (M + +l), 76 (bp) (2) 3-Isobutyryl- (2-methoxycarbonylbenzyl) -2-propylindole-6- carboxamide mp : 170- 172 β C IR (KBr) : 3420, 1720, 1650 cm "1 NMR (CDC1 3 , δ) : 1.00 (3H, t, J=7Hz) , 1.33 (6H, d, J=7Hz), 1.56-1.69 (2H, m) , 3.00-3.06 (2H, m) , 3.54- 3.63 (IH, m) , 4.02 (3K, ε), 5.91 (2H, ε), 6.69 (IH, d, J=7.5Hz), 7.24-7.36 (IK, m) , 7.63 (IH, dd, J=8, 1Hz), 7.80 (IH, s), 7.99 (IH, d, J=8Hz), 8.12-8.16 (IH, m) MASS (m/z) : 421 (M τ +1) Example 26 A. mixture of 3-isobutyryl-2-propylindole-6-carboxamide (100 mg) , 4-chlcrobenzyl bromide (113 mg) and potasεium carbonate (152 mg) in dimethylformamide (2 ml) was heated at 60°C for 2 hours, and partitioned between ethyl acetate and water. The organic layer was washed with water and brine, and dried over magnesium sulfate. After evaporation of solvent, the residue was crystallized from a mixture of ethyl acetate and hexane. The crude crystals were recrystallized from a mixture of ethyl acetate and hexane to give l-(4- chicrobenzyl) -3-isobutyryI-2-propylindole-6-carboxamide (97 mg) as colorless crystalε. mp : 183-184°C NMR (CDC1 3 , δ) : 1.01 (3H, t, J=7Kz) , 1.29 (6H, d, J=7Hz), 1.50-1.64 (2H, m) , 3.06-3.12 (2H, m) , 3.55 (2H, εeptet, J=7Hz), 5.42 (2H, s), 6.87 (2H, d, J=8Hz), 7.25 (2E, d, J=8Hz) , 7.60 (IH, dd, J=l, 8Hz), 7.87 (IH, d, J=lHz) , 7.95 (IK, d, J=8Hz) Example 7 The following compoundε described in 1) tc 8) were prepared by reacting the compound (II) obtained in Preparation 8 (2) or Preparation 15 (3), and a εuitable halide (III) in a εimilar manner to that of Example 26. (1) l-Benzyl-3-iεobutyryl-2-propylindole-6-carboxamide mp : 164-166°C NMR (CDC1 3 , δ) : 1.00 (3K, t, J=7Hz), 1.29 (6H, d, J=7Hz), 1.60 (2H, εextet, J=7Hz), 3.C9-3.13 (2H, m) , 3.55 (2H, septet, J=7Hz) , 5.46 (2H, s), 6.96-6.98 (2H, m) , 7.24-7.32 (2H, m) , 7.61 (IH, d, J=8Hz), 7.91 (IH, s), 7.95 (IH, d, J=8Hz) (2) 1- (3-Chlorobenzyl) -3-iεobutyryl-2-propylindole-6- carboxamide mp : 164-166°C NMR (CDCI3, δ) : 1.00 (3H, t, J=7Hz), 1.30 (6H, d, J=7Hz), 1.50-1.65 (2H, m) , 3.06-3.12 (2H, m) , 3.55 (2H, εeptet, J=7Hz) , 5.42 (2H, s) , 6.78 (IH, dd, J=l, 8Hz), 6.96 (IH, d, J=iHz) , 7.18-7.27 (2K, m) , 7.60 (IH, d, J=8Hz), 7.88 (IH, s) , 7.95 (IH, d, J=8Hz) (3) 3-Isobutyryl-2-propyl-l- (2-trifluoromethylbenzyl) indole- 6-carboxamide mp : 86-87°C NMR (CDCI3, δ) : 0.99 (3H, t, J=7Hz) , 1.30 (6H, d, J=7Hz), 1.52-1.65 (2H, m) , 2.98-3.04 (2K, m) , 3.56 (2H, septet, J=7Hz), 5.62 (2H, s), 6.33 (IH, d, J=8Hz), 7.30 (IH, t, J=lHz) , 7.38 (IH, t, J=lHz), 7.64 (IK, d, J=8Hz), 7.75 (IH, d, J=6Hz), 7.84 (IH, ε), 7.98 (IH, d, J=8Hz) (4) 3-Iεobutyryl-l- (2-phenylbenzyl) -2-propylindoie-6- carboxamide mp : 162-164°C NMR (CDCI3, δ) : 0.89 (3H, t, J=7Hz) , 1.27 (6H, d, J=7Hz), 1.36-1.50 (2K, m) , 2.90-2.96 (2H, m) , 3.53 (2K, septet, J=7Hz) , 5.32 (2K, s), 6.48 (IH, d, J=8Hz), 7.10-7.16 (IH, m) , 7.30-7.34 (2K, m) , 7.42- I , ( BAD ORluiiMM-- ^ 7 . 84 ( 3H, m) , 7 . 52-7 . 55 ( 2H, m) , 7 . 60 ( IH, d, J=8Hz ) , 7 . 84 ( IH, s ) , 7 . 93 ( IH, d, J=8Hz ) (5) l-[ (5-Chlorothien-2-yl)methyl]-3-isobutyryl-2- propylindole-6-carboxamide mp : 178-180°C NMR (CDC1 3 , δ) : 1.07 (3H, t, J=7Hz) , 1.27 (6H, d, J=7Hz), 1.65 (2H, sextet, J=7Hz), 3.15-3.20 (2H, m) , 3.54 (2H, septet, J=7Hz) , 5.46 (2H, s) , 6.59 (IH, d, J=2Hz), 6.72 (2H, d, J=2Hz) , 7.60 (IH. d, J=8Hz), 7.92 (IH, d, J=8Hz) , 8.04 (IH, s) (6) 3-Isobutyryl-l-phenethyl-2-propylindole-6-carboxamide mp : 180-181°C NMR (CDC1 3 , δ) : 1.02 (3H, t, J=7Hz) , 1.26 (6H, d, J=7Hz), 1.61 (2H, septet, J=7Hz) , 2.88-2.92 (2H, m) , 3.10 (2H, t, J=7Hz) , 3.52 (2H, septet, J=7Hz) , 4.42 (2H, t, J=7Hz), 7.05-7.09 (2H, m) , 7.22-7.32 (3H, m) , 7.52 (IH, d, J=8Hz) , 7.92 (IH, d, J=8Hz) , 7.96 (IH, s) (7) 1- (2-Chlorobenzyl) -3-methoxyacetyl-2-propylindole-6- carboxamide mp : 165-167°C NMR (DMSO-d 6 , δ) : 0.92 (3H, t, J=8Hz) , 1.46 (2H, sextet, J=8Hz), 3.01-3.05 (2H, m) , 3.42 (3H, s) , 4.68 (2H, s), 5.62 (2H, s) , 6.22 (IH, d, J=8Hz) , 7.16 (IH, t, J=8Hz), 7.28 (IH, br s) , 7.32 (IH, t, J=8Hz), 7.56 (IH, d, J=8Hz) , 7.92 (IH, d, J=8Hz) , 7.93 (IH, br s) , 8.01 (IH, s) (8) 1- (6-Chloro-3, 4-methylenedioxybenzyl) -3-methoxyacetyl-2- propylindole-6-carboxamide mp : 204-206°C NMR (DMSO-d 6 , δ) : 0.95 (3H, t, J=8Hz) , 1.50 (2H, sextet, J=8Hz), 3.02-3.06 (2H, ) , 3.40 (3H, s) , 4.70 (2H, s), 5.51 (IH, ε), 5.98 (2H, ε), 7.23 (IH, s), 7.32 (IH, br s) , 7.80 (IH, d, J=8Hz) , 7.93 (IH, d, J=8Hz), 7.96 (IK, br ε), 8.02 (IH, ε) Example 28 The following compoundε deεcribed in 1) to 16) were prepared by reacting the compound (II) obtained in Preparation 2, Preparation 6 (1), Preparation 9, Preparation 10, Preparation 12, Preparation 13 (4) or Preparation 14 (5) and a εuitable halide (III) in a εimilar manner to that of Example 1. (1) Methyl 1- (2-fluorobenzyl) -3-iεobutyryl-2-propylindole-6- carboxylate mp : 120-121.5°C IR (KBr) : 1710, 1700, 1660 cm -1 NMR (CDC1 3 , δ) : 1.02 (3H, t, J=7Kz), 1.29 (6H, d, J=7Hz), 1.55-1.64 (2H, m) , 3.06-3.12 (2H, m) , 3.51- 3.61 (IH, m) , 3.92 (3H, ε), 5.50 (2H, s), 6.43 (IH, t, J=7.5Hz), 6.95 (IK, t, J=7Hz), 7.10-7.17 (IH, m) , 7.22-7.28 (IH, ) , 7.95 (2H, 5), 8.02 (IH, s) MASS (m/z) : 396 (M + +l), 76 (bp) (2) Methyl 1- (2-bromobenzyI) -3-iscbutyryl-2-propylindole-6- carboxylate mp : 90-92°C IR (KBr) : 1705, 1650 cm "1 NMR (CDC1 3 , δ) : 1.02 (3H, t, J=7Hz) , 1.30 (6H, d, J=7Hz), 1.56-1.67 (2K, ) , 3.04 (2H, t, J=7Hz) , 3.52-3.61 (IH, m) , 3.93 (3K, ε), 5.47 (2H, ε), 6.20 (IH, t, J=7.5Hz), 7.06-7.18 (2H, m) , 7.65 (IH, t, J=7.5Hz), 7.95 (IK, s), 7.97 (2H, ε) MASS (m/z) : 458 (M + τl 2), 458 (M + +l), 76 (bp) BADORMi *** (3) Methyl 1- (2-iodobenzyl)-3-isobutyryl-2-propylindole-6- carboxylate IR (KBr) : 1710, 1650, 1430 cm "1 NMR (CDC1 3 , δ) : 1.03 (3H, t, J=7Hz), 1.30 (6H, d, J=7Hz), 1.53-1.67 (2H, m) , 2.98-3.05 (2H, m) , 3.53- 3.62 (IH, m) , 3.93 (3H, s), 5.37 (2H, s), 6.16 (IH, t, J=7.5Hz), 6.99 (IK, t, J=7.5Kz), 7.12 (IH, t, J=7.5Hz), 7.90-7.97 (4E, m) MASS (m/z) : 504 (M + +l) (4) Methyl 3-isobutyryl-l- (2-methylbenzy.l) -2-propylindole-6- carboxylate mp : 99-102°C IR (KBr) : 1705, 1650, 1285 cm "1 NMR (CDC1 3 , δ) : 1.00 (3H, t, J=7Hz), 1.30 (6H, d, J=7Hz), 1.54-1.69 (2H, ) , 2.50 (3H, s), 3.00-3.06 (2H, m) , 3.51-3.65 (IH, m) , 3.89 (3H, ε), 5.39 (2H, s), 6.17 (IH, t, J=7.5Hz), 6.98 (IH, t, J=7.5Hz), 7.18 (IH, t, J=7.5Hz), 7.25 (IH, d, J=7.5Hz), 7.92 (IH, s), 7.96 (2K, s) MASS (m/z) : 392 (M + +l) (5) Methyl 3-iεobutyryl-l- (2-methoxybenzyI) -2-propylindole- 6-carboxyiate mp : 103-105°C IR (K3r) : 1710, 1650 cm "1 NMR (CDCI3, δ) : 1.01 (3H, t, J=7Hz), 1.30 (6H, d, J=7Hz), 1.56-1.68 (2H, ) , 3.05-3.10 (2K, m) , 3.53- 3.62 (IH, m) , 3.90 (3H, s), 3.98 (3K, s), 5.44 (2H, s), 6.27 (IK, d, J=7.5Kz), 6.74 (IH, t, J=7.5Hz), 6.94 (IH, d, J=7.5Hz), 7.25 (IH, t, J=7.5Hz), 7.95 (2H, ε), 8.00 (IH, d, J=7.5Hz) MASS (m/z) : 408 (M + +l), 76 (bp) (6) Methyl 1- (2-cyanobenzyl) -3-isobutyryl-2-propylindole-6- BAD ORIGINAL y) carboxylate p : 159-161°C IR (KBr) : 2220, 1730, 1660 cm "1 NMR (CDC1 3 , δ) : 1.C4 (3H, t, J=7Hz) , 1.30 (6H, d, J=7Hz), 1.52-1.65 (2H, m) , 3.03-3.08 (2H, m) , 3.53- 3.60 (IK, ) , 3.92 (3H, ε) , 5.66 (2H, s) , 6.44-6.49 (IH, ) , 7.38-7.43 (2K, m) , 7.76-7.80 (IH, m) , 7.95 (IH, ε), 7.98 (2K, s) MASS (m/z) : 403 (M ' +l), 76 (bp) (7) Methyl 3-iεobutyryl-l- (2-nitrobenzyl) -2-propylindole-6- carboxylate mp : 165.5-166.5°C IR (KBr) : 1705, 1650, 1530, 1520 cm "1 NMR (CDCI3, δ) : 1.00 (3H, t, J=7Hz) , 1.31 (6H, d, J=7Hz), 1.56-1.65 (2K, m) , 3.03 (2H, t, J=7Hz), 3.54-3.65 (IH, m) , 3.90 (3H, ε) , 5.89 (2H, ε) , 6.27 (IH, d, J=7.5Hz), 7.40-7.51 (2H, m) , 7.89 (IH, s), 8.00 (2K, s), 8.30 (IH, d, J=7.5Hz) MASS (m/z) : 423 (M τ +1), 76 (bp) (8) Methyl 1- (2, 6-dichlorobenzyI) -3-isobutyryl-2- propylindole-6-carboxylate mp : I29.5-I32°C IR (KBr) : 1710, 1660, 1430- cm "1 NMR (CDCI3, δ) : 0.96 (3H, t, J=7Hz) , 1.27 (6H, d, J=7Hz), 1.38-1.50 (2K, m) , 3.15-3.20 (2H, m) , 3.47- 3.60 (IH, m) , 3.92 (3H, ε), 5.70 (2K, ε), 7.17-7.39 (3H, m) , 7.88 (2H, s) , 8.03 (IH, s) MASS (m/z) : 446 (M + +l) (9) Methyl 1- (2-chloro-4-fluorobenzyl) -3-iεobutyryl-2- propylindole-6-carboxylate mp : 140-141°C IR (KBr) : 1705, 1649, I486, 1279 cm "1 BAD OHKa iN ^- ≠ NMR (CDC1 3 , δ) : 1.03 (3H, t, J=7Hz) , 1.40 (6H, d, J=7Hz), 1.52-1.66 (2H, m) , 3.01-3.06 (2H, m) , 3.52- 3.60 (IH, m) , 3.93 (3H, ε) , 5.48 (2H, s), 6.20-6.25 (IH, m) , 6.79 (IH, ddd, J=7.5, 7.5, 1Hz) , 7.21-7.25 (IH, m) , 7.94 (IH, s), 7.97 (2H, s) MASS (m/z) : 430 (M + +l), 76 (bp) (10) Methyl 1- (4-bromo-2-fluorobenzyl) -3-isobutyryl-2- propylindole-6-carboxylate mp : 110-111.5 β C. IR (KBr) : 1705, 1649, 1488, 1279 cm" 1 NMR (CDCi 3 , δ) : 1.03 (3H, t, J=7Hz), 1.29 (6H, d, J=7Kz), 1.53-1.65 (2H, m) , 3.05-3.10 (2H, m) , 3.51- 3.60 (IH, m) , 3.94 (3H, s) , 5.44 (2H, s) , 6.28 (IH, t, J=7.5Hz), 7.10 (IH, dd, J=7.5, 1Hz) , 7.35 (IH, d, J=7.5Hz), 7.96 (IH, s) MASS (m/z) : 476 (M + +l), 474 (M + ), 76 (bp) (11) Methyl 3-benzoyl-l- (2-chlorobenzyl) -2-propylindole-6- carboxylate NMR (CDC1 3 , δ) : 0.94 (3H, t, J-8Hz) , 1.56-1.70 (2H, m) , 2.93-2.98 (2H, m) , 3.87 (3H, s) , 5.55 (2H, ε), 6.33 (IH, ddd, J=l, 8Hz) , 7.08 (IH, dt, J=l, 8Hz), 7.21 (IH, d, J=8Hz), 7.22-7.28 (IH, m) , 7.46-7.52 (3K, m) , 7.57-7.63 (IK, m) , 7.72-7.82 (3H, m) , 7.93 (IH, d, J=lHz) (12) Methyl 1- (2-chlorobenzyl) -3-cyano-2-propylindole-6- carboxylate mp : 132-133°C IR (KBr) : 2215, 1709, 1284 cm "* NMR (CDCI3, δ) : 1.01 (3H, t, J=7Hz) , 1.70 (2H, εextet, J=7Hz), 2.89 (2H, t, J=7.5Hz), 3.92 (3H, s), 5.49 (2H, s), 6.24 (IE, d, J=7.5Hz), 7.08 (IH, t, J=7.5Hz), 7.22-7.28 (IK, m) , 7.47 (IH, d, 1 ~~ ' & % J=7.5Hz), 7.77 (IH, d, J=7.5Hz) , 7.95-8.00 (2K, m) MASS (m/z) : 367 (M~+l; , 76 (bp) (13) Methyl 1- (2-chlorobenzyI) -2-ethyI-3-isobutyrylindole-6- carboxylate NMR (CDC1 3 , δ) : 1.22 (3H, t, J=7Hz), 1.31 (6H, d, J=7Hz), 3.08 (2K, q, J=7Hz), 3.56 (IH, m) , 3.91 (3H, s), 5.50 (2H, ε), 6.23 (IH, d, J=8Hz) , 7.04 (IH, t, J=8Hz), 7.22 (IH, t, J=8Hz) , 7.46 (IH, d, J=8Hz), 7.93-7.98 (3K, m) (14) Methyl 1- (2-chlorobenzyi) -3-iεobutyryl-2-methylindole-6- carbcxylate NMR (CDCI3, δ) : 1.32 ;6K, ά, J=7Hz) , 2.71 (3K, s), 3.56 (IK, m) , 3.92 (3H, ε), 5.52 (2H, ε), 6.24 (IH, d, J=8Hz), 7.05 (IH, t, J=8Hz), 7.23 (IH, t, J=8Hz), 7.46 (IH, d, J=8Hz), 7.92-8.05 (3H, m) (15) Methyl 1- (2-chlorobenzyl) -3-iεobutyryl-2- methoxymethylindole-6-carboxylate NMR (CDC1 3 , δ) : 1.29 (6H, d, J=7Hz), 3.31 (3H, ε) , 3.55 (IK, ml, 3.89 (3K, ε), 4.91 (2K, ε) , 5.63 (2H, s , 6.23 (IK, d, J=8Hz), 7.02 (IH, t, J=8Hz), 7.19 (IH, t, J=8Hz), 7.44 (IK, d, J=8Kz), 7.95-8.02 (3H, m) (16) Methyl 1- (2-chlorobenzyl) -3-iεobutyrylindole-6- carbcxylate NMR (C CI3, δ) : 1.26 (6H, α, J=7Kz), 3.28 (IH, m) , 3.93 (3H, s), 5.52 (2H, s), 6.77 (IH, d, J=8Kz), 7.18 (IH, t, J=8Hz), 7.29 (IH, t, J=8Hz), 7.48 (IH, d, J=8Hz), 7.89 (IH, ε), 8.02 (IH, d, J=8Hz), 8.10 (IH, ε), 8.49 (IH, C, J=8Hz) Example 29 'BAD ORIGINAL - 110 - The following compoundε deεcribed in 1) to 2) were prepared from the compound (II) obtained in Preparation 1 (5) and Preparation 2 in a εimilar manner to that of Example 26. (1) Methyl 3-isobutyryl-2-propyl-l- (2-pyridylmethyl) indole- 6-carboxylate NMR (CDC1 3 , δ) : 1.01 (3H, t, J=7Hz) , 1.30 (6H, d, J=7Hz), 1.60 (2H, sextet, J=7Hz), 3.12-3.16 (2H, m) , 3.56 (2H, septet, J=7Hz) , 3.90 (3H, s), 5.58 (2H, ε), 6.58 (IH, d, J=8Hz) , 7.22 (IH, dd, J=5, 8Hz), 7.55 (IH, dt, J=l, 8Hz) , 7.94 (2H, s) , 8.02 (IH, s), 8.63 (IH, dd, J=l, 5Kz) (2) Methyl 3-acetyi-l- (6-chloro-3, -methylenedioxybenzyl) -2- propylindole-6-carboxylate mp : 210-212°C NMR (CDCI3, δ) : 1.04 (3K, t, J=7Hz) , 1.63 (2H, sextet, J=7Hz), 2.37 (3H, s) , 3.04-3.08 (2H, ) , 3.92 (3H, s), 5.40 (2H, s) , 5.70 (IH, s) , 5.90 (2H, s), 6.92 (IH, s), 7.95 (IH, s) , 7.97 (IH, d, J=8Hz), 8.04 (IH, d, J=8Hz) Example 30 To a solution of methyl 3-acetyl-l- (2-chlorobenzyl)-2- ethyϋndole-6-carboxylate (110 mg) in tetrahydrofuran (5 ml) was added IM solution of boran in tetrahydrofuran (0.6 ml) in one portion at 0°C. The mixture was stirred at 20°C for 1 hour, then quenched with water and extracted with ethyl acetate. The organic phase was waεhed with brine, dried over magneεium εulfate and evaporated in vacuo. The reεidue was chromatographed on silica gel eluting with a mixture of hexane and ethyl acetate (2:1) to give methyl l-(2- chlorobenzyl)-2,3-diethylindole-6-carboxylate (42 mg) as colorless crystalε. mp : 86-88°C BAD ORIGINAL ^ - Ill - IR (KBr) : 1710, 1240 cm "1 NMR (CDC1 3 , δ) : 1.13 (3H, t, J=7Hz), 1.30 (3H, t, J=7Hz), 2.69 (2H, t, J=7Hz) , 2.79 (2H, q, J=7Kz) , 3.90 (3H, s), 5.44 (2H, ε) , 6.17 (IH, d, J=8Hz) , 7.00 (IK, t, J=8Hz), 7.19 (IK, t, J=8Hz) , 7.42 (IH, d, J=7.5Hz), 7.60 (IK, d, J=8Hz) , 7.80 (IH, d, J=8Hz), 7.88 (IH, s) MASS (m/z) : 356 (M + +l) Example 31 Methyl 1- (2-chiorobenzyl) -2-propylindole-6-carboxylate (400 mg) waε prepared from methyl 2-propylindole-6- carboxyiate (350 mg! and 2-chlorobenzyl bromide (364 mg) in a εimilar manner to that of Example 1. NMR (CDCI3, δ) : 0.99 (3H, t, J=8Hz) , 1.74 (2H, sextet, J=8Hz), 2.60 (2H, t, J=8Hz) , 3.87 (3H, s), 5.43 (2K, s), 6.16 (IH, d, J=8Hz) , 6.43 (IH, s) , 7.00 (IK, t, J=8Hz), 7.18 (IH, t, J=8Hz) , 7.43 (IH, d, J=8Hz), 7.60 (IH, d, J=8Hz) , 7.80 (IH, d, J=8Hz), 7.90 (IK, ε) Example 32 To a εtirred εclution of dimethylformamide (3 ml) and phosphorus oxychloride (0.056 ml) was added methyl 2- propylindole-6-carboxylate (187 mg) , and the mixture was stirred at 0°C for 20 minutes. The resulting mixture was poured into ammonia water (3 ml) and extracted with ethyl acetate. The combined organic phase was waεhed with brine, then dried over εodium εulfate and evaporated in vacuo. The residue was chromatographed on silica gel to give methyl 1- (2-chlorobenzyl) -3-formyl-2-propylindole-6-carboxylate (153 mg) as colorlesε oil. NMR (CDCi 3 , δ) : 1.00 (3K, t, J=7Hz) , 1.66 (2H, m) , 3.01 (2K, t, J=7Hz), 3.90 (3K, ε) , 5.48 (2H, ε) , 5.29 (IK, d, J=8Hz), 7.06 (IH, t, J=8Hz) , 7.24 (IH, t, J=8Hz ) , 7 . 47 ( IH, d, J=8Hz ) , 7 . 91 ( IH, s ) , 8 . 01 ( IH, d, J=8Hz ) , 8 . 37 ( IH, d, J=8Hz ) , >10 ( IH, s ) Example 33 Methyl 1- (2-chlorobenzyl) -3-phenylacetyl-2-propylindole- 6-carboxylate (230 mg) was prepared from methyl l-(2- chlorobenzyl) -2-propylindole-6-carboxylate (380 mg) and phenylacetyl chloride (189 mg) in a similar manner to that of Preparation 1 (5) . NMR (CDC1 3 , δ) : 0.97 (3H, t, J=8Hz) , 1.55-1.67 (2H, m) , 3.02-3.07 (2H, ) , 3.91 (3H, s) , 4.42 (2H. s), 5.52 (2H, s), 6.24 (IH, d, J=8Hz) , 7.05 (IH, t, J=8Hz), 7.20-7.40 (6H, m) , 7.46 (IH, d, J=8Hz) , 7.97 (IH, s), 7.99 (IH, d, J=8Hz) , 8.11 (IH, d, J=8Hz) Example 34 The following compounds described in 1) to 21) were prepared from the compound (I-l) obtained in Example 28, Example 29, Example 30, Example 32 or Example 33 in a similar manner to that of Example 2. (1) 1- (2-Fluorobenzyl) -3-isobutyryl-2-propylindole-6- carboxylic acid mp : 212-213 β C IR (KBr) : 1685, 1650 cm "1 NMR (CDC1 3 , δ) : 1.03 (3H, t, J=7Hz) , 1.30 (6H, d, J=7Hz), 1.55-1.68 (2H, m) , 3.09-3.14 (2H, ) , 3.52- 3.62 (IH, m) , 5.50 (2H, s) , 6.47 (IH, t, J=7.5Hz), 6.97 (IH, t, J=7.5Hz), 7.15 (IH, t, J=7.5Hz), 7.24- 7.30 (IH, m) , 7.95-8.04 (2H, m) , 8.08 (IH, s) MASS (m/z) : 380 (M + -l) (2 ) 1- (2-Bromobenzyl) -3-isobutyryl-2-propylindole-6- carboxylic acid mp : 193-194°C IR (KBr) : 1690, 1670 cm "1 NMR (CDC1 3 , δ) : 1.03 (3H, t, J=7Hz), 1.31 (6H, d, J=7Hz), 1.57-1.65 (2H, m) , 3.01-3.07 (2H, ) , 3.52- 3.61 (IH, m) , 5.49 (2H, s), 6.22 (IH, t, J=7.5Hz), 7.07-7.18 (2H, m) , 7.66 (IH, t, J=7.5Hz), 7.97-8.01 (3H, m) MASS (m/z) : 442 (M ÷ ), 440 (M + -2) (3) 1- (2-Iodobenzyl) -3-isobutyryl-2-propylindole-6- carboxylic acid mp : 210°C IR (KBr) : 1710, 1640, 1435, 1200 cm "1 NMR (CDC1 3 , δ) : 1.04 (3K, t, J=7Kz) , 1.31 (6H, d, J=7Hz), 1.55-1.68 (2H, m) , 3.00-3.06 (2H, m) , 3.53- 3.62 (IH, m) , 5.38 (2H, s) , 6.18 (IH, d, J=7.5Hz), 6.99 (IH, t, J=7.5Hz), 7.14 (IH, t, J=7.5Hz), 7.94 (IH, d, J=7.5Hz), 7.97-8.03 (3H, m) MASS (m/z) : 488 (M + -l), 61 (bp) (4) 3-Iεobutyryl-l- (2-methylbenzyl) -2-propylindole-6- carboxylic acid mp : 186-188°C IR (KBr) : 1690 cm "1 NMR (CDCI3, δ) : 1.01 (3H, t, J=7Hz) , 1.31 (6H, d, J=7Hz), 1.56-1.69 (2H, m) , 2.50 (3H, ε), 3.02-3.09 (2H, m) , 3.52-3.67 (IH, m) , 5.39 (2K, ε), 6.17 (IH, d, J=7.5Hz), 6.98 (IH, t, J=7.5Hz), 7.17 (IH, t, 7.97 (IH, ε), 8.00 (2H, ε) MASS (m/z) : 378 (M ÷ +l), 76 (bp) (5) 3-Iεobutyryl-l- (2-methoxybenzyl) -2-propylindole-6- carboxylic acid mo : 190-191°C BAD OW«'^ IR (KBr) : 1685, 1650, 1250 cm "1 NMR (CDC1 3 , δ) : 1.03 (3K, t, J=7Hz) , 1.30 (6H, d, J=7Hz), 1.58-1.68 (2H, m) , 3.07-3.13 (2H, m) , 3.54- 3.63 (IH, m) , 3.98 (3H, s), 5.45 (2H, ε) , 6.30 (IH, d, J=7.5Hz), 6.75 (IH, t, J=7.5Hz), 6.94 (IH, d, J=7.5Hz), 7.24 (IH, t, J=7.5Hz), 7.94-8.02 (2H, m) , 8.05 (IH, s) MASS (m/z) : 394 (M + +l), 76 (bp) (6) 1- (2-Cyanobenzyl) -3-isobutyryl-2-propylindole-6- carboxylic acid mp : 213.5-215°C IR (KBr) : 2220, 1717 cm "1 NMR (CDC1 3 , δ) : 1.04 (3K, t, J=7Hz), 1.31 (6H, d, J=7Hz), 1.53-1.67 (2H, m) , 3.04-3.09 (2H, ) , 3.52- 3.62 (IH, m) , 5.69 (2H, s), 6.47-6.50 (IH, ) , 7.39-7.44 (2H, m) , 7.77-7.80 (IH, m) , 7.99-8.04 (3H, m) MASS (m/z) : 389 (M + -l), 76 (bp) (7) 3-Isobutyryl-l- (2-nitrobenzyl) -2-propylindole-6- carboxylic acid mp : 214-215°C IR (KBr) : 1695, 1655, 1545 cm "1 NMR (CDCI3, δ) : 1.02 (3K, t, J=7Hz) , 1.32 (6H, d, J=7Hz), 1.57-1.65 (2H, m) , 3.03 (2H, t, J=7Hz) , 3.54-3.63 (IH, m) , 5.89 (2H, s), 6.28 (IH, d, J=7.5Hz), 7.39-7.51 (2K, m) , 7.92 (IH, ε), 8.02 (2H, ε), 8.30 (IH, d, J=7.5Hz) MASS (m/z) : 409 (M + +l) ( 8 ) 1- ( 2 , c-Dichlorobenzyl ) -3-iεobutyryl-2-propylindole- 6- carboxylic acid p : 241 . 5-243 °C ( dec . ) IR (KBr ) : 1 675 , 1650 cm " 1 BAD ORIGINAL ώ NMR (CDC1 3 , δ) : 0.99 (3H, t, J=7Hz) , 1.28 (6H, d, J=7Hz), 1.39-1.52 (2K, m) , 3.17-3.22 (2H, m) , 3.50- 3.59 (IH, ) , 5.71 (2H, ε) , 7.24-7.28 (IK, m) , 7.37-7.40 (2H, m) , 7.94 (2H, q, J=7.5Hz), 8.10 (IH, s) MASS (m/z) : 432 (M x +1), 76 (bp) (9) 1- (2-Chloro-4-fluorobenzyl) -3-isobutyryl-2-propylindole- 6-carboxylic acid mp : 243-244°C IR (KBr) : 1676, 1648, 1491 cm "1 NMR (CDCI3, δ) : 1.03 (3H, t, J=7Hz) , 1.30 (6H, d, J=7Hz), 1.60 (2H, εextet, J=7Hz), 3.01-3.07 (2H, m) , 3.53-3.62 (IH, m) , 5.49 (2H, ε) , 6.20-6.26 (IH, ) , 6.79 (IH, ddd, J=7.5, 7.5, 1Hz), 7.23 (IH, dd, J=7.5, 1Hz), 7.96 (IH, s) , 7.99 (IH, d, J=7.5Hz) MASS (m/z) : 414 (M + -l) (10) 1- (4-Bromo-2-fluorobenzyl)-3-isobutyryl-2-propylindole- 6-carboxylic acid mp : 210-211 β C IR (KBr) : 1677, 1646, 1486 cm "1 NMR (CDC1 3 , δ) : 1.04 (3H, t, J=7Hz) , 1.30 (6H, d, J=7Hz), 1.55-1.67 (2H, m) , 3.07-3.12 (2H, ) , 3.52- 3.60 (IH, m) , 5.46 (2H, ε), 6.32 (IH, t, J=7.5Hz), 7.11 (IH, d, J=7.5Hz), 7.35 (IH, d, J=7.5Hz), 7.96- 8.03 (3H, m) MASS (m/z) : 460 (M τ ) , 458 (M + -2) (11 ) 3-Benzoyl-l- (2-chlorobenzyI) -2-propylindole-6-carboxylic acid NMR (DMSO-d 6 , δ) : 0.95 (3H, t, J=8Hz) , 1.66 (2H, sextet, J=8Hz), 2.98 (2K, t, J=8Hz), 5.55 (2H, s), 6.35 (IH, dd, J=l, 8Hz) , 7.09 (IH, dt, J=l, 8Hz) , 7.20-7.27 (2H, m) , 7.48 (IK, t, J=8Kz), 7.57-7.62 96/32379 - 116 - (IK, m) , 7.72-7.82 (3H, m) , 7.98 (IH, s) (12) 1- (2-Chlorobenzyl) -3-cyano-2-propylindole-6-carboxylic acid mp : 239.5-241°C IR (KBr) : 2224, 1671, 1287, 1264 cm "1 NMR (CDC1 3 , δ) : 1.00 (3H, t, J=7Hz) , 1.70 (2H, sextet, J=7Hz), 2.89 (2H, t, J=7Hz) , 5.50 (2H, s), 6.25 (IH, d, J=7.5Hz), 7.18 (IH, ddt, J=7.5, 7.5, 1Hz), 7.25 (IH, ddd, J=7.5, 7.5, 1Hz) , 7.47 (IH, d, J=7.5Hz), 7.78 (IK, dd, J=7.5, 1Hz) , 7.99 (IK, d, J=lHz), 8.01 (IH, d, J=7.5Hz) MASS (m/z) : 351 (M + -l) (13) 1- (2-Chlorobenzyl)-2-ethyi-3-isobutyrylindole-6- carboxylic acid NMR (CDCi 3 , δ) : 1.22 (3H, t, J=7Hz), 1.31 (6H, d, J=7Hz), 3.12 (2H, q, J=7Hz) , 3.57 (IH, m) , 5.51 (2K, ε), 6.23 (IH, d, J=8Hz), 7.04 (IH, t, J=8Hz) , 7.22 (IH, t, J=8Hz), 7.47 (IH, d, J=8Hz), 7.95-8.05 (3H, m) (14) 1- (2-ChIorobenzyl)-3-iεobutyryl-2-methylindole-6- carboxylic acid NMR (CDC1 3 , δ) : 1.31 (6H, d, J=7Hz), 2.72 (3H, s) , 3.56 (IH, m) , 5.51 (2H, ε), 6.25 (IK, d, J=8Hz), 7.05 (IH, t, J=8Hz), 7.23 (IK, t, J=8Kz), 7.46 (IH, ά, J=8Hz), 8.05 (3H, ε) (15) 1- (2-ChIorobenzyl) -3-iεobutyryl-2-methoxymethylindole-6- carboxyiic acid NMR (CDCI3, δ) : 1.32 (6E, d, J=7Hz), 3.35 (3H, s) , 3.58 (IH, m) , 4.94 (2H, s) , 5.68 (2H, s) , 6.28 (IH, d, J=8Hz), 7.03 (IH, t, J=8Hz), 7.20 (IH, t, J=8Hz), 7.45 (IH, d, J=8Hz) , 8.0-8.05 (3H, m) BAD ORIGINAL (16) 1- (2-Chlorobenzyl) -3-isobutyrylindole-6-carboxylic acid NMR (CDC1 3 , δ) : 1.25 (6H, d, J=7Hz), 3.30 (IH, m) , 5.52 (2H, s), 6.79 (IH, d, J=8Hz), 7.18 (IH, t, J=8Hz), 7.28 (IH, t, J=8Hz) , 7.47 (IH, d, J=8Hz) , 7.91 (IH, ε), 8.03 (IH, d, J=8Hz) , 8.12 (IH, ε) , 8.48 (IH, d, J=8Hz) (17) 3-Iεobutyryl-2-propyl-l- (2-pyridylmethyl) indole-6- carboxylic acid NMR (DMSO-d 6 , δ) : 0.92 (3H, t, J=7Hz), 1.16 (6H, d, J=7Hz), 1.46 (2H, sextet, J=7Hz) , 3.12-3.17 (2¥. f rc) , 3.52 (2H, septet, J=7Hz) , 5.72 (2H, s) , 7.16 (IK, d, J=8Hz), 7.29 (IK, dd, J=5, 8Hz), 7.76 (IH, t, J=8Hz), 7.81 (IH, d, J=8Hz) , 7.96 (IH, t, J=8Hz), 8.06 (IH, s), 8.48 (IH, d, J=5Hz) (18) 1- (2-Chlorobenzyl) -2, 3-diethylindole-6-carboxylic acid mp : 258-259 β C (dec.) IR (KBr) : 1675, 1290 cm "1 NMR (CDC1 3 , δ) : 1.14 (3H, t, J=7Hz) , 1.30 (3H, t, J=7Hz), 2.71 (2H, q, J=7Kz), 2.80 (2H, q, J=7Hz) , 5.45 (2K, s), 6.18 (IH, d, J=7.5Hz), 7.00 (IH, t, J=7.5Hz), 7.19 (IH, t, J=7.5Hz) , 7.42 (IH, d, J=7.5Hz), 7.62 (IH, d, J=7.5Hz) , 7.84 (IH, d, J=7.5Hz), 7.91 (IH, s) MASS (m/z) 340 (M + -l) (19) I- (2-Chlorobenzyl) -3-formyl-2-propylindole-6-carboxylic acid NMR (CDC1 3 , δ) : 1.01 (3H, t, J=7Hz) , 1.67 (2H, m) , 3.03 (2H, t, J=7Hz), 5.50 (2H, s), 6.40 (IH, d, J=8Hz), 7.08 (IH, t, J=8Hz), 7.24 (IH, t, J=8Hz) , 7.48 (IH, d, J=8Hz), 7.98 (IK, s), 8.07 (IH, d, J=8Hz), ,8.40 (IH, d, J=8Hz) BAD Hl iNΛu ^ (20) (2-Chlorobenzyl) -3-phenyl__cetyl-2-propylindole-6- carboxylic acid NMR (DMSO-d 6 , δ) : 0.90 (3H, t, J=8Hz), 1.45 (2H, sextet, J=8Hz), 3.04-3.08 (2H, m) , 4.43 (2H, s), 5.68 (2H, s), 6.27 (IH, d, J=8Hz) , 7.18 (IH, t, J=8Hz), 7.23-7.35 (6K, m) , 7.58 (IH, d, J=8Hz), 7.85 (IH, d, J=8Hz), 7.98 (IH, ε), 8.19 (IH, d, J=8Hz) (21) 3-Acetyl-l- (6-chloro-3, -methylenedioxybenzyl) -2- propylindole-6-carboxylic acid mp : 238-239°C NMR (CDCi 3 -CD 3 OD = 1:1, δ) : 1.06 (3H, t, J=8Hz) , 1.65 (2H, sextet, J=8Hz), 2.76 (3H, s) , 3.08-3.14 (2H, m) , 5.48 (2H, s), 5.74 (IH, ε) , 5.92 (2H, ε), 6.96 (IH, ε), 7.99 (IH, d, J=8Kz) , 8.02 (IH, ε), 8.08 (IH, d, J=8Hz) Example 35 Methyl 3-acetyl-l- (2-chlorobenzyl) -2-ethylindole-6- carboxylate (170 mg) waε prepared from methyl 3-acetyl-2- ethylindole-6-carboxylate (100 mg) and 2-chIorobenzyl bromide (CO6 ml) in a εimilar manner to that of Example 1. This product was used immediately without purification m the below-mentioned Example 36. Example 36 3-AcetyI-l- (2-chlorobenzyi) -2-ethylindole-6-carboxylic acid (137 mg) was prepared from methyl 3-acetyl-l- (2- chiorobenzyl) -2-ethylindole-6-carboxylate (170 mg) in a similar manner to that of Example 2. NMR (DMSO-d 6 , δ) : 1.11 (3H, t, J=7Hz), 2.67 (3K, s), 3.11 (2H, q, J=7Hz), 5.68 (2H, ε) , 6.26 (IH, d, J=8Hz), 7.19 (IK, t, J=8Hz) , 7.32 (IH, t, J=8Hz), 'BAD ORIGINAL ( 7 . 58 ( IH, d, J=8Hz ) , 7 . 83 ( IH, d, J=8Hz ) , 7 . 94 ( IH, s ) , 8 . 13 ( IH, d, J=8Hz ) Example 37 The following compounds described in 1) to 19) were prepared from the compound (1-2) obtained in Example 34 and Example 36 in a similar manner to that of Example 3. (1) 1- (2-Fluorobenzyl) -3-isobutyryl-2-propylindole-6- carboxyamide mp : 198°C IR (KBr) : 3200, 1650, 1610 cm -1 NMR (CDC1 3 , δ) : 1.03 (3H, t, J=7Hz) , 1.30 (6H, d, J=7Hz), 1.55-1.64 (2H, m) , 3.06-3.12 (2H, m) , 3.50- 3.60 (IH, m) , 5.50 (2H, s) , 6.42 (IH, t, J=7.5Hz), 6.95 (2H, t, J=7.5Hz), 7.09-7.17 (IH, m) , 7.22-7.28 (IH, m) , 7.61 (IH, t, J=7.5Hz), 7.90 (IH, s) , 7.96 (IH, t, J=7.5Hz) MASS (m/z) : 381 (M + +l) (2) 1- (2-Bromobenzyl) -3-isobutyryl-2-propylindole-6- carboxamide mp : 173-174°C IR (KBr) : 3400, 1660, 1630 cm "1 NMR (CDC1 3 , δ) : 1.03 (3H, t, J=7Hz) , 1.30 (6H, d, J=7Hz), 1.57-1.68 (2H, m) , 3.00-3.06 (2H, m) , 3.51- 3.61 (IH, m) , 5.46 (2H, s) , 6.20 (IH, t, J=7.5Hz), 7.05-7.18 (2H, m) , 7.60-7.66 (IH, m) , 7.83 (IH, s), 7.99 (IH, t, J=7.5Hz) MASS (m/z) : 443 (M + +2), 441 (M + ) , 76 (bp) (3) 1- (2-Iodobenzyl) -3-isobutyryl-2-propylindole-6- carboxamide mp : 186-187 β C IR (KBr) : 3400, 1665, 1640 cm "1 NMR (CDC1 3 , δ) : 1.03 (3H, t, J=7Hz) , 1.30 (6H, d, J=7Hz), 1.54-1.67 (2H, m) , 2.99-3.05 (2H, m) , 3.51- 3.60 (IH, m) , 5.39 (2H, ε), 6.15 (IH, d, J=7.5Hz), 6.99 (IH, t, J=7.5Kz), 7.11 (IH, t, J=7.5Hz), 7.64 (IH, d, J=7.5Hz), 7.82 (IH, ε), 7.92 (IH, d, J=7Hz), 7.99 (IH, d, J=7Hz) MASS (m/z) : 489 (M + +l), 76 (bp) (4) 3-Iεcbutyryl-l- (2-methylbenzyl) -2-propylindole-6- carbcxamide mp : 190-191°C IR (KBr) : 3395, 1650, 1625, 1410 cm "1 NMR (CDCI3, δ) : 1.00 (3H, t, J=7Hz) , 1.31 (6H, d, J=7Hz), 1.54-1.68 (2H, m) , 2.49 (3H, ε), 3.00-3.07 ;2H, m) , 3.52-3.61 (IK, m) , 5.38 (2H, ε), 6.14 (IH, d, J=7.5Hz), 6.98 (IH, t, J=7.5Hz), 7.17 (IH, t, J=7.5Hz), 7.24 (IH, d, J=7.5Hz), 7.60 (IH, d, J=7.5Hz), 7.82 (IH, s) , 7.99 (IH, d, J=7.5Hz) MASS ;m/z) : 377 (M + +l), 76 (bp) (5) 3-Iscbutyryl-l- (2-methoxybenzyl) -2-propylindole-6- carboxamide mp : 174-175°C IR (KΞr) : 3370, 1655, 1650, 1625 cm "1 NMR (CDC1 3 , δ) : 1.01 (3K, t, J=7Hz) , 1.30 (6H, d, :=7Kz), 1.57-1.69 (2H, m) , 3.05-3.10 (2H, m) , 3.52- 3.61 (IH, m) , 3.97 (3H, s), 5.43 (2H, s), 6.24 (IH, c, J=7.5Hz), 6.74 (2H, t, J=7.5Hz), 6.93 (IH, d, =7.5Hz), 7.24 (IK, t, J=7.5Hz), 7.59 (IH, d, =7.5Hz), 7.88 (IH, ε), 7.97 (IH, d, J=7.5Hz) MASS ,.-/z) : 393 (M + +i), 76 (bp) ( 6 ) 1- ( 2-Cyanobenzyl ) -3-iεobutyryl-2-propylindoie-6- carboxamide mo : 143-144 β C 1 BAD ORIGINAL 96/32379 - 121 - IR (KBr) : 3377, 3190, 2227, 1645 cm "1 NMR (CDC1 3 , δ) : 1.04 (3K, t, J=7Hz), 1.30 (6H, d, J=7Hz), 1.52-1.65 (2H, m) , 3.02-3.08 (2H, m) , 3.50- 3.59 (IH, m) , 5.68 (2H, s) , 6.45-6.49 (IH, m) , 7.38-7.43 (2H, ) , 7.65 (IH, d, J=7.5Hz), 7.74-7.78 (IH, m) , 7.87 (IH, s), 7.99 (IH, d, J=7.5Hz) MASS (m/z) : 388 (M + τl), 62 (bp) (7) 3-Iεobutyryl-l- (2-nitrobenzyl) -2-propylindole-6- carboxamide mp : 181-182°C IR (KBr) : 3190, 1670, 1610, 1535, 1400 cm -1 NMR (CDCI3, δ) : 1.00 (3H, t, J=7Hz), 1.32 (6H, d, J=7Hz), 1.58-1.67 (2H, ) , 3.02 (2H, t, J=7Hz) , 3.52-3.61 (IH, ) , 5.89 (2H, s), 6.27 (IH, d, J=7.5Hz), 7.39-7.50 (2H, m) , 7.63 (IH, d, J=7.5Hz), 7.80 (IH, ε), 7.99 (IH, d, J=7.5Hz), 8.28 (IH, d, J=7.5Hz) MASS (m/z) : 408 (M ÷ ÷l), 76 (bp) (8) 1- (2, 6-DichlorobenzyI) -3-isobutyryi-2-propylindole-6- carboxamide p : 207.5-209°C IR (KBr) : 3395, 1650, 1615 cm "1 NMR (CDCI3, δ) : 0.98 (3H, t, J=7Hz), 1.28 (6H, d, J=7Hz), 1.39-1.50 (2H, m) , 3.16-3.21 (2H, m) , 3.49-3.58 (IH, m) , 5.70 (2H, s), 7.22-7.25 (IH, m) , 7.35-7.39 (2H, m) , 7.60 (IH, d, J=7.5Hz), 7.86-7.90 (2K, m) , 7.99 (IH, d, J=7.5Hz) MASS (m/z) : 431 (M + τl), 76 (bp) ( ) 1- (2-Chloro-4-fluorobenzyl) -3-isobutyryl-2-propylindole- 6-carboxamide mp : 192-193°C IR (KBr) : 3336, 318C, 1650, 1494, 1411 cm "1 96/32379 - 122 - NMR (CDCI3, δ) : 1.03 (3H, t, J=7Hz) , 1.30 (6H, d, J=7Hz), 1.53-1.65 (2H, m) , 3.C1-3.07 (2H, m) , 3.50- 3.60 (IH, m) , 5.47 (2H, ε), 6.20 (IH, dd, J=8, 7.5Hz), 6.78 (IH, ddd, J=7.5, 7.5, 1Hz) , 7.23 (IH, dd, J=8, 1Hz), 7.63 (IH, d, J=7.5Hz), 7.85 (IH, ε), 7.99 (IH, d, J=8Hz) MASS (m/z) : 415 (M + +l), 76 (bp) (10) 1- (4-Bromo-2-fluorobenzyl) -3-isobutyryl-2-propylindole- 6-carboxamide mp : 197-198.5°C IR (KBr) : 3377, 3189, 1652, 1617, 1487, 1408 cm "1 NMR (CDCI3, δ) : 1.04 (3H, t, J=7Hz), 1.30 (6H, d, J=7Hz), 1.53-1.64 (2H, m) , 3.05-3.11 (2H, m) , 3.48- 3.60 (IH, m) , 5.44 (2H, s), 6.29 (IH, t, J=7.5Hz), 7.09 (IH, d, J=7.5Hz), 7.33 (IH, dd, J=7.5, 1Hz), 7.62 (IK, d, J=7.5Hz), 7.90 (IK, d, J=lHz) , 7.97 (IH, d, J=7.5Hz) MASS (m/z) : 461 (M + +2), 459 (M + ), 76 (bp) (11) 1- (2-Chlorobenzyl)-3-cyano-2-propylindole-6-carboxamide mp : 222-223.5°C IR (KBr) : 3443, 3183, 2215, 1679, 1394 cm "1 NMR (CDCI3, δ) : 1.02 (3H, t, J=7Hz), 1.70 (2H, sextet, J=7Hz), 2.89 (2H, t, J=7.5Hz), 5.50 (2K, s), 6.21 (IH, d, J=7.5Kz), 7.08 (IH, t, J=7.5Hz), 7.24 (IH, ddd, J=7.5, 7.5, 1Hz), 7.47 (IH, d, J=7.5Hz), 7.61 (IH, d, J=7.5Hz), 7.77 (IH, d, J=7.5Hz), 7.89 (IK, d, J=lHz) MASS (m/z) : 352 (M + +l), 76 (bp) ( 12 ) 1- ( 2-Chlorobenzyl ) -2-ethyl-3-isobutyrylindole- 6- carboxamide mp : 178- i S C . 5°C NMR ( CDCI 3 , δ ) : 1 .22 ( 3H, t , J=7Hz ) , 1 . 30 ( 6H, d, 1 l L Ai O 96/32379 - 123 - J=7Hz), 3.09 (2H, q, J=7Hz) , 3.56 (IH, m) , 5.51 (2H, ε), 6.22 (IH, d, J=8Hz) , 7.04 (IH, t, J=8Hz) , 7.22 (IH, t, J=8Hz), 7.44 (IH, d, J=8Hz) , 7.63 (IK, d, J=8Hz), 7.82 (IK, ε), 7.98 (IH, d, J=8Hz) (13) 1- (2-Chlorobenzyl) -3-isobutyryl-2-methylindole-6- carboxamide mp : 212-215°C NMR (CDC1 3 , δ) : 1.30 (6H, d, J=7Hz), 2.69 (3H, ε), 3.53 (IH, m) , 5.48 (2H, ε), 6.21 (IH, d, J=8Hz) , 7.04 (IK, t, J=8Hz), 7.23 (IH, t, J=8Hz) , 7.45 (IH, d, J=8Hz), 7.62 (IK, d, J=8Hz), 7.87 (IK, ε), 8.03 (IH, d, J=8Hz) (14) 1- (2-Chlorobenzyl) -3-isobutyryl-2-methoxymethylindole-6- carboxamide mp : 204-206°C NMR (CDCI3, δ) : 1.32 (6H, d, J=7Hz) , 3.34 (3H, s) , 3.57 (IH, ) , 4.92 (2K, s), 5.65 (2K, ε), 6.24 (IH, d, J=8Hz), 7.03 (IH, t, J=8Hz) , 7.21 (IK, t, J=8Hz), 7.44 (IH, d, J=8Hz) , 7.67 (IH, d, J=8Kz), 7.83 (IK, s), 8.02 (IK, d, J=8Hz) (15) 1- (2-Chlorobenzyl)-3-isobutyrylindole-6-carboxamide mp : 235-237°C NMR (DMSO-d β , δ) : 1.16 (6K, d, J=7Hz) , 3.40 (IK, m) , 5.67 (2K, s), 6.70 (IK, d, J=8Hz) , 7.2-7.4 (3K, m) , 7.56 (IK, d, J=8Hz), 7.80 (IK, d, J=8Hz), 7.96 (IH, br s), 8.04 (IH, s), 8.27 (IH, d, J=8Hz), 8.64 (IH, s) (16) 3-Isobutyryl-2-propyl-l- (2-pyridylmethyl) indole-6- carboxamide NMR (DMSO-d 6 , δ; : 0.90 (3H, t, J=7Hz) , 1.17 (6H, d, J=7Hz), 1.4c (2H, sextet, J=7Hz), 3.0S-3.15 (2H, - 124 - m) , 3.52 (2H, septet, J=7Hz) , 5.66 (2H, s), 7.08 (IH, d, J=8Hz), 7.28-7.32 (2H, m) , 7.78 (IH, d, J=8Hz), 7.92 (IH, d, J=8Hz) , 8.09 (IH, s) , 8.50 (IH, d, J=5Hz) (17) 1- (2-Chlorobenzyl) -2, 3-diethylindole-6-carboxamide mp : 185-187.5°C IR (KBr) : 3400, 1650, 1610 cm "1 NMR (CDC1 3 , δ) : 1.15 (3H, t, J=7Hz) , 1.29 (3H, t, J=7Hz), 2.69 (2H, q, J=7Hz) , 2.80 (2H, q, J=7Hz', , 5.44 (2H, s), 6.17 (IH, d, J=7.5Hz), 7.00 (IH, t, J=7.5Hz), 7.18 (IH, t, J=7.5Hz), 7.41 (IH, d, J=7.5Hz), 7.47 (IK, d, J=7.5Hz), 7.62 (IH, d, J= 7 .5Hz), 7.76 (IH, s) MASS (m/z) : 341 (M + +l), 76 (bp) (18) 3-AcetyI-i- (2-chlorobenzyl) -2-ethylindole-6-carboxamide mp : 217-220°C NMR (CDCI3, δ) : 1.22 (3K, t, J=7Kz) , 2.73 (3H, s) , 3.12 (2K, q, J=7Hz), 5.49 (2H, s), 6.20 (IH, d, J=8Kz), 7.02 (IH, t, J=8Hz), 7.22 (IH, t, J=8Hz), 7.43 (IH, d, J=8Hz), 7.63 (IH, d, J=8Hz), 7.83 (IH, s), 8.08 (IH, d, J=8Hz) (19) 1- (2-Chlcroben∑yl) -3-formyl-2-propylindole-6-carboxamide mp : 245°C (dec.) NMR (DMSO-Dg, δ) : 0.92 (3H, t, J=7Hz) , 1.63 (2H, m) , 3.11 (2H, t, J=7Hz), 5.64 (2H, s), 6.32 (IH, d, J=8Hz), 7.21 (IH, t, J=8Hz), 7.25-7.35 (2H, m) , 7.60 (IK, d, J=8Hz), 7.83 (IH, d, J=8Hz) , 7.95 (IH, d, J=8Hz), 7.97 (IK, ≤), 8.21 (IH, d, J=8Hz), >10 (IH, ε; Example 38 The following compounds described in 1) to 3) were - * prepared from the compound (1-2) obtained in Example 34-11), Example 34-20) or Example 34-21) in a similar manner to that of Example 6. (1) 3-Benzoyl-l- (2-chlorobenzyl) -2-propylindole-6- carboxamide NMR (DMS0-d 6 , δ) : 0.78 (3H, t, J=8Hz) , 1.46 (2H, sextet, J=8Hz), 2.88 (2H, t, J=8Hz) , 5.66 (2H, s), 6.33 (IH, dd, J=l, 8Hz) , 7.08 (IH, dt, J=l, 8Hz) , 7.20-7.38 (3H, m) , 7.52-7.72 (7H, m) , 7.88 (IH, br s), 7.99 (IH, s) (2) 1- (2-Chlorobenzyl) -3-phenylacetyl-2-propylindole-6- carboxamide NMR (DMS0-d 6 , δ) : 0.88 (3H, t, J=8Hz) , 1.47 (2H, sextet, J=8Hz), 2.98-3.03 (2H, m) , 4.42 (2H, s) , 5.63 (2H, s), 6.20 (IH, d, J=8Hz) , 7.17 (IH, t, J=8Hz), 7.24-7.35 (6H, m) , 7.57 (IH, d, J=8Hz) , 7.82 (IH, d, J=8Hz) , 7.95 (IH, br s), 8.02 (IH, s) , 8.14 (IH, d, J=8Hz) (3) 3-Acetyl-l- ( 6-chloro-3, 4-methylenedioxybenzyl) -2- propylindole-6-carboxamide p : 220-223°C NMR (DMS0-d 6 , δ) : 0.94 (3H, t, J=8Hz) , 1.50 (2H, sextet, J=8Hz), 2.65 (3H, s), 3.02-3.06 (2H, m) , 5.52 (2H, s), 5.66 (IH, s) , 5.99 (2H, ε) , 7.23 (IH, s), 7.86 (IH, d, J=8Hz) , 8.01 (IH, s), 8.05 (IH, d, J=8Hz) Example 39 To a solution of 3-isobutyryl-2-propyl-l- (2- pyridylmethyl) indole-6-carboxamide (80 mg) in chloroform (2 ml) waε added IM solution of hydrogen chloride in methanol (1 ml) at 25°C, and the mixture was stirred for 15 minutes. After evaporation of solvent, the residue was crystallized from a mixture of ethanol and ethyl acetate to give 3- iεobutyryl-2-propyl-l- (2-pyridylmethyl) indole-6-carboxamide hydrochloride (80 mg) as colorlesε crystals. mp : 230-235°C NMR (DMSO-d 6 , δ) : 0.92 (3H, t, J=7H∑), 1.17 (6H, d, J=7Hz), 1.45 (2H, sextet, J=7Hz) , 3.08-3.14 (2K, m) , 3.52 (2H, εeptet, =7Hz) , 5.74 (2H, s), 7.09 (IH, d, J=8Hz), 7.46 (IH, dd, J=5, 8Hz) , 7.79 (IH, d, J=8Hz), 7.90 (IH, d, J=8Hz) 7.92 (IH, t, J=8K∑), 8.12 (IH, s), 8.62 (IH, d, J=5Hz) Example 40 1- (2-Carboxybenzyl)-3-isobutyryi-2-propylindole-6- carboxamide (242 mg) was prepared from 3-isobutyryl-l- (2- ethoxycarbonylbenzyl) -2-propyiindole-6-carboxamide (265 mg) in a similar manner to that of Example 2. mp : 268-269°C (dec.) IR (KBr) : 1740, 1690, 1625, 1620 cm "1 NMR (DMS0-d 6 , δ) : 0.90 (3H, t, J=7Hz), 1.19 (6H, d, J=7Hz), 1.42-1.51 (2H, ) , 2.94-3.06 (2H, m) , 3.50- 3.60 (IK, m) , 5.96 (2H, s), 6.06-6.10 (IK, m) , 7.37-7.40 (2H, m) , 7.79-7.82 (IH, m) , 7.91-7.95 (IH, m) , 7.99 (IH, s), 8.03-8.06 (IH, m) MASS (m/z) : 407 (M + +l), 86 (bp) Example 41 1- (2-Carbamoylbenzyl) -3-isobutyryl-2-propylindole-6- carboxamide (102 mg) was prepared from 1- (2-carboxybenzyl) -3- iεobutyryl-2-propylindole-6-carboxamide (164 mg) in a similar manner to that of Example 3. p : 273-274 β C IR (KBr) : 1690 cm "1 NMR (DMSO-d 6 , δ) : 0.91 (3K, t, J=7Hz), 1.19 (6K, d, J=7Hz), 1.41-1.51 (2H, m) , 2.94-2.99 (2H, m) , 3.48- I ' AD ORIGINAL f A 1 3.57 (IH, ) , 5.79 (2K, s), 6.17 (IH, d, J=7.5Hz), 7.22-7.35 (3H, m) , 7.61-7.68 (2H, m) , 7.80 (IH, d, J=7.5Hz), 7.92-7.97 (2H, m) , 8.04 (IH, s) , 8.13 (IH, s) MASS (m/z) : 406 (M + +l), 87 (bp) Example 42 To a solution of phosphoruε oxychloride (0.031 ml) in dimethylformamide (1.2 ml) waε added 1- (2-chlorobenzyl)-2- ethyl-3-propionylindole-6-carboxamide (112 mg) at 0°C, and the mixture was stirred for 15 minutes. The resulting mixture was poured into ammonia water and ice, and then extracted with ethyl acetate. The organic phase was washed with brine, dried over sodium sulfate and evaporated in vacuo. The residue was triturated with a mixture of hexane and isopropyl ether to give 1- (2-chlorobenzyl)-2-ethyl-3- propionylindole-6-carbonitrile (93 mg) as a solid. mp : 115-118 β C NMR (CDC1 3 , δ) : 1.25 (3H, t, J=7Hz) , 1.30 (3H, t, J=7Hz), 3.09 (2H, q, J=7Hz) , 3.17 (2H, q, J=7Hz) , 5.47 (2H, s), 6.21 (IH, d, J=8Hz), 7.07 (IH, t, J=8Hz), 7.25 (IH, t, J=8Hz) , 7.45-7.55 (3H, m) , 8.09 (IK, d, J=7Hz) Example 43 1- (2-Chlorobenzyl)-2-ethyl-3-iεobutyrylindole-6- carbonitrile (239 mg) waε prepared from 1- (2-chlorobenzyl) -2- ethyl-3-isobutyrylindole-6-carboxamide (280 mg) in a similar manner to that of Example 42. mp : 132-134°C NMR (CDC1 3 , δ) : 1.23 (3H, t, J=7Hz) , 1.31 (6H, d, J=7Hz), 3.13 (2H, q, J=7Hz) , 3.50 (IH, m) , 5.48 (2H, S), 6.22 (IH, d, J=8Hz) , 7.07 (IH, t, J=8Hz) , 7.27 (IH, t, J=8Hz), 7.27 (IK, d, =8Hz), 7.44-7.53 (2H, m) , 8.02 (IH, d, J=8Hz) D OHlGiNAL QW Example 44 To a solution of 1- (2-chlorobenzyl) -2-ethyl-3- propionylindole-6-carbonitrile (107 mg) in xylene (5 ml) was added trimethyltin azide (190 mg) , and the mixture was stirred at 120°C for 14 hourε. The resulting mixture was poured into IN HC1 and extracted with ethyl acetate. The organic phase waε washed with brine, dried over sodium εulfate and evaporated in vacuo. The reεidue waε chromatographed on silica gel eluting with 20% methanol in chloroform to give 1- (2-chlorobenzyl) -2-ethyl-3-propionyl-6- (lH-tetrazol-5-yl) indole (77 mg) as a solid, mp : 178-181°C NMR (CDC1 3 , δ) : 1.18 (3H, t, J=7Hz), 1.34 (3H, t, J=7Hz), 3.0-3.15 (4H, m) , 5.42 (2H, ε), 6.21 (IH, d, J=8Hz), 6.94 (IH, t, J=8Hz) , 7.13 (IH, t, J=8Hz), 7.33 (IH, d, J=8Hz) , 8.03 (IH, d, J=8Hz) , 6.05 (IH, ε), 8.25 (IH, d, J=8Hz) Example 45 1- (2-ChIorobenzyl) -2-ethyi-3-ioεbutyryl-6- (IH-tetrazol- 5-yl) indole (109 mg) was prepared from 1- (2-chIorobenzyl)-2- ethyl-3-iεcbutyrylindole-6-carbonitrile (130 mg) in a similar manner to that of Example 44. mp : 160-163°C NMR ( C?Zl y , δ) : 1.18 (3K, t, J=7Hz) , 1.31 (6H, d, J=7Hz), 3.04 (2H, q, J=7Hz) , 3.52 (IH, m) , 5.37 (ΣH, s), 6.20 (IH, d, J=8Hz), 6.94 (IH, t, J=8Hz) , 7.11 (In, t, J=8Hz), 7.33 (IH, d, J=8Hz), 8.00 (IK, c, J=8Hz), 8.02 (IK, ε), 8.13 (IK, d, J=8Hz) Example 46 The following compounds described in (1) to (2) were prepared in a similar manner to that of Preparation 30. (1) Methyl 2- (3-carboxypropyl) -1- (2-chlorobenzyl) indole-6- RIGIN*' ) carboxylate NMR (CDC1 3 , δ) : 2.04 (2H, m) , 2.45 (2H, t, J=7Hz) , 2.73 (2H, t, J=7Hz), 3.89 (3H, s) , 5.44 (2H, s) , 6.14 (IH, d, J=8Hz), 6.47 (IH, s), '7.01 (IH, t, J=8Hz), 7.18 (IH, t, J=8Hz) , 7.44 (IH, d, J=8Hz) , 7.62 (IH, d, J=8Hz), 7.83 (IH, d, J=8Hz), 7.93 (IH, s) (2) 2- (2-Carboxyethyl) -1- (2-chlorobenzyl) indole-6- carboxylate NMR (CDC1 3 , δ) : 2.76 (2K, t, J=7Hz), 2.96 (2H, t, J=7Hz), 3.88 (3H, s), 5.46 (2H, s), 6.16 (IH, d, J=8Hz), 6.46 (IH, ε) , 7.01 (IH, t, J=8Hz) , 7.20 (IH, t, J=8Hz), 7.43 (IH, d, J=8Hz) , 7.62 (IH, d, J=8Hz) , 7.82 (IH, d, J=8Hz) , 7.93 (IH, s) Preparation 47 The following compounds described in (1) to (2) were prepared in a similar manner to that of Preparation 31. (1) Methyl 9- (2-chIorobenzyl) -5-oxo-5, 6, 7, 8- tetrahydrocarbazole-2-carboxylate NMR (CDC1 3 , δ) : 2.24 (2H, m) , 2.62 (2H, t, J=7Hz) , 2.86 (2H, t, J=7Hz), 3.90 (3H, s), 5.47 (2H, s), 6.34 (IK, d, J=8Hz) , 7.09 (IH, t, J=8Hz) , 7.25 (IH, t, J=8Hz), 7.47 (IH, d, J=8Hz), 7.97 (IH, s) , 7.99 (IK, d, J=8Hz), 8.33 (IH, d, J=8Hz) (2) Methyl 4- (2-chlorobenzyI) -1-oxo-l, 2, 3, 4- tetrahydrocyclopent [b] indole-6-carboxylate NMR (CDCI3, δ) : 2.9-3.15 (4H, m) , 3.91 (3H, s), 5.46 (2H, s), 6.66 (IH, d, J=8Hz), 7.17 (IH, t, J=8Hz) , 7.29 (IH, t, J=8Kz), 7.48 (IH, d, J=8Hz), 7.94-8.06 (3H, m) B D OR»« lN b Φ. fryample 48 The following compounds described in (1) to (2) were prepared in a similar manner to that of Preparation 1 (5) . (1) Methyl 3-chloroacetyl-l- (2-chlcrobenzyl)-2-propylindole- 6-carboxylate mp : I43-145°C IR (KBr) : 1722, 1666 cm "1 NMR (CDC1 3 , δ) : 1.03 (3H, t, J=7Hz) , 1.55-1.66 (2H, m) , 3.05-3.10 (2H, ) , 3.91 (3H, s), 4.82 (2K, ε), 5.53 (2H, ε), 6.25 (IH, d, J=7.5Hz), 7.05 (IH, t, J=7.5Kz), 7.20-7.25 (IK, m) , 7.49 (IK, d, J=7.5Hz), 7.88 (IH, d, J=8Hz), 7.98 (IH, ε), 8.00 (IH, d, J=8Hz) MASS (m/z) : 418 (M τ -i), 76 (bp) (2) 1- (2-Chlorobenzyl) -3-crotoncyl-2-propylindole-6- carboxamide mp : 185.5-186.5°C IR (KBr) : 1648, 1614, 1443, 1414, 1388 cm "1 NMR (CDCI3, δ) : 1.00 (3K, t, J=7Hz), 1.64 (2H, sextet, J=7Kz), 2.04 ;3H, d, J=7Kz), 3.00 (2H, t, J=7Hz), 5.51 (2H, ε), 6.24 (IH, d, J=8Kz) , 6.92 (IH, d, J=15Hz), 7.00-7.06 (2H, m) , 7.23 (IH, t, J=8Hz), 7.46 (IH, d, J=7.5Hz), 7.60 (IH, d, J=7.5Hz), 7.83 (IH, ε), 7.99 (IH, d, J=8Hz) MASS (m/z) : 395 (M + +l), 74 (bp) Example 49 A mixture of methyl 3-chloroacetyl-l- (2-chlorobenzyl) -2- propylindole-6-carboxylate (123 mg) and morpholine (1 ml) waε εtirred at 50°C for 2.5 hourε. After cooled to 20°C, the reaction mixture was extracted with ethyl acetate. The organic phase was washed with IN hydrochloric acid and water, dried over magnesium sulfate and evaporated in vacuo. The BAD ORIGINAL $ residue waε chromatographed on εilica gel eluting with a mixture of ethyl acetate and hexane (1:2) to give methyl 1- (2-chlorobenzyl)-3-morpholinoacetyl-2-propylindole-6- carboxylate (94 mg) as colorlesε amorphous. IR (KBr) : 1712, 1657 cm -1 NMR (CDC1 3 , δ) : 1.01 (3H, t, J=7Hz) , 1.60-1.65 (2H, m) , 2.70-2.75 (4H, m) , 3.06 (2K, t, J=7Hz) , 3.84 (4H, t, J=7Hz), 3.90 (2H, s) , 3.92 (3H, s) , 5.52 (2H, ε), 6.24 (IH, d, J=7.5Hz), 7.06 (IH, t, J=7.5Hz), 7.24 (IH, t, J=7.5Hz), 7.48 (IH, d, J=7.5Hz), 7.94-7.98 (3H, m) MASS (m/z) : 469 (M + +l) Example 50 To a mixture of methyl 1- (2-chIorobenzyl)-3-formyl-2- propylindole-6-carboxylate (263 mg) , 2-methyl-2-butene (220 mg) and εodium dihydrogenphosphate (128 mg) in a mixture of tert-butancl (7 ml) and water (1.3 ml) was added sodium chlorite (219 mg) at 20 β C. The reaction mixture was stirred at 40°C for 2 hours. The reaction mixture was acidified with IN hydrochloric acid at 0°C and extracted with chloroform three times. The organic phase was dried over sodium sulfate and evaporated in vacuo. The residue waε chromatographed on silica gel eluting with a mixture of ethyl acetate and hexane (1:2) to give 1- (2-chlorobenzyl) -6-methoxycarbonyl-2- propylindole-3-carboxylic acid (94 mg) as pale yellow crystals. mp : 229-231°C (dec.) IR (KBr) : 1715, 1658, 1441, 1275, 1227 cm "1 NMR (CDCI3, δ) : 1.05 (3K, t, J=7Hz), 1.60-1.70 (2H, m) , 3.10-3.18 (2H, m) , 3.93 (3H, s), 5.54 (2H, s), 6.78 (IK, d, J=7.5Hz) , 7.06 (IH, t, J=7.5Hz), 7.21- 7.25 (IK, ) , 7.49 (IH, d, J=7.5Hz), 7.95 (IH, ε) , 7.99 (IK, d, J=8Hz) , 8.33 (IH, d, J=8Hz) MASS (m/z) : 384 (M + -l) , 77 (bp) I BAD O ivaiw- Example 51 To a stirred suspension of 60% sodium hydride (470 mg) in N,N-dimethylformamide (6 ml) waε added a solution of methyl 2-ethylindole-6-carboxylate (1.99 g) in N,N- dimethylformamide (12 ml) at 20°C. The mixture was stirred at 20°C for 30 minutes. To this mixture was added 2- chlorobenzyibromide (2.21 g) at 20°C and the mixture was stirred at 20°C for 5.5 hours. N,N-Dimethylformamide was evaporated off, and the residue waε extracted with ethyl acetate. The organic phase was washed with water and brine, dried over sodium sulfate and evaporated in vacuo. The residue was chromatographed on silica gel eluting with mixture of ethyl acetate and hexane (1:8) to give crystals which were washed with hexane to give methyl l-(2- chlorobenzyl' -2-ethylindole-6-carboxylate (2.71 g) as colorless crystals, mp : 87-89°C IR (KBr! : 1709, 1278, 1236 cm "1 NMR (CDC1 3 , δ) : 1.35 (3K, t, J=7Hz) , 2.67 (2H, q, J=7Hz), 3.91 (3H, s), 5.45 (2H, s), 6.17 (IH, d, J= Kz), 6.46 (IH, s), 7.02 (IH, dd, J=7, 7Hz) , 7.19 (IK, dd, J=7, 7Hz), 7.44 (IK, d, J=7Hz) , 7.62 (IH, d, J=7Hz), 7.72 (IH, d, J=7Hz), 7.93 (IH, ε) MASS (m/z) : 328 (M + +l), 76 (bp) Example 52 The following compound waε prepared in a εimilar manner to that of Example 32. Methyl 1- (2-chIorobenzyl) -2-ethyl-3-formylindole-6- carboxylate mp : 166-169°C IR (KBr! : 1715, 1650 cm "1 NMR (CDCI3, δ) : 1.27 (3H, t, J=7Hz) , 3.06 (2H, q, J=7Kz , 3.90 (3K, s), 5.50 (2H, s), 6.18 (IH, d, I L O 96/32379 - 133 - J=7Hz), 7.05 (IH, t, J=7Hz), 7.21-7.24 (IH, ) , 7.48 (IK, d, J=7.5Hz), 7.95 (IH, s) , 8.01 (IH, d, J=7Hz), 8.28 (IH, d, J=7Hz) , 10.25 (IH, s) MASS (m/z) : 356 (M + +l), 76 (bp) Example 53 A mixture of 1- (2-chlorobenzyl)-3-isobutyryl-2- propylindoIe-6-carboxyiic acid (100 mg) , diphenylphosphoryl azide (97 mg) and triethylamine (53 mg) in tert-butanol (4 ml) was refluxed for 2 hourε, and then partitioned between ethyl acetate and diluted with hydrochloric acid. The organic layer waε washed with aqueouε sodium bicarbonate and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by silica gel thin layer chromatography with a mixture of hexane and ethyl acetate (2:1) to give 6-tert-butoxycarbonylamino-l- (2-chlorobenzyl)- 3-isobutyryl-2-propylindole (125 g) as a pale yellow oil. NMR (CDC1 3 , δ) : 0.98 (3H, t, J=7Hz) , 1.28 (6H, d, J=7Hz), 1.48 (9H, s), 1.52-1.64 (2H, m) , 2.96-3.02 (2H, m) , 3.54 (IH, septet, J=7Hz), 5.42 (2H, s), 6.30 (IH, d, J=8Hz), 6.52 (IH, ε), 7.05 (IH, t, J=8Hz), 7.09 (IH, d, J=8Hz) , 7.20 (IH, t, J=8Hz), 7.36-7.45 (2H, m) , 7.82 (IH, d, J=8Hz) Example 54 To a εolution of 6-tert-butoxycarbonylamino-l- (2- chlorooenzyl)-3-iεobutyryl-2-propylindole (110 mg) in ethyl acetate (1 mi, waε added 4N hydrogen chloride in ethyl acetate at 20°C, and the mixture waε stirred at the same temperature for 4 hours. The precipitates were collected by filtration and washed with ethyl acetate to give 6-amino-l- (2-chlcrobenzyl)-3-isobutyryl-2-propylindole hydrochloride (50 mg) aε powder. NMR (DMS0-d 6 , δ) : 0.92 (3H, t, J=7Hz), 1.18 (6H, d, J=7Hz), 1.49 (2K, sextet, J=7Hz) , 3.02-3.08 (2H, BAD ORIGINAL m) , 3.52 (IH, septet, J=7Hz) , 5.58 (2H, s) , 6.24 (IH, d, J=8Hz), 7.17-7.35 (4H, m) , 7.57 (IH, d, J=8Hz), 8.02 (IH, d, J=8Hz) Example 55 To a εtirred εolution of 6-tert-butoxycarbonylamino-l- (2-chlorobenzyl) -3-iεobutyryl-2-propylindole (581 mg) in ethyl acetate (5 ml) waε added 4N hydrogen chloride in ethyl acetate (5 ml) at 20°C. The reaction mixture waε εtirred at 20 β C for 6.5 hours, then diluted with IN aσueous sodium hydroxide and extracted. The organic phase was dried over magnesium sulfate and evaporated in vacuo. The residue waε chromatographed on εilica gel eluting with a mixture of ethyl acetate and hexane (1:6 to 1:4) to give 6-amino-l- (2- chlorobenzyl)-3-iεobutyryl-2-propylindole (361 mg) as yellow oil. NMR (CDC1 3 , δ) : 1.00 (3H, t, J=7Hz), 1.29 (6H, d, J=7Hz), 1.51-1.64 (2H, m) , 2.98-3.03 (2H, m) , 3.49- 3.57 (IH, m) , 5.34 (2H, ε) , 6.36 (IH, d, J=7.5Hz), 6.46 (IH, s), 6.71 (IH, d, J=7.5Hz), 7.08 (IH, t, J=7.5Hz), 7.21 (IH, t, J=7.5Hz), 7.45 (IH, d, J=7.5Hz), 7.85 (IH, d, J=7.5Hz) MASS (m/z) : 369 (M + ÷l) Example 56 To a stirred solution of 6-amino-l- (2-chlorobenzyl) -3- isobutyryl-2-propylindole (79 mg) and triethylamine (0.065 ml) in dichloromethane (2 ml) was added acetyl chloride (0.02 ml) at 0°C. The reaction mixture was stirred at 20°C for 2 hours, then diluted with dichloromethane. The organic phase was washed with IN hydrochloric acid, water, aσueous sodium bicarbonate, water and brine, dried over magnesium εulfate and evaporated in vacuo. The residue was chromatographed on silica gel eluting with a mixture of ethyl acetate and hexane (2:3) to give crystalε which were recryεtallized from a * mixture of ethyl acetate and hexane to give 6-acetamide-l- (2- chlorobenzyl)-3-isobutyryl-2-propylindole (48 mg) as colorless crystals, mp : 147-148°C IR (KBr) : 1664, 1648, 1507, 1412 cm "1 NMR (CDC1 3 , δ) : 1.00 (3H, t, J=7Hz) , 1.29 (6H, d, J=7Hz), 1.51-1.65 (2H, m) , 2.17 (3H, s), 2.99-3.05 (2H, m) , 3.49-3.58 (IH, ) , 5.43 (2H, s) , 6.30 (IH, d, J=7.5Hz), 7.04 (IH, t, J=7.5Hz), 7.13-7.23 (3H, m) , 7.44 (IH, d, J=7.5Hz), 7.72 (IH, s) , 7.85 (IH, d, J=7.5Hz) MASS (m/z) : 411 (M + +l) Example 57 To a stirred solution of 6-amino-l- (2-chlorobenzyl) -3- isobutyryl-2-propylindole (100 mg) in chloroform (2 ml) was added methylisocyanate (0.5 ml) at 0 β C. The reaction mixture was stirred at 20°C for 1 hour, then evaporated. The residue was chromatographed on silica gel eluting with a mixture of ethyl acetate and hexane (1:1) to give crystals which were recrystallized from a mixture of ethyl acetate and hexane to give 1- (2-chlorobenzyl)-3-isobutyryl-6- (3-methylureido)-2- propylindole (75 mg) as colorless crystals, mp : 106-108.5 β C IR (KBr) : 1635, 1550, 1506 cm "1 NMR (CDC1 3 , δ) : 1.01 (3H, t, J=7Hz) , 1.30 (6H, d, J=7Hz), 1.53-1.65 (2H, ) , 2.78 (3H, d, J=7Hz) , 3.00-3.06 (2H, m) , 3.49-3.57 (IH, m) , 4.61 (IH, d, J=7Hz), 5.42 (2H, s), 6.29-6.32 (2H, m) , 7.02-7.07 (2H, m) , 7.22 (IH, ddd, J=7.5, 7.5, 1Hz) , 7.46 (IH, d, J=7.5Hz), 7.88 (IH, d, J=7.5Hz) MASS (m/z) : 426 (M + +l), 76 (bp) Example 58 To a stirred solution of 6-amino-l- (2-chlorobenzyl)-3- isobutyryl-2-propylindoie (147 mg) in dichloromethane (2 ml) was added acetic formic anhydride (0.5 ml) at 0°C. The reaction mixture was stirred at 0°C for 10 minutes, then diluted with dichloromethane. The organic phase was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was chromatographed on silica gel eluting with a mixture of ethyl acetate and hexane (1:2) to give crystals which were recrystallized from a mixture of ethyl acetate and hexane to give l-(2- chlorobenzyl) -6-formamido-3-isobutyryl-2-propylindole (85 mg) aε colorleεε crystals, mp : 113-115°C IR (KBr) : 1666, 1647, 1508 cm "1 NMR (CDC1 3 , δ) : 1.00, 1.03 (3H, t and t, J=7Hz) , 1.28, 1.30 (6H, d and d, J=7Hz) , 1.54-1.65 (2H, ) , 2.99-3.09 (2H, m) , 3.47-3.57 (IH, ) , 5.43 (2H, d, J=4Hz), 6.31 (IH, d, J=7.5Hz), 6.82-7.10 (2H, m) , 7.17-7.25 (2H, m) , 7.43-7.77 (2H, m) , 7.90 (IH, dd, J=10, 7.5Hz), 8.37-8.58 (IK, m) MASS (m/z) : 397 (M τ +1) Example 59 A solution of 3-isobutyryl-l- (2-nitrobenzyl)-2- propylindole-6-carboxamide (316 mg) in methanol (10 ml) was hydrogenated over 10% palladium on carbon at 20°C for 6 hours. The catalyst was filtered off and the filtrate was evaporated in vacuo. The residue waε chromatographed on silica gel eluting with a mixture of methanol and chloroform •1:30) to give an oil which was dissolved in a mixture of chloroform (10 ml) and methanol (20 ml) . To this solution was added 101 hydrogen chloride in methanol (0.9 ml), and the mixture was stirred at 20°C for 1 hour and evaporated in vacuo. The residue waε recrystallized from a mixture of methanol and diisopropyl ether to give 1- (2-aminobenzyl) -3- isobutyryl-2-propylindole-6-carbcxamide hydrochloride (415 .ΔD ORIGINAL g) as colorlesε crystals. mp : 255-257°C IR (KBr) : 1650, 1550, 1455 cm "1 NMR (DMSO-d 6 , δ) : 0.95 (3H, t, J=7Hz) , 1.20 (3H, t, J=7Hz), 1.46-1.59 (2H, m) , 2.96-3.01 (2H, m) , 5.67 (2H, s), 5.89 (IH, d, J=7.5Hz), 6.87 (IH, br t, J=7Hz), 7.19-7.34 (3H, m) , 7.80 (IH, d, J=7.5Hz), 7.92-7.98 (2H, m) , 8.03 (IH, s) MASS (m/z) : 378 (M x +1), 86 (bp) Example 60 To a solution of 1- (2-chIorobenzyl) -3-methoxyacetyl-2- propyIindole-6-carboxamide (168 mg) in a mixture of dichloromethane (10 ml) and methanol (0.5 ml) was added IM solution of boron tribromide in dichloromethane (2.5 ml) at -53°C. The reaction mixture was warmed gradually to -12°C during 3 hourε. Then IM εolution of boron tribromide in dichloromethane (2.5 ml) waε added, and the mixture waε εtirred for 20 minuteε at -12 β C. The reaction mixture was diluted with water and extracted with 10% methanol in chloroform. The organic phase was washed with aσueous sodium bicarbonate, water and brine, dried over magnesium εulfate and evaporated in vacuo. The residue was crystallized from ethyl acetate and washed with hexane tc give 1- (2- chlorobenzyl)-3-hydroxyacetyl-2-propylindole-6-carboxamide (120 mg) as colorleεε cryεtalε. mp : 231-233.5°C IR (KBr) : 3405, 3159, 1673, 1647, 1616, 1395 cm "1 NMR (DMSO-d 6 , δ) : 0.94 (3H, t, J=7Hz) , 1.40-1.52 (2K, m) , 3.05 (3H, t, J=7Hz), 4.75 (2H, t, J=6Hz) , 4.90 (IH, t, J=6Hz), 5.65 (2K, ε), 6.22 (IK, d, J=7.5HZ), 7.18 (IH, t, J=7.5Hz), 7.27-7.35 (2H, m) , 7.58 (IH, d, J=7.5Hz), 7.81 (IH, d, J=7.5Hz), 7.92 (2H, d, J=7.5Hz), 8.01 (IH, s) MASS (m/z) : 385 (M ÷ +l), 86 (bp) D ORIGINAL Example 61 To a stirred mixture of benzyl 3-isobutyryl-2- propylindole-6-carboxylate (207 mg) and diisopropylethylamine (295 mg) in dichloromethane (6 ml) were added 2-chlorobenzoyl chloride (299 mg) and 4-dimethylaminopyridine (12 mg) at 0°C. The reaction mixture waε refluxed for 15 hourε. The reaction mixture waε cooled to 20°C and washed with IN hydrochloric acid, water, εaturated sodium bicarbonate, water and brine. The organic phaεe waε dried over sodium sulfate and evaporated in vacuo. The residue was chromatographed on silica gel eluting with a mixture of ethyl acetate and hexane (1:10) to give benzyl 1- (2-chlorobenzoyl) -3-isobutyryl-2- propylindole-6-carboxylate (330 mg) aε yellow cryεtalε. p : 67.5-70°C IR (KBr) : 1780, 1710, 1700, 1300 cm "1 NMR (CDC1 3 , δ) : 0.99 (3H, t, J=7Hz) , 1.27 (6H, t, J=7Hz), 1.74 (2H, εextet, J=7Hz) , 3.12 (2H, t, J=7Hz), 3.39-3.48 (IH, m) , 5.25 (2H, s), 7.33-7.45 (8H, m) , 7.53-7.58 (2H, m) , 7.80 (IH, d, J=7.5Hz), 7.98-8.05 (IH, m) MASS (m/z) : 502 (ϊf+1) Example 62 A solution of benzyl 1- (2-chlorobenzoyl)-3-isobutyryl-2- propylindole-6-carboxylate (304 mg) in methanol (6 ml) waε hydrogenated over 10% palladium on carbon at 20°C for 9 hourε. The catalyεt waε filtered off and the filtrate waε evaporated in vacuo. The reεidue waε chromatographed on εilica gel eluting with a mixture of methanol and chloroform (1:30) to give cryεtals which were recrystallized from a mixture of ethyl acetate and hexane to give I- (2- chlcrobenzoyl)-3-isobutyryl-2-propylindoie-6-carboxylic acid (189 mg) as colorless crystalε. IR (KBr) : 1710, 1695, 1980, 1315 cm "1 NMR (CDCI3, δ) : 0.95 (3H, t, J=7Hz), 1.27 (6H, t, J=7Hz), 1.64-1.75 (2H, m) , 3.03-3.09 (IH, m) , 3.40- 3.49 (IH, m) , 7.48-7.52 (2H, ) , 7.58-7.67 (3H, ) , 7.92 (2H, AB, J=8, 7.5Hz) Example 63 To a stirred solution of 1- (2-chlorobenzyl)-3- formylindole-6-carboxamide (47 mg) in dimethylformamide (1.6 ml) was added chromic anhydride (125 mg) and sulfuric acid (0.05 ml), and the mixture was stirred at 20 β C for 5 hours. The resulting mixture was evaporated in vacuo and the residue was chromatographed on silica gel eluting with a mixture of chloroform and methanol (9:1) to give 6-carbamoyl- 1- (2-chlorobenzyl) indole-3-carboxylic acid (8.3 mg) as a solid. mp : 240°C (dec.) NMR (DMS0-d 6 , δ) : 5.64 (2H, s) , 6.71 (IH, d, J=8Hz) , 7.26 (IH, t, J=8Hz), 7.28 (IH, br s) , 7.36 (IH, t, J=8Hz), 7.56 (IH, d, J=8Hz), 7.78 (IH, d, J=8Hz) , 7.92 (IH, br s) , 8.06 (IH, s) , 8.07 (IH, d, J=8Hz) , 8.20 (IH, s) Example 6 To a solution of 1-(2-chlorobenzyl)-2-(1-hydroxypropyl) - 3-isobutyrylindole-6-carboxamide (19 mg) in acetone (3 ml) was added Jone's reagent until the red color existed continuously. The reaction was quenched by 2-propanol, then the mixture was diluted with ethyl acetate and washed with aqueous sodium bicarbonate and brine. The organic phase was dried over sodium sulfate and evaporated in vacuo. The residue was triturated with diisopropyl ether to give l-(2- chlorobenzyl) -3-isobutyryl-2-propionylindole-6-carboxamide (9.3 mg) . mp : 145-147°C NMR (CDC1 3 , δ) : 1.15 (3H, t, J=7Hz) , 1.33 (6H, d, J=7Hz), 2.60 (2H, q, J=7Hz) , 3.47 (IH, m) , 5.46 (2H, s), 6.50 (IH, d, J=8Hz), 7.09 (IH, t, J=8Hz) , 7.21 (IH, t, J=8Hz), 7.42 (IH, d, J=8Hz) , 7.70 (IH, d, J=8Hz), 7.88 (IH, s) , 7.98 (IH, s) Example 65 The following compound was prepared in a similar manner to that of Preparation 45. 3-Chloro-l- (2-chlorobenzyl)-2-propylindole-6-carboxamide mp : 163-166°C NMR (CDC1 3 , δ) : 0.95 (3H, t, J=7Hz) , 1.58 (2H, m) , 2.73 (2H, t, J=7Hz), 5.43 (2H, s) , 6.19 (IH, d, J=8Hz), 7.01 (IH, t, J=8Hz), 7.18 (IH, t, J=8Hz) , 7.43 (IH, d, J=8Hz), 7.54 (IH, d, J=8Hz) , 7.67 (IH, d, J=8Hz), 7.82 (IH, s) Example 66 To a stirred solution of methyl 1- (2-bromobenzyl) -2- propylindole-6-carboxamide (52 mg) in a mixture of dichloromethane (3 ml) and pyridine (1 ml) was added pyridinium bromide perbromide (50 mg) , and the mixture was stirred at 0 β C for 1.5 hours. The resulting mixture was diluted with ethyl acetate and washed with diluted hydrochloric acid, aqueous sodium bicarbonate and brine, then dried over sodium sulfate and evaporated in vacuo. The residue was triturated with a mixture of hexane and diisopropyl ether to give 3-bromo-l- (2-bromobenzyl)-2- propylindole-6-carboxamide (33 mg) as a solid, mp : 122-125°C NMR (CDC1 3 , δ) : 0.98 (3H, t, J=7Hz) , 1.57 (2H, m) , 2.73 (2H, t, J=7Hz), 5.42 (2H, s) 6.15 (IH, d, J=8Hz), 7.0-7.16 (2H, m) , 7.5-7.65 (3H, m) , 7.79 (IH, s) Example 6 " ? The following compounds described in (1) to (2) were prepared in a similar manner to that of Example 42. (1) 1- (2-Chlorobenzyl) -3-isobutyryl-2-propylindole-6- carbonitrile mp : 130-131 β C NMR (CDC1 3 , δ) : 1.03 (3H, t, J=7Hz) , 1.30 (6H, d, J=7Hz), 1.56-1.68 (2H, m) , 3.06-3.12 (2H, m) , 3.51 (IH, septet, J=7Hz), 5.46 (2H, s), 6.23 (IH, d, J=8Hz), 7.08 (IH, t, J=8Hz) , 7.27 (IH, t, J=8Hz) , 7.46-7.52 (3H, m) , 8.01 (IH, d, J=8Hz) (2) 9- (2-Chlorobenzyl) -8-OXO-5, 6, 7, 8-tetrahydrocarbazole-2- carbonitrile mp : 173-176 β C NMR (CDC1 3 , δ) : 2.29 (2H, m) , 2.69 (2H, t, J=7Hz) , 3.08 (2H, t, J=7Hz), 5.94 (2H, s), 6.30 (IH, d, J=8Hz), 7.02 (IH, t, J=8Hz), 7.19 (IH, t, J=8Hz) , 7.38 (IH, d, J=8Hz), 7.42 (IH, d, J=8Hz) , 7.54 (IH, s), 7.78 (IH, d, J=8Hz) Example 68 To a solution of 1- (2-chlorobenzyl) -3-isobutyryl-2- propylindole-6-carbonitrile (70 mg) in a mixture of methanol (2 ml) and tetrahydrofuran (2 ml) was added sodium borohydride (21 mg) at 25°C. After stirred at 25 β C for 2 hours, the reaction mixture was partitioned between ethyl acetate and IN hydrochloric acid. The organic layer was washed with water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was crystallized from diisopropyl ether to give 1- (2-chlorobenzyl) -3- (l-hydroxy-2- methylpropyl) -2-propylindole-6-carbonitrile (28 mg) as pale yellow crystals. mp : 126-127^ NMR (CDC1 3 , δ) : 0.76 (3H, d, J=7Hz) , 0.98 (3H, t, J=7Hz), 1.22 (3H, d, J=7Hz), 1.50-1.64 (2H, ) , 1.87 (IH, d, J=2Hz), 2.32-2.44 (2H, ) , 2.63-2.80 (2H, m) , 4.58 (IH, dd, J=2, 8Hz), 5.38 (2H, s) , 6.15 (IH, d, J=8Hz), 7.05 (IH, t, J=8Hz) , 7.22 (IH, t, J=8Hz), 7.32 (IH, d, J=8Hz) , 7.38 (IH, s) , 7.46 (IH, d, J=8Hz), 7.91 (IH, d, J=8Hz) Example 69 The following compound was prepared in a similar manner to that of Example 68. 1- (2-Chlorobenzyl)-2-ethyl-3- (l-hydroxy-2-methylpropyl) - indole-6-carboxamide mp : 169-172°C NMR (CDC1 3 , δ) : 0.78 (3H, d, J=7Hz) , 1.17 (3H, t, J=7Hz), 1.23 (3H, d, J=7Hz) , 2.41 (IH, m) , 2.74 (2H, m) , 4.60 (IH, m) , 5.43 (2H, s) , 6.14 (IH, d, J=8Hz), 6.98 (IH, t, J=8Hz) , 7.17 (IH, t, J=8Hz) , 7.4-7.5 (2H, m) , 7.76 (IH, s) , 7.85 (IH, d, J=8Hz) Example 7Q To a suspension of 3-acetyl-l- (2-chlorobenzyl) -2- propylindole-6-carboxamide (36.5 mg) in ethanol (5 ml) was added hydroxylamine hydrochloride (70 mg) and sodium acetate (200 mg) , and the mixture was heated in a sealed tube at 100 β C. The reaction was evaporated in vacuo, then the residue was diluted with ethyl acetate and washed with water and brine. The organic phase was dried over sodium sulfate and evaporated in vacuo. The residue was triturated with diisopropyl ether to give 1- (2-chlorobenzyl)-3- (1- hydroxyiminoethyl) -2-propylindole-6-carboxamide (32.7 mg) . mp : 212-216 β C NMR (CDC1 3 , δ) : 0.94 (3H, t, J=7Hz) , 1.56 (2H, m) , 2.39 (3H, s), 2.80 (2H, m) , 5.45 (2H, s), 6.21 (IH, d, J=8Hz), 6.99 (IH, t, J=8Hz) , 7.20 (IH, t. J=8Hz ) , 7 . 42 ( IH, d, J=8Hz ) , 7 . 50 ( IH, m) , 7 . 70- 7 . 78 ( 2H, m) Example 71 1- (2-Aminobenzyl) -3-isobutyryl-2-propylindole-6- carboxamide hydrochloride (111 mg) was dissolved in chloroform, and the solution was washed with IN aqueous sodium hydroxide, dried over magnesium sulfate and evaporated in vacuo. The residue was dissolved in chloroform (3 ml), and then methyl isocyanate (1.5 ml) was added at 0°C. After stirred at 20 β C for 2 hours, the mixture was evaporated in vacuo. The residue was dissolved in a mixture of ethyl acetate and tetrahydrofuran, and the solution was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The crystalline residue was recrystallized from a mixture of 1,4-dioxane and hexane to give 3-isobutyryl-l-[2- (3-methylureido)benzyl]-2-propylindole-6-carboxamide (74 mg) as colorless crystals, mp : 222-223 β C IR (KBr) : 1648, 1617, 1557 cm "1 NMR (DMSO-d 6 , δ) : 0.91 (3H, t, J=7Hz) , 1.18 (6H, d, J=7Hz), 1.42-1.50 (2H, m) , 2.71 (3H, d, J=5Hz) , 2.92-3.00 (2H, m) , 3.50-3.56 (IH, m) , 5.48 (2H, s), 5.99 (IH, d, J=8Hz), 6.34-6.39 (IH, m) , 6.86 (IH, t, J=7.5Hz), 7.18 (IH, t, J=7.5Hz), 7.28 (IH, s) , 7.55 (IH, t, J=7.5Hz), 7.78 (IH, d, J=7.5Hz), 7.92- 7.97 (3H, ) , 8.21 (IH, s) MASS (m/z) : 435 (M + +l), 86 (bp) Example 12 To a solution of methyl 1- (2-chlorobenzyl)-2- propylindole-6-carboxylate (200 mg) in trifluoroacetic acid (2 ml) was added concentrated nitric acid (0.3 ml) at 0°C. After εtirred at 0°C for 30 minuteε, the reaction mixture waε partitioned between ethyl acetate and water. The organic layer was washed with aqueous sodium bicarbonate, water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by preparative thin layer chromatography on silica gel eluting with a mixture of ethyl acetate and hexane (1:3) to give methyl 1- (2-chlorobenzyl) -3- nitro-2-propylindole-6-carboxylate (73 mg) as pale yellow crystals. NMR (CDC1 3 , δ) : 1.04 (3H, t, J=7Hz) , 1.68 (2H, sextet, J=7Hz), 3.14-3.18 (2H, m) , 3.91 (3H, s) , 5.13 (2H, s), 6.32 (IH, d, J=8Hz) , 7.08 (IH, t, J=8Hz), 7.27 (IH, t, J=8Hz) , 7.48 (IH, d, J=8Hz) , 7.98 (IH, s), 8.08 (IH, d, J=8Hz) , 8.43 (IH, d, J=8Hz) Example 73 The following compounds described in (1) to (44) were prepared in a similar manner to that of Example 1. (1) Methyl 1- (2-chlorobenzyl) -2- (3-methoxycarbonylpropyl) - indole-6-carboxylate NMR (CDC1 3 , δ) : 2.04 (2H, m) , 2.88 (2H, t, J=7Hz) , 2.69 (2H, t, J=7Hz), 3.62 (3H, s) , 3.89 (3H, ε) , 5.43 (2H, ε), 6.14 (IH, d, J=8Hz) , 6.46 (IH, ε) , 7.01 (IH, t, J=8Hz), 7.18 (IH, t, J=8Hz) , 7.42 (IH, d, J=8Hz), 7.59 (IH, d, J=8Hz) , 7.80 (IH, d, J=8Hz), 7.90 (IH, s) (2) Methyl 1- (2-chlorobenzyl) -2- (2-methoxycarbonylethyl) - indole-6-carboxylate NMR (CDC1 3 , δ) : 2.77 (2H, m) , 2.98 (2H, m) , 3.69 (3H, s), 3.88 (3H, s), 5.45 (2H, s) , 6.16 (IH, d, J=8Hz), 6.41 (IH, s), 7.02 (IH, t, J=8Hz) , 7.19 (IH, t, J=8Hz), 7.42 (IH, d, J=8Hz) , 7.60 (IH, d, J=8Hz), 7.81 (IH, d, J=8Hz), 7.91 (IH, s) (3) Methyl 1- (2-chlorobenzyl) -3-isobutyryl-2-propylindole-7- carboxylate NMR (CDC1 3 , δ) : 1.02 (3H, t, J=7Hz) , 1.79 (6H, d, J=7Hz), 1.63 (2H, m) , 3.01 (2H, ) , 3.52 (IH, ) , 3.56 (3H, s), 5.61 (2H, s) , 6.08 (IH, d, J=8Hz) , 6.98 (IH, t, J=8Hz), 7.17 (IH, t, J=8Hz) , 7.2-7.45 (3H, m) , 8.12 (IH, d, J=8Hz) (4) Methyl 1- (2-chlorobenzyl) -3-isobutyryl-2-propylindole-5- carboxylate NMR (CDCI3, δ) : 1.03 (3H, t, J=8Hz) , 1.34 (6H, d, J=8Hz), 1.62 (2H, sextet, J=8Hz), 3.06-3.10 (2H, m) , 3.64 (IH, septet, J=8Hz), 3.96 (3H, s) , 5.47 (2H, s), 6.26 (IH, d, J=8Hz) , 7.06 (IH, t, J=8Hz) , 7.20 (IH, t, J=8Hz), 7.25 (IH, d, J=8Hz) , 7.47 (IH, dd, J=l, 8Hz), 7.92 (IH, d, J=8Hz), 8.68 (IH, d, J=lHz) (5) Methyl 1- (6-chloro-3, 4-methylenedioxybenzyl) -3- isobutyryl-2-propylindole-5-carboxylate NMR (CDCI3, δ) : 1.05 (3H, t, J=8Hz) , 1.32 (6H, d, J=8Hz), 1.62 (2H, sextet, J=8Hz) , 3.06 (2H, t, J=8Hz), 3.63 (IH, septet, J=8Hz) , 3.96 (3H, s), 5.36 (2H, s), 5.74 (IH, s) , 5.88 (2H, s) , 6.92 (IH, s), 7.20 (IH, d, J=10Hz), 7.82 (IH, d, J=10Hz) , 8.76 (IH, s) (6) Methyl 1- (2-chlorobenzyl) -2-propylindole-4-carboxylate NMR (CDCI3, δ) : 1.01 (3H, t, J=7Hz) , 1.78 (2H, m) , 2.67 (2H, t, J=7Hz), 3.99 (3H, s) , 5.42 (2H, ε) , 6.18 (IH, d, J=8Hz), 7.01 (IH, t, J=8Hz) , 7.03 (IH, s), 7.11 (IH, t, J=8Hz), 7.18 (IH, t, J=8Hz) , 7.30 (IH, d, J=8Hz), 7.43 (IH, d, J=8Hz) , 7.89 (IH, d, J=8Hz) (7) Methyl 9- (2-chlorobenzyl) -8-oxo-5, 6, 7, 8- tetrahydrocarbazole-2-carboxylate NMR (CDC1 3 , δ) : 2.27 (2H, m) , 2.67 (2H, t, J=7Hz) , 3.11 (2H, t, J=7Hz), 3.90 (3H, s) , 5.95 (2H, s) , 6.25 (IH, d, J=8Hz), 6.98 (IH, t, J=8Hz) , 7.15 (IH, t, J=8Hz), 7.40 (IH, d, J=8Hz) , 7.74 (IH, d, J=8Hz), 7.84 (IH, d, J=8Hz) , 7.99 (IH, s) (8) Methyl 9- (6-chloro-3, 4-methylenedioxybenzyl) -8-oxo- 5,6,7, 8-tetrahydrocarbazole-2-carboxylate NMR (CDCI3, δ) : 2.18 (2H, m) , 2.63 (2H, t, J=7H∑.) , 3.07 (2H, t, J=7Hz), 3.84 (3H, s) , 5.68 (IH, s), 5.83 (2H, s), 5.96 (2H, s), 7.18 (IH, s), 7.84 (IH, d, J=8Hz), 7.92 (IH, d, J=8Hz) , 8.03 (IH, ε) (9) Methyl 1- (4-bromo-2-chlorobenzyl) -3-isobutyryl-2- propylindole-6-carboxylate mp : 65-67°C IR (KBr) : 1715, 1705, 1656, 1456, 1433 cm "1 NMR (CDC1 3 , δ) : 1.03 (3H, t, J=7Hz) , 1.30 (6H, d, J=7Hz), 1.52-1.64 (2H, m) , 2.99-3.05 (2H, m) , 3.51- 3.60 (IH, m) , 3.92 (3H, s) , 5.45 (2H, ε) , 6.09 (IH, d, J=7.5Hz), 7.18 (IH, d, J=7.5Hz), 7.66 (IH, s) , 7.90 (IH, s), 7.99 (2H, s) MASS (m/z) : 492 (M + +2) (10) 1- (2-Acetamidobenzyl)-3-isobutyryl-2-propylindole-6- carboxamide mp : 235-236 β C IR (KBr) : 1693, 1656, 1457 cm "1 NMR (CDC1 3 , δ) : 0.91 (3H, t, J=7Hz) , 1.18 (6H, d, J=7Hz), 1.39-1.50 (2H, m) , 2.17 (3H, s) , 2.92-2.99 (2H, m), 3.50-3.59 (IH, m) , 5.49 (2H, s), 6.07 (IH, d, J=7.5HZ), 7.00 (IH, t, J=7.5Hz), 7.21-7.29 (2H, m) , 7.39 (IH, d, J=7.5Hz), 7.79 (IH, d, J=7.5Hz), 7 . 92-7 . 96 ( 3H, m) , 9 . 85 ( IH, s ) MASS (m/ z ) : 420 (M + +l ) , 86 (bp) (11) Methyl 1- (2-chlorobenzyl) -3-formylindole-6-carboxylate NMR (CDC1 3 , δ) : 3.93 (3H, s) , 5.52 (2H, s) , 6.88 (IH, dd, J=l, 8Hz), 7.21 (IH, dt, J=l, 8Hz) , 7.32 (IH, dt, J=l, 8Hz), 7.49 (IH, dd, J=l, 8Hz) , 7.82 (IH, s), 8.02 (IH, dd, J=l, 8Hz) , 8.13 (IH, d, J=lHz) , 8.36 (IH, d, J=8Hz), 10.0 (IH, s) (12) Methyl 3-acetyl-l- (2-chlorobenzyl) -2-methylindole-6- carboxylate This compound was used immediately without purification. (13) Methyl 1- (2-chlorobenzyl) -2-methyl-3-propionylindole-6- carboxylate NMR (CDC1 3 , δ) : 1.31 (3H, t, J=7Hz), 2.70 (3H, s) , 3.09 (2H, q, J=7Hz) , 3.90 (3H, s), 5.50 (2H, s), 6.22 (IH, d, J=8Hz), 7.04 (IH, t, J=8Hz) , 7.24 (IH, t, J=8Hz), 7.46 (IH, d, J=8Hz) , 7.92-7.98 (2H, m) , 8.08 (IH, d, J=8Hz) (14) Methyl 1- (2-chlorobenzo [b] thiophen-3-ylmethyl) -3- isobutyry1-2-methylindole-6-carboxylate NMR (DMSO-d 6 , δ) : 1.14 (6H, d, J=7Hz) , 2.72 (3H, s), 3.48 (IH, m) , 3.81 (3H, ε) , 5.91 (2H, ε), 7.3-7.5 (3H, m) , 7.80 (IH, d, J=8Hz) , 7.98 (IH, d, J=8Hz) , 8.06 (IH, d, J=8Hz), 8.19 (IH, s) (15) Methyl 1- (benzothiazol-2-ylmethyl) -2-ethyl-3- iεobutyrylindole-6-carboxylate NMR (CDC1 3 , δ) : 1.28 (3H, t, J=7Hz) , 1.30 (6H, d, J=7Hz), 3.24 (2H, q, J=7Hz) , 3.53 (IH, m) , 3.91 (3H, s), 5.82 (2H, s), 7.25-7.53 (2H, m) , 7.72 (IH, m) , 7.8-8.1 (3H, ) , 8.18 (IH, s) (16) Methyl 1- (benzo [b] thiophen-5-ylmethyl) -3-iεobutyryl-2- propylindole-6-carboxylate NMR (CDC1 3 , δ) : 1.02 (3H, t, J=7Hz) , 1.32 (6H, d, J=7Hz), 1.62 (2H, m) , 3.13 (2H, m) , 3.57 (IH, m) , 3.87 (3H, s), 5.57 (2H, s) , 7.03 (IH, d, J=8Hz) , 7.18 (IH, d, J=6Hz), 7.29 (IH, s), 7.44 (IH, d, J=6Hz), 7.79 (IH, d, J=8Hz) , 7.94 (2H, ε) , 8.02 (IH, s) (17) Methyl l-allyl-3-isobutyryl-2-propylindole-6-carboxylate NMR (CDC1 3 , δ) : 1.07 (3H, t, J=7Hz) , 1.28 (6H, d, J=7Hz), 1.69 (2H, m) , 3.12 (2H, m) , 3.54 (IH, m) , 3.94 (3H, s), 4.84 (2H, m) , 4.87 (IH, m) , 5.22 (IH, m) , 5.98 (IH, m) , 7.89 (IH, d, J=8Hz) , 7.94 (IH, d, J=8Hz), 8.04 (IH, s) (18) Methyl 1- (2-chlorobenzyl) -3-isobutyryl-2- (I- propenyl) indole-6-carboxylate NMR (CDC1 3 , δ) : 1.23 (6H, d, J=7Hz) , 1.93 (3H, d, J=7Hz), 3.51 (IH, m) , 3.89 (3H, s) , 5.50 (2H, s) , 6.41 (IH, m) , 6.42 (IH, d, J=8Hz) , 6.73 (IH, d, J=16Hz), 7.07 (IH, t, J=8Hz), 7.23 (IH, t, J=8Hz) , 7.47 (IH, d, J=8Hz) , 7.89 (IH, s) , 7.95 (IH, d, J=8Hz), 8.18 (IH, d, J=8Hz) (19) Methyl 2- (1-acetoxypropyl) -1- (2-chlorobenzyl) -3- isobutyrylindole-6-carboxylate NMR (CDC1 3 , δ) : 1.04 (3H, t, J=7Hz) , 1.2-1.35 (9H, m) , 1.9-2.1 (2H, m) , 3.59 (IH, m) , 3.89 (3H, s), 5.61 (IH, d, J=17Hz), 5.79 (IH, d, J=17Hz) , 6.04 (IH, d, J=8Hz), 6.71 (IH, m) , 7.01 (IH, t, J=8Hz) , 7.21 (IH, t, J=8Hz), 7.47 (IH, d, J=8Hz) , 7.87 (IH, ε), 7.92 (IH, d, J=8Hz) , 7.97 (IH, d, J=8Hz) (20) Methyl 3- (3, 3-dimethylbutanoyl) -1- (2- chlorobenzyl) indole-6-carboxylate NMR (CDC1 3 , δ) : 1.09 (9H, s) , 2.69 (2H, s) , 3.93 (3H, s), 5.50 (2H, s), 6.73 (IH, d, J=8Hz) , 7.17 (IH, t, J=8Hz), 7.28 (IH, t, J=8Hz) , 7.47 (IH, d, J=8Hz) , 7.82 (IH, s), 8.00 (IH, d, J=8Hz) , 8.08 (IH, s) , 8.53 (IH, d, J=8Hz) (21) Ethyl 1- (2-chlorobenzyl) -3-isobutyryl-2-propylindol-6- ylacetate IR (Neat) : 1730, 1655 cm "1 NMR (CDCI3, δ) : 1.00 (3H, t, J=7Hz) , 1.20 (3H, t, J=7Hz), 1.29 (6H, d, J=7Hz) , 1.55-1.65 (2H, m) , 3.01-3.08 (2H, m) , 3.54-3.60 (IH, m) , 3.69 (2H, s) , 4.11 (2H, q, J=7Hz) , 5.44 (2H, ε) , 6.30 (IH, d, J=7.5Hz), 7.03-7.10 (2H, m) , 7.21 (2H, d, J=7.5Hz), 7.46 (IH, d, J=7.5Hz), 7.89 (IH, d, J=7.5Hz) MASS (m/z) : 440 (M + +l), 74 (bp) (22) Methyl 1- (6-chloro-3, 4-methylenedioxybenzyl) -3- iεobutyryl-2-propylindol-6-ylacetate mp : 119-120.5°C IR (KBr) : 1744, 1735, 1732, 1644, 1508 cm "1 NMR (CDCI3, δ) : 1.03 (3H, t, J=7Hz) , 1.29 (6H, d, J=7Hz), 1.55-1.65 (2H, m) , 3.00-3.07 (2H, m) , 3.53- 3.61 (IH, m) , 3.70 (3H, ε) , 3.72 (2H, ε), 5.33 (2H, ε), 5.80 (2H, s), 5.91 (2H, s),6.93 (IH, ε), 7.01 (IH, ε), 7.21 (IH, d, J=7.5Hz), 7.89 (IH, d, J=7.5Hz) MASS (m/z) : 470 (M + +l) , 74 (bp) (23) Methyl 1- (2-chlorobenzyl) -2-propylindole-6-carboxylate NMR (CDC1 3 , δ) : 1.02 (3H, t, J=7Hz) , 1.75 (2H, m) , 2.62 (2H, t, J=7Hz), 3.87 (3H, ε) , 5.42 (2H, s) , 6.16 (IH, d, J=8Hz) , 6.42 (IH, s) , 7.01 (IH, t, J=8Hz ) , 7 . 19 ( IH, t, J=8Hz ) , 7 . 42 ( IH, t, J=8Hz ) , 7 . 58 ( IH, t, J=8Hz) , 7 . 79 ( IH, d, J=8Hz ) , 8 . 92 ( IH, s ) (24) Methyl 1-(2-bromobenzyl)-2-propylindole-6-carboxylate NMR (CDC1 3 , δ) : 0.99 (3H, t, J=7Hz) , 1.74 (2H, m) , 2.59 (2H, t, J=7Hz), 3.88 (3H, s), 5.37 (2H, s) , 6.12 (IH, d, J=8Hz), 6.42 (IH, s) , 7.0-7.15 (2H, m) , 7.52-7.65 (2H, m) , 7.79 (IH, d, J=8Hz) , 7.89 (IH, s) (25) Methyl 2-acetyl-l- (2-chlorobenzyl)-3-methylindole-€- carboxylate NMR (CDC1 3 , δ) : 2.61 (3H, s), 2.71 (3H, s) , 3.90 (3H, s), 5.82 (2H, s), 6.19 (IH, d, J=8Hz) , 6.97 (IH, t, J=8Hz), 7.14 (IH, t, J=8Hz), 7.41 (IH, d, J=8Hz) , 7.79 (IH, d, J=8Hz), 7.86 (IH, d, J=8Hz) , 7.99 (IH, s) (26) Methyl 2-chloro-l- (2-chlorobenzyl) -3-ethylindole-6- carboxylate NMR (CDC1 3 , δ) : 1.29 (3H, t, J=7Hz) , 2.83 (2H, q, J=7Hz), 3.90 (3H, s), 5.50 (2H, s) , 6.29 (IH, d, J=8Hz), 7.04 (IH, t, J=8Hz), 7.19 (IH, t, J=8Hz) , 7.42 (IH, d, J=8Hz) , 7.61 (IH, d, J=8Hz), 7.83 (IH, d, J=8Hz), 7.90 (IH, s) (27) Methyl 1- (2-chlorobenzyl) -2-propionyl-3-propylindole-6- carboxylate NMR (CDC1 3 , δ) : 1.07 (3H, t, J=7Hz) , 1.17 (3H, t, J=7Hz), 1.78 (2H, m) , 2.94 (2H, q, J=7Hz) , 3.09 (2H, m) , 3.89 (3H, s), 5.72 (2H, s) , 6.23 (IH, d, J=8Hz), 6.98 (IH, t, J=8Hz) , 7.15 (IH, t, J=8Hz) , 7.39 (IH, d, J=8Hz), 7.76 (IH, d, J=8Hz), 7.83 (IH, d, J=8Hz), 7.96 (IH, s) (28) Methyl 1-(2-chlorobenzyl)-2-isobutyryl-3-propylindole-6- carboxylate NMR (CDC1 3 , δ) : 1.03 (3H, t, J=7Hz) , 1.11 (6H, d, J=7Hz), 1.75 (2H, m), 3.02 (2H, m) , 3.35 (IH, ) , 3.89 (3H, s), 5.64 (2H, s) , 6.28 (IH, d, J=8Hz) , 6.99 (IH, t, J=8Hz), 7.16 (IH, t, J=8Hz) , 7.38 (IH, d, J=8Hz), 7.73 (IH, d, J=8Hz) , 7.84 (IH, d, J=8Hz), 7.96 (IH, s) (29) Methyl 1- (2-chlorobenzyl)-3- (3-oxo-l-butenyl)indole-6- carboxylate NMR (CDC1 3 , δ) : 2.38 (3H, ε) , 3.93 (3H, ε), 5.48 (2H, s), 6.7-6.8 (2H, m) , 7.17 (IH, t, J=8Hz) , 7.28 (IH, t, J=8Hz), 7.47 (IH, d, J=8Hz) , 7.54 (IH, s), 7.74 (IH, d, J=15Hz), 7.96 (IH, s), 8.11 (IH, s) (30) Methyl 4- (2-chlorobenzyl)-3-oxo-l, 2, 3, 4- tetrahydrocyclopent[b]indole-6-carboxylate NMR {CDCI3, δ) : 3.06 (2H, m) , 3.17 (2H, m) , 3.92 (3H, ε), 5.72 (2H, ε) , 6.59 (IH, d, J=8Hz) , 7.06 (IH, t, J=8Hz), 7.19 (IH, t, J=8Hz), 7.42 (IH, d, J=8Hz) , 7.78 (IH, d, J=8Hz), 7.87 (IH, d, J=8Hz), 8.04 (IH, s) (31) Methyl 4- (6-chloro-3, 4-methylenedιoxybenzyl)-3-oxo- 1,2,3,4-tetrahydrocyclopent[b]indole-6-carboxylate NMR (CDCI3, δ) : 3.06 (3H, m) , 3.14 (2H, m) , 3.94 (3H, s), 5.60 (2H, s), 5.88 (2H, s), 6.11 (IH, ε) , 6.88 (IH, s), 7.76 (IH, d, J=8Hz) , 7.86 (IH, d, J=8Hz), 8.09 (IH, s) (32) 1- (2-Chlorobenzyl)-3-cyclopropanecarbonyl-2- propylindole-6-carboxamide mp : 162-163.5 β C IR (KBr) : 1675, 1612, 1444, 1383 cm "1 NMR (DMSO-d 6 , δ) : 0.90 (3H, t, J=7Hz) , 1.08 (4H, d, J=7Hz), 1.48 (2H, sextet, J=7Hz) , 2.65-2.72 (IH, m) , 3.00 (2H, t, J=7Hz), 5.62 (2H, s) , 6.21 (IH, d, J=8Hz), 7.18 (IH, t, J=8Hz), 7.32 (IH, t, J=8Hz) , 7.58 (IH, d, J=8Hz), 7.80 (IH, d, J=8Hz) , 7.93 (IH, s), 8.01 (IH, s), 8.10 (IH, d, J=7Hz) MASS (m/z) : 395 (M + +l), 74 (bp) (33) 1- (6-Chloro-3, 4-methylenedioxybenzyl) -3- cyclopropanecarbonyl-2-propylindole-6-carboxamide mp : 162-163.5 β C IR (KBr) : 1675, 1612, 1444, 1383 cm "1 NMR (DMSO-d 6 , δ) : 0.90 (3H, t, J=7Hz) , 1.08 (4H, d, J=7Hz), 1.48 (2H, sextet, J=7Hz) , 2.65-2.72 (IH, m) , 3.00 (2H, t, J=7Hz) , 5.62 (2H, s) , 6.21 (IH, d, J=8Hz), 7.18 (IH, t, J=8Hz), 7.32 (IH, t, J=8Hz) , 7.58 (IH, d, J=8Hz), 7.80 (IH, d, J=8Hz) , 7.93 (IH, s), 8.01 (IH, s), 8.10 (IH, d, J=7Hz) MASS (m/z) : 395 (M + +l), 74 (bp) ( 34 ) 1- (2-Chlorobenzyl ) -3-cyclobutanecarbonyl-2-propylindole- 6-carboxamide mp : 162-165 β C IR (KBr) : 1660, 1654, 1445, 1437 cm "1 NMR (CDCI3, δ) : 1.02 (3H, t, J=7Hz) , 1.62 (2H, sextet, J=7Hz), 1.95-2.14 (2H, m) , 2.35-2.52 (4H, m) , 3.05-3.10 (2H, m) , 4.05 (IH, quintet, J=7Hz) , 5.50 (2H, s), 6.22 (IH, d, J=7.5Hz), 7.04 (IH, t, J=7.5Hz), 7.21 (IH, t, J=7.5Hz), 7.47 (IH, d, J=7.5Hz), 7.63 (IH, d, J=7.5Hz), 7.82 (IH, s), 7.97 (IH, d, J=7.5Hz) MASS (m/z) : 409 (M + +l) , 74 (bp) (35) 1- (6-Chloro-3, 4-methylenedioxybenzyl) -3- cyclobutanecarbonyl-2-propylindole-6-carboxamide mp : 240-241 β C IR (KBr) : 1658, 1636, 1503, 1482, 1451 cm "1 NMR (DMSO-d 6 , δ) : 0.94 (3H, t, J=7Hz) , 1.49 (2H, sextet, J=7Hz), 1.79-1.90 (IH, m) , 1.96-2.07 (IH, m) , 2.24-2.33 (4H, m) , 3.03 (2H, t, J=7Hz) , 4.07 (IH, quintet, J=7Hz), 5.51 (2H, s) , 5.65 (IH, s) , 6.00 (2H, s), 7.24 (IH, s) , 7.31 (IH, br s) , 7.79 (IH, d, J=7.5Hz), 7.94 (IH, br s) , 7.95 (IH, d, J=7.5Hz), 8.00 (IH, s) MASS (m/z) : 453 (M + +l), 85 (bp) (36) 1- (2-Chlorobenzyl) -3-cyclopentanecarbonyl-2- propylindole-6-carboxamide mp : 201.5-202.5°C IR (KBr) : 1654, 1607, 1447, 1437, 1387 cm "1 NMR (CDC1 3 , δ) : 1.02 (3H, t, J=7Hz), 1.59-1.82 (6H, m) , 1.99-2.07 (4H, m) , 3.02-3.09 (2H, m) , 3.79 (IH, quintet, J=7Hz) , 5.52 (2H, s), 6.23 (IH, d, J=7.5Hz), 7.05 (IH, t, J=7.5Hz), 7.22 (IH, t, J=7.5Hz), 7.47 (IH, d, J=7.5Hz), 7.63 (IH, d, J=7.5Hz), 7.86 (IH, s), 8.04 (IH, d, J=7.5Hz) MASS (m/z) : 423 (M + +l), 74 (bp) (37) 1- (6-Chloro-3, 4-methylenedioxybenzyl)-3- cyclopentanecarbonyl-2-propylindole-6-carboxamide mp : 236-237 β C IR (KBr) : 1662, 1506, 1477 cm "1 NMR (DMSO-d 6 , δ) : 0.93 (3H, t, J=7Hz) , 1.40-1.50 (2H, m) , 1.61-1.68 (4H, m) , 1.81-1.95 (4H, m) , 3.00 (2H, t, J=7Hz), 3.73-3.82 (IH, m) , 5.50 (2H, ε), 5.64 (IH, ε), 6.00 (2H, s) , 7.24 (IH, s), 7.30 (IH, br s), 7.80 (IH, d, J=7.5Hz), 7.95 (IH, br ε), 8.00 (IH, d, J=7.5Hz), 8.01 (IH, s) MASS (m/z) : 467 (M + +l), 85 (bp) (38) 1- (2-Chlorobenzyl)-3-cyclohexanecarbonyl-2-propylindole- 6-carboxamide mp : 208-210°C IR (KBr) : 1686, 1625, 1609, 1444, 1410 cm "1 NMR (DMSO-d 6 , δ) : 0.90 (3H, t, J=7Hz) , 1.19-1.30 (IH, m) , 1.39-1.49 (6H, m) , 1.67-1.93 (5H, ) , 2.99 (2H, t, J=7Hz), 3.18-3.27 (IH, ) , 5.61 (2H, s), 6.19 (IH, d, J=7.5Hz), 7.18 (IH, t, J=7.5Hz), 7.29 (IH, s), 7.32 (IH, t, J=7.5Hz), 7.58 (IH, d, J=7.5Hz), 7.80 (IH, d, J=7.5Hz), 7.90 (2H, d, J=7.5Hz), <J.OO (IH, 8) MASS (m/z) : 437 (M + +l), 85 (bp) (39) 1- (6-Chloro-3, 4-methylenedioxybenzyl) -3- cyclohexanecarbonyl-2-propylindole-6-carboxamide mp : 209-211 β C IR (KBr) : 1623, 1611, 1506, 1391 cm "1 NMR (DMSO-d 6 , δ) : 0.93 (3H, t, J=7Hz) , 1.20-1.28 (IH, m) , 1.39-1.51 (6H, m) , 1.68-1.92 (5H, m) , 2.96-3.01 (2H, m). 3.19-3.27 (IH, m) , 5.52 (2H, s), 5.64 (IH, ε), 6.00 (2H, s), 7.24 (IH, ε) , 7.31 (IH, br ε), 7.85 (2H, AB, J=7.5, 7.5Hz), 7.96 (IH, br ε), 8.01 (IH, s) MASS (m/z) : 481 (M + +l), 85 (bp) (40) 1- (2-Chlorobenzyl) -3- (3-methyl-2-butenoyl) -2- propylindole-6-carboxamide mp : 187-188°C IR (KBr) : 1680, 1648, 1614, 1598, 1446, 1384 cm "1 NMR (DMSO-d 6 , δ) : 0.90 (3H, t, J=7Hz) , 1.49 (2H, sextet, J=7Hz), 2.01 (3H, s) , 2.10 (3H, s), 2.99 (2H, t, J=7Hz), 5.61 (2H, s) , 6.19 (IH, d, J=7.5Hz), 6.66 (IH, s), 7.19 (IH, t, J=7.5Hz), 7.29 (IH, br s), 7.32 (IH, t, J=7.5Hz), 7.58 (IH, d, J=7.5Hz), 7.78 (IH, d, J=7.5Hz), 7.90 (IH, br s), 7 . 97 ( 2H, d, J=7 . 5Hz ) MASS (m/ z ) : 409 (M + +l ) , 85 (bp) (41) 1- (6-Chloro-3,4-methylenedioxybenzyl)-3- (3-methyl-2- butenoyl)-2-propylindole-6-carboxamide mp : 227-229°C IR (KBr) : 1654, 1606, 1505, 1482, 1449, 1388 cm "1 NMR (DMSO-d 6 , δ) : 0.94 (3H, t, J=7Hz) , 1.50 (2H, sextet, J=7Hz), 2.01 (3H, s), 2.09 (3H, s), 3.00 (2H, t, J=7Hz), 5.50 (2H, s), 5.67 (IH, s), 6.00 (2H, s), 6.66 (IH, s), 7.25 (IH, s), 7.30 (IH, br s), 7.77 (IH, d, J=7.5Hz), 7.91-7.99 (3H, m) MASS (m/z) : 453 (M + +l), 85 (bp) (42) 1- (2-Chlorobenzyl)-3- (3-methoxybutanoyl) -2-propylindole- 6-carboxamide mp : 155-157°C IR (KBr) : 1656, 1610, 1447, 1437, 1389 cm "1 NMR (CDC1 3 , δ) : 1.03 (3H, t, J=7Hz), 1.34 (3H, d, J=7Hz), 1.63 (2H, sextet, J=7Hz) , 3.01-3.09 (3H, m) , 3.41 (3H, s) , 3.47 (IH, dd, J=16, 7Hz) , 4.14 (IH, sextet, J=7Hz), 5.51 (2H, s), 6.22 (IH, dd, J=7.5, IHz), 7.05 (IH, ddd, J=7.5, 7.5, IHz), 7.23 (IH, ddd, J=7.5, 7.5, IHz), 7.46 (IH, dd, J=7.5, IHz), 7.62 (IH, dd, J=7.5, IHz), 7.76 (IH, d, J=lHz), 8.09 (IH, d, J=7.5Hz) MASS (m/z) : 427 (M + +l), 74 (bp) (43) 1- (6-Chloro-3, 4-methylenedioxybenzyl) -3- (3- methoxybutanoyl)-2-propylindole-6-carboxamide mp : 190-192.5 β C IR (KBr) : 1654, 1652, 1608, 1505, 1482 cm "1 NMR (CDC1 3 , δ) : 1.04 (3H, t, J=7Hz) , 1.33 (3H, d, J=7Hz), 1.62 (2H, sextet, J=7Hz) , 3.00-3.09 (3H, m) , 3.40 (3H, s), 3.45 (IH, dd, J=16, 7Hz), 4.12 (IH, sextet, J=7Hz), 5.40 (2H, s) , 5.70 (IH, s), 5.90 (2H, s), 6.91 (IH, s), 7.61 (IH, d, J=7.5Hz), 7.88 (IH, s), 8.08 (IH, d, J=7.5Hz) MASS (m/z) : 471 (M + +l), 74 (bp) (44) 3-Acetyl-6-chloro-l- (2-chlorobenzyl) indole NMR (CDC1 3 , δ) : 2.49 (3H, s) , 5.41 (2H, s) , 6.75 (IH, d, J=8Hz), 7.18 (IH, t, J=8Hz), 7.19 (IH, t, J=8Hz), 7.2-7.33 (3H, m) , 7.48 (IH, d, J=8Hz) , 7.72 (IH, s), 8.33 (IH, d, J=8Hz) Example 7 The following compounds described in (1) to (43) were prepared in a similar manner to that of Example 2. (1) 9- (2-Chlorobenzyl) -5-oxo-5, 6, 7, 8-tetrahydrocarbazole-2- carboxylic acid NMR (CDC1 3 , δ) : 2.24 (2H, m) , 2.63 (2H, t, J=7Hz) , 2.88 (2H, t, J=7Hz), 5.47 (2H, s) , 6.36 (IH, d, J=8Hz) , 7.09 (IH, t, J=8Hz) , 7.26 (IH, t, J=8Hz) , 7.47 (IH, d, J=8Hz), 8.02 (IH, ε), 8.04 (IH, d, J=8Hz), 8.37 (IH, d, J=8Hz) (2) 4- (2-Chlorobenzyl) -1-oxo-l, 2, 3, 4-tetrahydrocyclopent- [b] indole-6-carboxylic acid NMR (DMSO-d 6 , δ) : 2.87 (2H, m) , 3.03 (2H, m) , 5.64 (2H, s), 6.93 (IH, d, J=8Hz) , 7.29 (IH, t, J=8Hz) , 7.37 (IH, t, J=8Hz), 7.58 (IH, d, J=8Hz) , 7.78 (IH, d, J=8Hz), 7.83 (IH, d, J=8Hz) , 8.05 (IH, -s) (3) 1- (2-Chlorobenzyl) -3-isobutyryl-2-propylindole-7- carboxylic acid NMR (CDC1 3 , δ) : 1.03 (3H, t, J=7Hz) , 1.29 (6H, d, J=7Hz), 1.64 (2H, m) , 3.03 (2H, m) , 3.56 (IH, m) , 5.75 (2H, s), 6.04 (IH, d, J=8Hz) , 6.96 (IH, t. J=8Hz), 7.12 (IH, t, J=8Hz), 7.29 (IH, t, J=8Hz) , 7.33 (IH, d, J=8Hz), 7.67 (IH, d, J=8Hz) 8.19 (IH, d, J=8Hz) (4) 1- (2-Chlorobenzyl) -3-isobutyryl-2-propylindole-5- carboxylic acid NMR (DMSO-d 6 , δ) : 0.90 (3H, t, J=8Hz) , 1.19 (6H, d, J=8Hz), 1.62 (2H, sextet, J=8Hz) , 3.02 (2H, t, J=8Hz), 3.51 (IH, septet, J=8Hz), 5.64 (2H, s) , 6.28 (IH, d, J=8Hz), 7.18 (IH, t, J=8Hz) , 7.32 (IH, t, J=8Hz), 7.50 (IH, d, J=8Hz) , 7.56 (IH, d, J=8Hz), 7.78 (IH, d, J=8Hz) , 8.58 (IH, s) (5) 1- (6-Chloro-3, 4-methylenedioxybenzyl) -3-isobutyryl-2- propylindole-5-carboxylic acid NMR (CDC1 3 , δ) : 1.04 (3H, t, J=7Hz) , 1.32 (6H, d, J=7Hz), 1.62 (2H, sextet, J=7Hz) , 3.06-3.12 (2H, m) , 3.66 (IH, septet, J=7Hz), 5.36 (2H, s), 5.74 (IH, s), 5.90 (2H, s), 6.93 (IH, s), 7.23 (IH, d, J=8Hz), 7.96 (IH, dd, J=l, 8Hz), 8.76 (IH, d, J=lHz) (6) 1- (2-Chlorobenzyl) -2-propylindole-4-carboxylic acid NMR (CDC1 3 , δ) : 1.03 (3H, t, J=7Hz) , 1.80 (2H, m) , 2.67 (2H, t, J=7Hz) , 5.43 (2H, s) , 6.19 (IH, d, J=8Hz), 7.03 (IH, t, J=8Hz), 7.1-7.25 (3H, m) , 7.34 (IH, d, J=8Hz), 7.41 (IH, d, J=8HZ) , 7.99 (IH, d, J=8Hz) (7) 9- (2-Chlorobenzyl) -8-OXO-5, 6,7, 8-tetrahydrocarbazole-2- carboxylic acid NMR (CDC1 3 , δ) : 2.28 (2H, m) , 2.68 (2H, t, J=7Hz) , 3.13 (2H, t, J=7Hz), 5.95 (2H, s) , 6.27 (IH, d, J=8Hz), 6.99 (IH, t, J=8Hz), 7.16 (IH, t, J=8Hz) , 7.42 (IH, d, J=8Hz), 7.77 (IH, d, J=8Hz) , 7.87 (IH, d, J=8Hz ) , 8 . 03 ( IH, s ) (8) 9- (6-Chloro-3, 4-methylenedioxybenzyl) -8-oxo-5, 6,7, 8- tetrahydrocarbazole-2-carboxylic acid NMR (DMSO-d 6 , δ) : 2.19 (2H, m) , 2.63 (2H, t, J=7Hz) , 3.06 (2H, t, J=7Hz), 5.70 (IH, s), 5.82 (2H, s) , 5.96 (2H, s), 7.16 (IH, s) , 7.73 (IH, d, J=8Hz) , 7.88 (IH, d, J=8Hz), 7.98 (IH, s) (9) 1- (4-Bromo-2-chlorobenzyl)-3-isobutyryl-2-propylindole- 6-carboxylic acid mp : 234-235°C IR (KBr) : 1677, 1648, 1418 cm "1 NMR (CDC1 3 , δ) : 1.04 (3H, t, J=7Hz) , 1.30 (6H, d, J=7Hz), 1.54-1.64 (2H, m) , 3.02-3.08 (2H, m) , 3.50- 3.61 (IH, m) , 5.44 (2H, s), 6.10 (IH, t, J=8Hz) , 7.18 (IH, dd, J=8, IHz), 7.65 (IH, d, J=lHz) , 7.94- 8.05 (3H, m) MASS (m/z) : 476 (M + ) (10) 1-(2-Chlorobenzyl) -3-morpholinoacetyl-2-propylindole-6- carboxylic acid IR (KBr) : 1652, 1441, 1115 cm "1 NMR (CDC1 3 , δ) : 1.02 (3H, t, J=7Hz) , 1.60 (2H, εextet, J=7Hz) , 2.74 (4H, t, J=6.5Hz), 3.03-3.09 (2H, m) , 3.86 (4H, t, J=6.5Hz), 3.93 (2H, s) , 5.52 (2H, s), 6.25 (IH, d, J=7.5Hz), 7.05 (IH, t, J=7.5Hz), 7.22 (IH, t, J=7.5Hz), 7.47 (IH, d, J=7.5Hz), 7.90-8.01 (3H, m) MASS (m/z) : 455 (M + -l) (11) 1- (2-Chlorobenzyl)-3- (N,N-dimethylcarbamoyl)-2- propylindole-6-carboxylic acid IR (KBr) : 1704, 1596, 1219 cm "1 NMR (CDC1 3 , δ) : 0.93 (3H, t, J=7Hz) , 1.52-1.63 (2H, m) , 2.80-2.90 (2H, m) , 3.13 (6H, s), 5.48 (2H, s) , 6.30 (IH, d, J=7.5Hz), 7.04 (IH, t, J=7.5Hz), 7.20 (IH, t, J=7.5Hz), 7.44 (IH, d, J=7.5Hz), 7.50 (IH, d, J=7.5Hz), 7.91 (IH, d, J=7.5Hz), 7.96 (IH, s) MASS (m/z) : 399 (M + -l) (12) 1- (2-Chlorobenzyl^ -3-morpholinocarbonyl-2-propylindole- 6-carboxylic acid IR (KBr) : 3410, 1615, 1540, 1444, 1400 cm "1 NMR (DMSO-d 6 , δ) : 0.84 (3H, t, J=7Hz) , 1.39-1.49 (2H, m) , 2.76-2.84 (2H, m) , 3.56 (6H, br s) , 3.68 (2H, br s), 5.52 (2H, s), 6.24 (IH, d, J=7.5Hz), 7.16 (IH, t, J=7.5Hz), 7.29 (IH, t, J=7.5Hz), 7.40 (IH, d, J=7.5Hz), 7.54 (IH, d, J=7.5Hz), 7.79 (IH, s) , 7.81 (IH, s) MASS (m/z) : 439 (M + -l), 99 (bp) (13) 1- (2-Chlorobenzyl) -2-propylindole-3, 6-dicarboxylic acid mp : 241-243 β C (dec.) IR (KBr) : 1669, 1525, 1443, 1385 cm "1 NMR (DMSO-d 6 , δ) : 0.90 (3H, t, J=7Hz) , 1.44-1.55 (2H, ) , 3.12 (2H, t, J=7Hz) , 5.56 (2H, s) , 6.22 (IH, d, J=7.5Hz), 7.17 (IH, t, J=7.5Hz), 7.30 (IH, t, J=7.5Hz), 7.57 (IH, d, J=7.5Hz), 7.79 (IH, s) , 8.06 (IH, d, J=7.5Hz) MASS (m/z) : 370 (M + -l), 99 (bp) (14) 1- (2-Chlorobenzyl) -2-ethyl-3-formylindole-6-carboxylic acid mp : 241-242°C (dec.) IR (KBr) : 1675, 1650, 1295 cm "1 NMR (CDC1 3 , δ) : 1.29 (3H, t, J=7Hz) , 3.09 (2H, q, J=7Hz), 5.52 (2H, s) , 6.30 (IH, d, J=7.5Hz), 7.08 (IH, t, J=7.5Hz), 7.25 (IH, t, J=7.5Hz), 7.49 (IH, d, J=7.5Hz), 7.97 (IH, s), 8.03 (IH, d, J=7.5Hz), 8.35 (IH, d, J=7.5Hz), 10.25 (IH, s) MASS (m/z) : 340 (M + -l) (15) 1- (2-Chlorobenzyl)-3-formylindole-6-carboxylic acid NMR (DMSO-d 6 , δ) : 5.73 (2H, s), 6.96 (IH, d, J=8Hz) , 7.23-7.4 (2H, m) , 7.56 (IH, d, J=8Hz) , 7.89 (IH, d, J=8Hz), 8.15 (IH, s), 8.21 (IH, s) , 8.54 (IH, s) , 10.0 (IH, s) (16) 3-Acetyl-l- (2-chlorobenzyl)-2-methylindole-6-carboxylic acid NMR (CDC1 3 , δ) : 2.71 (3H, s) , 2.76 (3H, s) , 5.50 (2H, s), 6.22 (IH, d, J=8Hz), 7.05 (IH, t, J=8Hz) , 7.22 (IH, t, J=8Hz), 7.47 (IH, d, J=8Hz), 7.95-8.15 (3H, m) , 8.08 (IH, d, J=8Hz) (17) 1- (2-Chlorobenzyl) -2-methyl-3-propionylindole-6- carboxylic acid NMR {DMSO-d 6 , δ) : 1.14 (3H, t, J=7Hz) , 2.69 (3H, s) , 3.04 (2H, q, J=7Hz) , 5.67 (2H, s), 6.24 (IH, d, J=8Hz), 7.18 (IH, d, J=8Hz), 7.22 (IH, t, J=8Hz) , 7.58 (IH, d, J=8Hz) , 7.83 (IH, d, J=8Hz) , 7.99 (IH, s), 8.16 (IH, d, J=8Hz) (18) 1- (2-Chlorobenzo[b]thiophen-3-ylmethyl) -3-isobutyryl-2- methylindole-6-carboxylic acid NMR (CDC1 3 , δ) : 1.25 (6H, d, J=7Hz) , 2.71 (3H, s) , 3.50 (IH, m) , 5.61 (2H, s) , 6.99 (IH, d, J=8Hz) , 7.12 (IH, t, J=8Hz), 7.28 (IH, t, J=8Hz) , 7.68 (IH, d, J=8Hz) ,7.95-8.02 (2H, m) , 8.23 (IH, s) (19) 1- (Benzothiazol-2-ylmethyl) -2-ethyl-3-isobutyrylindole- 6-carboxylic acid NMR (CDCI3, δ) : 1.28 (3H, t, J=7Hz) , 1.30 (6H, d, J=7Hz), 3.24 (2H, q, J=7Hz), 3.58 (IH, m) , 5.86 ( 2H, s ) , 7 . 39 ( IH, t , J=8Hz ) , 7 . 52 ( IH, t, J=8Hz ) , 7 . 87 ( IH, d, J=8Hz ) , 7 . 9-8 . 06 ( 3H, m) , 8 .20 ( IH, s ! (20) 1- (Benzo[b]thiophen-5-ylmethyl)-3-isobutyryl-2- propylindole-6-carboxylic acid NMR (CDC1 3 , δ) : 1.02 (3H, t, J=7Hz) , 1.32 <6H, d, J=7Hz), 1.63 (2H, m) , 3.14 (2H, m) , 3.57 (IH, m) , 5.58 (2H, s), 7.04 (IH, d, J=8Hz) , 7.19 (IH, d, J=6Hz), 7.31 (IH, s), 7.43 (IH, d, J=6Hz), 7.81 (IH, d, J=8Hz), 7.9-8.02 (2H, m) , 8.08 (IH, s) (21) 1- (2, 4-Dichlorobenzyl)-3-isobutyryl-2-propylindole-6- carboxylic acid NMR (DMSO-d 6 , δ) : 0.92 (3H, t, J=7Hz) , 1.18 (6H, d, J=7Hz), 1.46 (2H, sextet, J=7Hz), 3.02-3.07 (2H, m) , 3.54 (2H, septet, J=7Hz), 5.68 (2H, s), 6.27 (IH, d, J=8Hz), 7.28 (IH, dd, J=2, 8Hz) , 7.76 (IH, d, J=2Hz), 7.84 (IH, d, J=8Hz) , 7.96 (IH, s) , 8.01 (IH, d, J=8Hz) (22) 3-Isobutyryl-2-propyl-l- (3-pyridylmethyl) indole-6- carboxylic acid NMR (CDC1 3 , δ) : 1.04 (3H, t, J=7Hz) , 1.30 (6H, d, J=7Hz), 1.63 (2H, sextet, J=7Hz) , 3.15 (2H, t, J=7Hz), 3.57 (2H, septet, J=7Hz) , 5.51 (2H, s) , 7.19-7.28 (2H, m) , 7.95-8.01 (2H, m) , 8.04 (IH, s), 8.52-8.56 (2H, m) (23) 3-Isobutyryl-2-propyl-l- (1-naphthylmethyl) indole-6- carboxylic acid NMR (DMSO-d 6 , δ) : 0.86 (3H, t, J=7Hz) , 1.22 (6H, d, J=7Hz), 1.52 (2H, sextet, J=7Hz), 3.05-3.10 (2H, m) , 3.60 (IH, septet, J=7Hz) , 6.15 (IH, d, J=8Hz) , 6.17 (2H, S), 7.28 (IH, t, J=8Hz) , 7.64 (IH, t, J=8Hz), 7.72 (IH, t, J=8Hz) , 7.84 (2H, d, J=8Hz) , 7.92 (IH, s) , 8.12 (IH, d, J=8Hz) , 8.15 (IH, d, J=8Hz), 8.36 (IH, d, J=8Hz) (24) 3-Isobutyryl-2-propyl-l- (2-naphthylmethyl) indole-6- carboxylic acid NMR (DMSO-d 6 , δ) : 0.92 (3H, t, J=7Hz), 1.19 (6H, d, J=7Hz), 1.48 (2H, sextet, J=7Hz), 3.14-3.18 (2H, m) , 3.57 (IH, septet, J=7Hz) , 5.81 (2H, s) , 7.20 (IH, d, J=8Hz), 7.45-7.52 (3H, m) , 7.76-7.90 (4H, m) , 8.02 (IH, d, J=8Hz) , 8.08 (IH, s) (25) l-Allyl-3-isobutyryl-2-propylindole-6-carboxylic acid NMR (CDC1 3 , δ) : 1.08 (3H, t, J=7Hz) , 1.28 (6H, d, J=7Hz), 1.69 (2H, m) , 3.13 (2H, m) , 3.56 (IH, m) , 4.88 (2H, m) , 4.90 (IH, m) , 5.23 (IH, ) , 5.98 (IH, m) , 7.94 (IH, d, J=8Hz) , 8.02 (IH, d, J=8Hz), 8.13 (IH, s) (26) 1-(2-Chlorobenzyl) -3-isobutyryl-2-(1-propenyl) indole-6- carboxylic acid NMR (CDC1 3 , δ) : 1.26 (6H, d, J=7Hz) , 1.93 (3H, d, J=7Hz), 3.51 (IH, m) , 5.50 (2H, s), 5.92 (IH, m) , 6.44 (IH, d, J=8Hz), 6.74 (IH, d, J=16Hz), 7.09 (IH, t, J=8Hz), 7.23 (IH, t, J=8Hz) , 7.48 (IH, d, J=8Hz), 7.92 (IH, s) , 8.02 (IH, d, J=8Hz) , 8.21 (IH, d, J=8Hz) (27) 1- (2-Chlorobenzyl)-2- (1-hydroxypropyl)-3- isobutyrylindole-6-carboxylic acid NMR (CDC1 3 , δ) : 0.92 (3H, t, J=7Hz) , 1.29 (3H, d, J=7Hz), 1.36 (3H, d, J=7Hz) , 1.52 (IH, m) , 1.88 (IH, m) , 3.70 (IH, m) , 4.73 (IH, m) , 5.51 (IH, d, J=17Hz), 5.69 (IH, d, J=17Hz) , 6.44 (IH, d, J=8Hz) , 7.09 (IH, t, J=8HZ), 7.23 (IH, t, J=8Hz), 7.45 (IH, d, J=8Hz), 7.9-8.1 (3H, m) (28) 1- (2-Chlorobenzyl) -3- (3, 3-dimethylbutanoyl) indole-6- carboxylic acid NMR (CDC1 3 , δ) : 1.08 (9H, s) , 2.70 (2H, s) , 5.52 (2H, s), 6.77 (IH, d, J=8Hz), 7.17 (IH, t, J=8Hz) , 7.28 (IH, t, J=8Hz), 7.47 (IH, d, J=8Hz) , 7.86 (IH, s) , 8.03 (IH, d, J=8Hz), 8.12 (IH, s) , 8.53 (IH, d, J=8Hz) (29) 1- (6-Chloro-3, 4-methylenedioxybenzyl) -3-methoxyacetyl-2- propylindole-6-carboxylic acid NMR (CDCI3, δ) : 0.96 (3H, t, J=7Hz), 1.45-1.58 (2H, m) , 3.10 (2H, t, J=7Hz), 3.40 (3H, s), 4.69 (2H, s), 5.55 (2H, s), 5.76 (IH, s) , 5.98 (2H, s), 7.23 (IH, s), 7.82 (IH, d, J=8Hz) , 7.94 (IH, s), 7.96 (IH, d, J=8Hz) (30) 1- (2-Chlorobenzyl) -3-ethoxyacetyl-2-propylindole-6- carboxylic acid NMR (DMSO-d 6 , δ) : 0.94 (3H, t, J=7Hz) , 1.17 (3H, t, J=7Hz), 1.48 (2H, sextet, J=7Hz), 3.08 (3H, t, J=7Hz), 3.62 (2H, q, J=7Hz) , 4.74 (2H, s), 5.68 (2H, s), 6.28 (IH, d, J=8Hz) , 7.18 (IH, t, J=8Hz) , 7.32 (IH, t, J=8Hz), 7.56 (IH, d, J=8Hz), 7.82 (IH, d, J=8Hz), 7.96 (IH, s) , 7.98 (IH, d, J=8Hz) (31) 1- (2-Chlorobenzyl) -3-isobutyryl-2-propylindol-6-ylacetic acid IR (KBr) : 1715, 1650 cm "1 NMR {CDCI3, δ) : 1.00 (3H, t, J=7Hz) , 1.30 (6H, d, J=7Hz), 1.54-1.66 (2H, m) , 3.00-3.08 (2H, ) , 3.50- 3.62 (IH, m) , 3.71 (2H, s), 5.47 (2H, s), 6.30 (IH, d, J=7.5Hz), 7.01-7.08 (2H, m) , 7.19-7.25 (2H, m) , 7.45 (IH, d, J=7.5Hz), 7.89 (IH, d, J=7.5Hz) MASS (m/z) : 412 (M + +l), 74 (bp) (32) 1- (6-Chloro-3,4-methylenedioxybenzyl)-3-isobutyryl-2- propylindole-6-ylacetic acid mp : 81-83°C IR (KBr) : 1715, 1650 cm "1 NMR (CDC1 3 , δ) : 1.02 (3H, t, J=7Hz) , 1.29 (6H, d, J=7Hz), 1.54-1.67 (2H, ) , 3.01-3.07 (2H, m) , 3.51- 3.60 (IH, m) , 3.75 (2H, s), 5.33 (2H, s), 5.79 (IH, s), 5.89 (2H, s), 6.91 (IH, s) , 7.12 (IH, s) , 7.21 (IH, d, J=7.5Hz), 7.89 (IH, d, J=7.5Hz) MASS (m/z) : 456 (M + +l), 74 (bp) (33) 1- (2-Chlorobenzyl) -2-propylindole-6-carboxylic acid NMR (CDC1 3 , δ) : 1.02 (3H, t, J=7Hz) , 1.74 (2H, ) , 2.61 (2H, t, J=7Hz), 5.42 (2H, s), 6.19 (IH, d, J=8Hz), 6.46 (IH, s) , 7.02 (IH, t, J=8Hz) , 7.18 (IH, t, J=8Hz), 7.43 (IH, d, J=8Hz) , 7.61 (IH, d, J=8Hz), 7.85 (IH, d, J=8Hz) , 7.95 (IH, s) (34) 1- (2-Bromobenzyl)-2-propylindole-6-carboxylic acid NMR (CDC1 3 , δ) : 1.00 (3H, t, J=7Hz), 1.73 (2H, m) , 2.61 (2H, t, J=7Hz), 5.37 (2H, s), 6.12 (IH, d, J=8Hz), 6.46 (IH, s), 7.0-7.18 (2H, m) , 7.61 (IH, d, J=8Hz), 7.85 (IH, d, J=8Hz) , 7.96 (IH, s) (35) 2-Acetyl-l- (2-chlorobenzyl)-3-methylindole-6-carboxylic acid NMR (DMSO-d 6 , δ) : 2.62 (3H, s) , 2.69 (3H, s), 5.82 (2H, ε), 6.10 (IH, d, J=8Hz) , 7.09 (IH, t, J=8Hz) , 7.24 (IH, t, J=8Hz), 7.51 (IH, d, J=8Hz) , 7.72 (IH, d, J=8Hz), 7.93 (IH, d, J=8Hz) , 7.96 (IH, s) (36) 2-Chloro-l- (2-chlorobenzyl)-3-ethylindole-6-carboxylic acid NMR (CDC1 3 , δ) : 1.30 (3H, t, J=7Hz) , 2.84 (2H, q, J=7Hz), 5.50 (2H, s), 6.29 (IH, d, J=8Hz), 7.06 (IH, t, J=8Hz), 7.19 (IH, t, J=8Hz) , 7.43 (IH, d, J=8Hz), 7.63 (IH, d, J=8Hz) , 7.88 (IH, d, J=8Hz) , 7.93 (IH, s) (37) 1- (2-Chlorobenzyl) -2-propionyl-3-propylindole-6- caboxylic acid NMR (CDC1 3 , δ) : 1.06 (3H, t, J=7Hz) , 1.14 (3H, t, J=7Hz), 1.76 (2H, m) , 2.94 (2H, q, J=7Hz), 3.09 (2H, m) , 5.72 (2H, s), 6.27 (IH, d, J=8Hz) , 6.99 (IH, t, J=8Hz), 7.14 (IH, t, J=8Hz), 7.39 (IH, d, J=8Hz), 7.78 (IH, d, J=8Hz) , 7.87 (IH, d, J=8Hz) , 8.02 (IH, s) (38) 1- (2-Chlorobenzyl) -2-isobutyryl-3-propylindole-6- carboxylic acid NMR (CDC1 3 , δ) : 1.03 (3H, t, J=7Hz) , 1.11 (6H, d, J=7Hz), 1.76 (2H, m) , 3.03 (2H, m) , 3.34 (IH, m) , 5.64 (2H, s), 6.30 (IH, d, J=8Hz) , 7.01 (IH, t, J=8Hz), 7.14 (IH, t, J=8Hz), 7.39 (IH, d, J=8Hz), 7.78 (IH, d, J=8Hz) , 7.88 (IH, d, J=8Hz), 8.02 (IH, s) (39) 1- (2-Chlorobenzyl) -3- (3-oxo-l-butenyl) indole-6- carboxylic acid NMR (DMS0-d 6 , δ) : 2.32 (3H, s), 5.67 (2H, ε), 6.76 (IH, d, J=15Hz), 6.86 (IH, d, J=8Hz) , 7.28 (IH, t, J=8Hz), 7.37 (IH, t, J=8Hz) , 7.54 (IH, d, J=8Hz) , 7.79 (IH, d, J=8Hz), 7.83 (IH, d, J=15Hz) , 8.08 (IH, d, J=8Hz), 8.11 (IH, ε), 8.21 (IH, ε) (40) 4- (2-Chlorobenzyl) -3-oxo-l, 2, 3, 4-tetrahydrocyclopent [b] - indole-6-carboxylic acid NMR (CDC1 3 , δ) : 3.07 (2H, m) , 3.17 (2H, m) , 5.72 (2H, s), 6.58 (IH, d, J=8Hz), 7.06 (IH, t, J=8Hz) , 7.18 (IH, t, J=8Hz), 7.40 (IH, d, J=8Hz) , 7.78 (IH, d, J=8Hz ) , 7 . 89 ( IH, d, J=8Hz ) , 8 . 09 ( IH, s ) (41) 4- (6-Chloro-3, 4-methylenedioxybenzyl) -3-oxo-l, 2, 3, 4- tetrahydrocyclopent [b] indole-6-carboxylic acid NMR (CDC1 3 , δ) : 3.07 (2H, m) , 3.16 (2H, ) , 5.61 (2H, s), 5.88 (2H, s), 6.10 (IH, s) , 6.88 (IH, s) , 7.78 (IH, d, J=8Hz), 7.88 (IH, d, J=8Hz) , 8.12 (IH, s) (42) 1- (2-Chlorobenzyl) -3-nitro-2-propylindole-6-carboxylic acid NMR (DMS0-d 6 , δ) : 0.95 (3H, t, J=7Hz) , 1.55 (2H, sextet, J=7Hz), 3.18-3.22 (2H, ) , 5.78 (2H, ε) , 6.52 (IH, d, J=8Hz), 7.22 (IH, t, J=8Hz) , 7.33 (IH, t, J=8Hz), 7.58 (IH, d, J=8Hz), 7.97 (IH, d, J=8Hz), 8.08 (IH, s) 8.27 (IH, d, J=8Hz) (43) 1- (2-Chloro-4-carboxybenzyl) -3-isobutyryl-2- propylindole-6-carboxamide NMR (DMSO-d 6 , δ) : 0.90 (3H, t, J=7Hz) , 1.18 (6H, d, J=7Hz), 1.46 (2H, sextet, J=7Hz), 3.00-3.05 (2H, ) , 3.55 (IH, septet, J=7Hz) , 5.68 (2H, s) , 6.33 (IH, d, J=8Hz), 7.30 (IH, s) , 7.72 (IH, dd, J=2, 8Hz), 7.92 (IH, s), 7.95-7.99 (2H, m) , 8.03 (IH, d, J=8Hz) Example 75 The following compounds described in (1) to (41) were prepared in a similar manner to that of Example 3- (1) 9-(2-Chlorobenzyl)-5-oxo-5, 6,7, 8-tetrahydrocarbazole-2- carboxamide mp : 295 β C (dec.) NMR (DMS0-d 6 , δ) : 2.13 (2H, m) , 2.48 (2H, t, J=7Hz) , 2.92 (2H, t, J=7Hz), 5.62 (2H, s) , 6.41 (IH, d, J=8Hz), 7.21 (IH, t, J=8Hz) , 7.27 (IH, br s) , 7.33 (IH, t, J=8Hz), 7.57 (IH, d, J=8Hz) , 7.79 (IH, d, J=8Hz), 7.92 (IH, br s) , 8.02 (IH, s) , 8.08 (IH, d, J=8Hz) (2) 4- (2-Chlorobenzyl) -1-oxo-l, 2, 3, 4-tetrahydrocyclopent [b] - indole- 6-carboxamide mp : >300°C NMR (DMS0-d 6 , δ) : 2.88 (2H, m) , 2.97 (2H, m) , 5.61 (2H, s), 6.81 (IH, d, J=8Hz) , 7.27 (IH, t, J=8Hz) , 7.36 (IH, br s) , 7.38 (IH, t, J=8Hz) , 7.57 (IH, d, J=8Hz), 7.76 (IH, d, J=8Hz), 7.79 (IH, d, J=8Hz) , 7.96 (IH, br s) , 8.05 (IH, ε) (3) 1- (2-Chlorobenzyl) -3-iεobutyryl-2-propylindole-7- carboxamide mp : 181-183°C NMR (CDC1 3 , δ) : 1.03 (3H, t, J=7Hz) , 1.27 (6H, d, J=7Hz), 1.61 (2H, m) , 3.02 (2H, m) , 3.53 (IH, m) , 5.34 (IH, br ε), 5.46 (IH, br s), 5.69 (2H, s), 5.99 (IH, d, J=8Hz), 6.96 (IH, t, J=8Hz) , 7.14 (IH, t, J=8Hz), 7.15-7.25 (2H, m) , 7.37 (IH, d, J=8Hz) , 8.07 (IH, m) (4 ) 1- (2-Chlorobenzyl) -3-isobutyryl-2-propylindole-5- carboxamide NMR (CDC1 3 , δ) : 1.03 (3H, t, J=8Hz) , 1.32 (6H, d, J=8Hz), 1.64 (2H, sextet, J=8Hz) , 3.06 (2H, t, J=8Hz), 3.62 (IH, septet, J=8Hz) , 5.46 (2H, s) , 6.26 (IH, d, J=8Hz), 7.05 (IH, t, J=8Hz) , 7.20 (IH, t, J=8Hz), 7.2 (IH, d, J=8Hz) , 7.47 (IH, d, J=8Hz) , 7.65 (IH, d, J=8Hz), 8.55 (IH, s) (5) 1- (6-Chloro-3, 4-methylenedioxybenzyl) -3-isobutyryl-2- propylindole-5-carboxamide NMR (CDC1 3 , δ) : 1.05 (3H, t, J=7Hz), 1.32 (6H, d. J=7Hz), 1.60-1.72 (2H, ) , 3.04-3.10 (2H, m) , 3.59 (IH, septet, J=7Hz), 5.38 (2H, s), 5.74 (IH, s), 5.92 (2H, s), 6.92 (IH, s), 7.22 (IH, d, J=8Hz) , 7.66 (IH, dd, J=l, 8Hz), 8.50 (IH, d, J=lHz) (6) 1- (2-Chlorobenzyl) -2-propylindole-4-carboxamide mp : 198-200°C NMR (CDC1 3 , δ) : 1.02 (3H, t, J=7Hz) , 1.76 (2H, m) , 2.66 (2H, t, J=7Hz), 5.41 (2H, s) , 6.18 (IH, d, J=8Hz), 6.85 (IH, s) , 7.1-7.3 (3H, m) , 7.43 (IH, d, J=8Hz), 7.52 (IH, d, J=8Hz) (7) 9- (2-Chlorobenzyl) -8-oxo-5, 6, 7, 8-tetrahydrocarbazole-2- carboxamide mp : 255 β C (dec.) NMR (DMSO-d 6 , δ) : 2.18 (2H, m) , 2.56 (2H, t, J=7Hz) , 3.07 (2H, t, J=7Hz), 5.88 (2H, s) , 6.08 (IH, d, J=8Hz), 7.11 (IH, t, J=8Hz), 7.25 (IH, t, J=8Hz) , 7.36 (IH, br s) , 7.52 (IH, d, J=8Hz) , 7.72 (IH, d, J=8Hz), 7.85 (IH, d, J=8Hz) , 8.02 (2H, m) (8) 9- (6-Chloro-3, 4-methylenedioxybenzyl) -8-oxo-5, 6,7,8- tetrahydrocarbazole-2-carboxamide mp : 270 β C (dec.) NMR (DMSO-d 6 , δ) : 2.17 (2H, m) , 2.58 (2H, t, J=7Hz) , 3.08 (2H, t, J=7Hz), 5.52 (IH, s), 5.78 (2H, s) , 5.96 (2H, s), 7.17 (IH, s) , 7.40 (IH, br s), 7.71 (IH, d, J=8Hz), 7.86 (IH, d, J=8Hz) , 7.96 (IH, ε), 8.01 (IH, br s) (9) 1- (4-Bromo-2-chlorobenzyl) -3-isobutyryl-2-propylindole- 6-carboxamide mp : 199-201°C IR (KBr) : 3382, 1654, 1619, 1488, 1404 cm "1 NMR (CDC1 3 , δ) : 1.04 (3H, t, J=7Hz) , 1.30 (6H, d, J=7Hz), 1.54-1.66 (2H, m) , 3.00-3.05 (2H, m) , 3.50- 3.60 (IH, m) , 5.45 (2H, s) , 6.09 (IH, t, J=7.5Hz), 7.17 (IH, dd, J=7.5, 2Hz) , 7.62 (IH, dd, J=7.5, 2Hz), 7.65 (IH, d, J=2Hz) , 7.83 (IH, s) , 7.99 (IH, d, J=7.5Hz) MASS (m/z) : 477 (M + +2) (10) 1- (2-Chlorobenzyl) -3-morpholinoacetyl-2-propylindole-6- carboxamide IR (KBr) : 1654, 1616, 1452 cm "1 NMR (CDC1 3 , δ) : 1.02 (3H, t, J=7Hz) , 1.58-1.68 (2H, m) , 2.73 (4H, t, J=6.5Hz), 3.05-3.10 (2H, m) , 3.84 (4H, t, J=6.5Hz), 3.89 (2H, s) , 5.51 (2H, s), 6.23 (IH, d, J=7.5Hz), 7.05 (IH, t, J=7.5Hz), 7.22 (IH, t, J=7.5Hz), 7.46 (IH, d, J=7.5Hz), 7.64 (IH, d, J=7.5Hz), 7.84 (IH, s) , 7.98 (IH, d, J=7.5Hz) MASS (m/z) : 454 (M + +l) (11) Methyl 1- (2-chlorobenzyl)-3- (N,N-dimethylcarbamoyl)-2- propylindole-6-carboxylate IR (KBr) : 1703, 1610 cm "1 NMR (CDCI3, δ) : 0.94 (3H, t, J=7Hz), 1.56-1.63 (2H, m) , 2.76-2.87 (2H, m) , 3.11 (6H, br s), 3.90 (3H, s), 5.49 (2H, s), 6.29 (IH, d, J=7.5Hz), 7.04 (IH, t, J=7.5Hz), 7.21 (IH, t, J=7.5Hz), 7.45 (IH, d, J=7.5Hz), 7.49 (IH, d, J=7.5Hz), 7.86 (IH, d, J=7.5Hz), 7.90 (IH, s) MASS (m/z) : 413 (M + +l) (12) Methyl 1- (2-chlorobenzyl)-3- (morpholinocarbonyl)-2- propylindole-6-carboxylate IR (KBr) : 1715, 1617, 1277, 1227 cm "1 NMR (CDCI3, δ) : 0.85 (3H, t, J=7Hz) , 1.56-1.63 (2H, m) , 2.82-2.90 (2H, m) , 3.69 (6H, br s) , 3.77 (2H, br ε), 3.90 (3H, ε), 5.48 (2H, s), 6.29 (IH, d, J=7.5Hz), 7.04 (IH, t, J=7.5Hz), 7.21 (IH, ddd, J=7.5, 7.5, 2Hz), 7.45 (IH, d, J=7.5Hz) , 7.54 (IH, d, J=7.5Hz), 7.88 (IH, s) , 7.91 (IH, d, J=2Hz) MASS (m/z) : 455 (M + +l), 76 (bp) (13) 6-Carbamoyl-l- (2-chlorobenzyl)-N,N-dimethyl-2- propylindole-3-carboxamide mp : 213-214°C IR (KBr) : 1676, 1601 cm "1 NMR (CDC1 3 , δ) : 0.93 (3H, t, J=7Hz) , 1.52-1.62 (2H, m) , 2.76-2.86 (2H, m) , 3.12 (6H, br s), 5.47 (2H, s), 6.27 (IH, d, J=7.5Hz), 7.03 (IH, t, J=7.5Hz), 7.20 (IH, t, J=7.5Hz), 7.44 (IH, d, J=7.5Hz), 7.49- 7.54 (2H, m) , 7.78 (IH, s) MASS (m/z) : 398 (M + +l), 76 (bp) (14) 1- (2-Chlorobenzyl)-3- (morpholinocarbonyl)-2- propylindole-6-carboxamide mp : 229-230°C IR (KBr) : 3448, 3359, 3326, 1675, 1606 cm "1 NMR (CDC1 3 , δ) : 0.95 (3H, t, J=7Hz) , 1.57-1.62 (2H, m) , 2.82-2.89 (2H, m) , 3.69 (6H, br s) , 3.78 (2H, br s), 5.49 (2H, s), 6.28 (IH, d, J=7.5Hz), 7.04 (IH, t, J=7.5Hz), 7.21 (IH, t, J=7.5Hz), 7.45 (IH, t, J=7.5Hz), 7.55 (2H, s), 7.80 (IH, s) MASS (m/z) : 440 (M + +l), 76 (bp) (15) 1- (2-Chlorobenzyl) -2-propylindole-3, 6-dicarboxamide mp : 296°C (dec.) IR (KBr) : 3376, 3188, 1644, 1613 cm "1 NMR (DMS0-d 6 , δ) : 0.88 (3H, t, J=7Hz) , 1.40-1.51 (2H, m) , 2.98 (2H, t, J=7Hz) , 5.57 (2H, s), 6.17 (IH, d, J=7.5Hz), 7.14-7.35 (6H, m) , 7.58 (IH, d, J=7.5Hz), 7.73 (IH, d, J=7.5Hz), 7.83-7.89 (IH, m) , 7.95 (IH, s) MASS (m/z ) : 370 (M + + l ) , 86 (bp) (16) 1- (2-Chlorobenzyl) -2-ethyl-3-formylindole-6-carboxamide mp : 260-261°C IR (KBr) : 3400, 1685, 1635, 1615, 1390 cm "1 NMR (CDC1 3 , δ) : 1.29 (3H, t, J=7Hz) , 3.08 (2H, q, J=7Hz), 5.52 (2H, s) , 6.29 (IH, d, J=7.5Hz), 7.07 (IH, t, J=7.5Hz), 7.24 (IH, t, J=7.5Hz), 7.49 (IH, d, J=7.5Hz), 7.69 (IH, d, J=7.5Hz), 7.86 (IH, ε), 8.35 (IH, d, J=7.5Hz), 10.24 (IH, s) MASS (m/z) : 341 (M + +l) (17) 1- (2-Chlorobenzoyl) -3-isobutyryl-2-propylindole-6- carboxamide p : 125-126.5°C IR (KBr) : 1700, 1650 cm "1 NMR (CDC1 3 , δ) : 0.90 (3H, t, J=7Hz) , 1.28 (6H, d, J=7Hz), 1.61-1.74 (2H, m) , 2.98-3.05 (2H, m) , 3.40- 3.49 (IH, m) , 7.48-7.53 (3H, m) , 7.59-7.65 (2H, m) , 7.79 (2H, AB, J=8, 7.5Hz) MASS (m/z) : 411 (M + +l), 76 (bp) (18) 1- (2-Chlorobenzyl) -3-formylindole-6-carboxamide mp : 237-240 β C NMR (DMSO-d 6 , δ) : 5.68 (2H, s) , 6.86 (IH, d, J=8Hz), 6.25-6.4 (3H, m) , 7.58 (IH, d, J=8Hz) , 7.84 (IH, d, J=8Hz), 7.98 (IH, br s), 8.14 (IH, s), 8.17 (IH, d, J=8Hz), 8.46 (IH, ε), 9.98 (IH, s) (19) 3-Acetyl-l- (2-chlorobenzyl) -2-methylindole-6-carboxamide mp : 272-276°C NMR (DMSO-d 6 , δ) : 2.63 (3H, ε) , 2.65 (3H, ε) , 5.61 (2H, s), 6.17 (IH, d, J=8Hz) , 7.18 (IH, t, J=8Hz) , 7.27 (IH, br s), 7.32 (IH, t, J=8Hz), 7.57 (IH, d, J=8Hz), 7.80 (IH, d, J=8Hz) , 7.94 (IH, br s), 8.03 ( IH, s ) , 8 . 11 ( IH, s ) (20) 1- (2-Chlorobenzyl)-2-methyl-3-propionylindole-6- carboxamide p : 215-217°C NMR (DMS0-d 6 , δ) : 1.14 (3H, t, J=7Hz) , 2.64 (3H, s) , 3.04 (2H, q, J=7Hz) , 5.62 (2H, s) , 6.18 (IH, d, J=8Hz), 7.18 (IH, t, J=8Hz), 7.29 (IH, br s) , 7.32 (IH, t, J=8Hz), 7.57 (IH, d, J=8Hz) , 7.79 (IH, d, J=8Hz), 8.02 (IH, s) , 8.10 (IH, d, J=8Hz) (21) 1- (2-Chlorobenzo[b]thiophen-3-ylmethyl)-3-iεobutyryl-2- methylindole-6-carboxamide mp : 255°C (dec.) NMR (DMSO-d 6 , δ) : 1.13 (6H, d, J=7Hz) , 2.63 (3H, s), 3.47 (IH, m) , 5.84 (2H, s) , 7.2-7.42 (4H, m) , 7.48 (IH, d, J=8Hz), 7.89 (IH, br s) , 7.95-8.0 (2H, m) , 8.23 (IH, s) (22) 1- (Benzothiazol-2-ylmethyl)-2-ethyl-3-isobutyrylindole- 6-carboxamide mp : 188-190.5 β C (dec.) NMR (CDC1 3 , δ) : 1.28 (3H, t, J=7Hz), 1.29 (6H, d, J=7Hz), 3.27 (2H, q, J=7Hz), 3.53 (IH, m) , 5.82 (2H, ε), 7.36 (IH, t, J=8Hz), 7.49 (IH, t, J=8Hz), 7.66 (IH, d, J=8Hz), 7.74 (IH, d, J=8Hz) , 7.97 (IH, d, J=8Hz), 8.02 (IH, d, J=8Hz) , 8.07 (IH, ε) (23) 1- (Benzo[b]thiophen-5-ylmethyl) -3-isobutyryl-2- propylindole-6-carboxamide mp : 189-192°C (dec.) NMR (CDC1 3 , δ) : 1.02 (3H, t, J=7Hz) , 1.31 (6H, d, J=7Hz), 1.62 (2H, m) , 3.14 (2H, m) , 3.57 (IH, m) , 5.58 (2H, s), 7.02 (IH, d, J=8Hz) , 7.18 (IH, d, J=6Hz), 7.29 (IH, ε), 7.43 (IH, d, J=6Hz) , 7.60 ( IH, d, J=8Hz ) , 7 . 79 ( IH, d, J=8Hz ) , 7 . 92 ( IH, s ) , 7 . 97 ( IH, d, J=8Hz ) (24) 1- (2,4-Dichlorobenzyl)-3-isobutyryl-2-propylindole-6- carboxamide mp : 191-192°C NMR (DMSO-d 6 , δ) : 0.92 (3H, t, J=7Hz) , 1.18 (6H, d, J=7Hz), 1.45 (2H, sextet, J=7Hz) , 3.00-3.05 (2H, m) , 3.55 (2H, septet, J=7Hz), 5.60 (2H, s), 6.18 (IH, d, J=8Hz), 7.28 (IH, dd, J=2, 8Hz) , 7.31 (IH, s), 7.76 (IH, d, J=2Hz), 7.82 (IH, d, J=8Hz) , 7.92 (IH, br s), 7.94 (IH, s) , 7.98 (IH, d, J=8Hz) (25) 3-Isobutyryl-2-propyl-l- (3-pyridylmethyl)indole-6- carboxamide mp : 230-235°C NMR (CDC1 3 , δ) : 1.02 (3H, t, J=7Hz) , 1.30 (6H, d, J=7Hz), 1.60 (2H, sextet, J=7Hz), 3.08-3.16 (2H, m) , 3.56 (2H, septet, J=7Hz), 5.48 (2H, s), 7.19- 7.24 (2H, m) , 7.61 (IH, d, J=8Hz) , 7.92 (IH, s), 7.96 (IH, d, J=8Hz), 8.38 (IH, d, J=2Hz) , 8.52 (IH, dd, J=2, 5Hz) (26) 3-Isobutyryl-2-propyl-l- (1-naphthylmethyl) indole-6- carboxamide mp : 202-203°C NMR (CDC1 3 , δ) : 0.96 (3H, t, J=7Hz) , 1.34 (6H, d, J=7Hz), 1.61-1.68 (2H, m) , 3.08 (2H, dd, J=7, 8Hz), 3.61 (IH, septet, J=7Hz), 5.90 (2H, s), 6.28 (IH, d, J=8Hz), 7.21 (IH, t, J=8Hz) , 7.58-7.69 (3H, m) , 7.76 (IH, d, J=8Hz), 7.78 (IH, s), 7.94 (IH, d, J=8Hz), 8.00 (IH, d, J=8Hz) , 8.08 (IH, d, J=8Hz) (27) 3-Iεobutyryl-2-propyl-l- (2-naphthylmethyl) indole-6- carboxamide mp : 189-190°C NMR (CDCI3, δ) : 0.98 (3H, t, J=7Hz) , 1.30 (6H, d, J=7Hz), 1.55-1.68 (2H, m) , 3.14-3.18 (2H, m) , 3.58 (IH, septet, J=7Hz), 5.58 (2H, s) , 7.15 (IH, dd, J=l, 8Hz), 7.28 (IH, s), 7.42-7.48 (2H, m) , 7.60- 7.66 (2H, m) , 7.78 (2H, d, J=8Hz) , 7.93 (IH, d, J=lHz), 7.98 (IH, d, J=8Hz) (28) l-Allyl-3-isobutyryl-2-propylindole-6-carboxamide mp : 155-158°C NMR (CDC1 3 , δ) : 1.06 (3H, t, J=7Hz), 1.27 (6H, d. J=7Hz), 1.71 (2H, m) , 3.11 (2H, m) , 3.51 (IH, m) , 4.83 (2H, m) , 4.86 (IH, m) , 5.19 (IH, m) , 5.96 (IH, ) , 7.58 (IH, d, J=8Hz), 7.89 (IH, d, J=8Hz) , 7.96 (IH, s) (29) 1- (2-Chlorobenzyl)-3-isobutyryl-2- (1-propenyl) indole-6- carboxamide mp : 190-193°C NMR (CDC1 3 , δ) : 1.23 (6H, d, J=7Hz) , 1.93 (3H, d, J=7Hz), 3.51 (IH, m) , 5.48 (2H, s) , 5.91 (IH, dq, J=15, 7Hz), 6.41 (IH, d, J=8Hz) , 6.71 (IH, d, J=15Hz), 7.07 (IH, t, J=8Hz) , 7.23 (IH, t, J=8Hz) , 7.46 (IH, d, J=8Hz), 7.62 (IH, d, J=8Hz), 7.80 (IH, s), 8.24 (IH, d, J=8Hz) (30) 1- (2-Chlorobenzyl)-2- (1-hydroxypropyl)-3- iεobutyrylindole-6-carboxamide mp : 220-223°C NMR (CDCI3, δ) : 0.94 (3H, t, J=7Hz) , 1.32 (3H, d, J=7Hz), 1.39 (3H, d, J=7Hz) , 1.52 (IH, m) , 1.93 (IH, m) , 3.69 (IH, m) , 4.68 (IH, m) , 5.48 (IH, d, J=17Hz), 5.66 (IH, d, J=17Hz), 6.33 (IH, d, J=10Hz), 6.43 (IH, d, J=8Hz), 7.07 (IH, t, J=8Hz) , 7.21 (IH, t, J=8Hz), 7.44 (IH, d, J=8Hz), 7.68 (IH, d, J=8Hz), 7.92 (IH, s), 7.96 (IH, d, J=8Hz) (31) l-(2-Chlorobenzyl)-3- (3, 3-dimethylbutanoyl) indole-6- carboxamide mp : 202-205 β C NMR (CDC1 3 , δ) : 1.08 (9H, s), 2.69 (2H, s) , 5.50 (2H, s), 6.73 (IH, d, J=8Hz), 7.14 (IH, t, J=8Hz) , 7.28 (IH, t, J=8Hz), 7.45 (IH, d, J=8Hz) , 7.62 (IH, d, J=8Hz), 7.80 (IH, s), 7.99 (IH, s), 8.53 (IH, d, J=8Hz) (32) 1- (2-Chlorobenzyl) -2-propylindole-6-carboxamide mp : 174-177°C NMR (CDC1 3 , δ) : 1.00 (3H, t, J=7Hz), 1.74 (2H, m) , 2.61 (2H, t, J=7Hz), 5.43 (2H, s), 6.15 (IH, d, J=8Hz), 6.44 (IH, s) , 7.00 (IH, t, J=8Hz) , 7.18 (IH, t, J=8Hz), 7.4-7.5 (2H, m) , 7.61 (IH, d, J=8Hz), 7.79 (IH, s) (33) 1- (2-Bromobenzyl) -2-propylindole-6-carboxamide mp : 166-168 β C NMR (CDC1 3 , δ) : 1.00 (3H, t, J=7Hz) , 1.73 (2H, m) , 2.59 (2H, m) , 5.36 (2H, s), 6.10 (IH, d, J=8Hz) , 6.42 (IH, s), 7.0-7.15 (2H, m) , 7.46 (IH, dd, J=l, 8Hz), 7.61 (IH, dd, J=l, 8Hz), 7.76 (IH, s) (34) 2-Acetyl-l- (2-chlorobenzyl) -3-methylindole-6-carboxamide mp : 234-236°C NMR (DMSO-d 6 , δ) : 2.58 (3H, s), 2.71 (3H, s), 5.79 (2H, s), 6.03 (IH, d, J=8Hz) , 7.09 (IH, t, J=8Hz), 7.24 (IH, t, J=8Hz), 7.35 (IH, br S) , 7.50 (IH, d, J=8Hz), 7.70 (IH, d, J=8Hz), 7.92 (IH, d, J=8Hz) , 7.98 (IH, s) , 7.99 (IH, br ε) (35; 2-Chloro-l- (2-chlorobenzyl) -3-ethylindole-6-carboxamide mp : 195-198°C NMR (CDCI3, δ) : 1.27 (3H, t, J=7Hz) , 2.83 (2H, q, J=7Hz), 5.49 (2H, s) , 6.29 (IH, d, J=8Hz) , 7.03 (IH, t, J=8Hz), 7.18 (IH, t, J=8Hz) , 7.42 (IH, d, J=8Hz), 7.50 (IH, d, J=8Hz) , 7.63 (IH, d, J=8Hz) , 7.77 (IH, s) (36) 1- (2-Chlorobenzyl) -2-propionyl-3-propylindole-6- carboxamide mp : 165-167°C NMR (CDC1 3 , δ) : 1.05 (3H, t, J=7Hz) , 1.13 (3H, t, J=7Hz), 1.76 (2H, m) , 2.93 (2H, q, J=7Hz) , 3.08 (2H, m) , 5.70 (2H, s), 6.23 (IH, d, J=8Hz) , 6.97 (IH, t, J=8Hz), 7.12 (IH, t, J=8Hz) , 7.47 (IH, d, J=8Hz), 7.53 (IH, d, J=8Hz) , 7.74 (IH, s), 7.76 (IH, d, J=8Hz) (37) 1- (2-Chlorobenzyl) -2-isobutyryl-3-propylindole-6- carboxamide mp : 159-160.5°C NMR (CDCI3, δ) : 1.03 (3H, t, J=7Hz) , 1.12 (6H, d, J=7Hz), 1.76 (2H, m) , 3.04 (2H, m) , 3.36 (IH, ) , 5.66 (2H, s), 6.29 (IH, d, J=8Hz) , 6.99 (IH, t, J=8Hz), 7.14 (IH, t, J=8Hz), 7.38 (IH, d, J=8Hz) , 7.56 (IH, d, J=8Hz) , 7.76 (IH, d, J=8Hz) , 7.77 (IH, s) (38) 1- (2-Chlorobenzyl) -3- (3-oxo-l-butenyl) indole-6- carboxamide mp : 248-250°C NMR (DMSO-d 6 , δ) : 2.30 (3H, s) , 5.61 (2H, s), 6.74 (IH, d, J=8Hz), 6.75 (IH, d, J=15Hz) , 7.2-7.4 (3H, m), 7.54 (IH, d, J=8Hz) , 7.77 (IH, d, J=8Hz) , 7.80 (IH, d, J=15Hz), 7.98 (IH, br s) , 8.04 (IH, d, J=8Hz), 8.11 (IH, s), 8.14 (IH, s) __,, ΛΛ^ „„_ a WO 96/32379 - 177 - (39) 4- (2-Chlorobenzyl) -3-oxo-l,2, 3, 4- tetrahydrocyclopent[b] indole-6-carboxamide mp : 289 β C (dec.) NMR (DMSO-d 6 , δ) : 2.95 (2H, m) , 3.10 (2H, m) , 5.67 (2H, s), 6.37 (IH, d, J=8Hz) , 7.16 (IH, t, J=8Hz) , 7.28 (IH, t, J=8Hz), 7.40 (IH, br s) , 7.53 (IH, d, J=8Hz), 7.74 (IH, d, J=8Hz) , 7.88 (IH, d, J=8Hz) , 8.01 (IH, br s) , 8.07 (IH, s) (40) 4- (6-Chloro-3, -methylenedioxybenzyl) -3-oxo-l,2, 3, 4- tetrahydrocyclopent [b] indole- 6-carboxamide mp : 282°C (dec.) NMR (DMS0-d 6 , δ) : 2.98 (2H, m) , 3.09 (2H, m) , 5.54 (2H, s), 5.97 (2H, s) , 5.98 (IH, s) , 7.17 (IH, s), 7.43 (IH, br s), 7.71 (IH, d, J=8Hz) , 7.86 (IH, d, J=8Hz), 8.03 (IH, br s) , 8.05 (IH, s) (41) 1-[2-Chloro-4- (N-phenylsulfonylcarbamoyl)benzyl]-3- isobutyryl-2-propylindole-6-carboxamide mp : 147-150°C NMR (DMSO-d 6 , δ) : 0.88 (3H, t, J=7Hz) , 1.18 (6H, d, J=7Hz), 1.45 (2H, sextet, J=7Hz), 2.98-3.03 (2H, m) , 3.55 (IH, septet, J=7Hz) , 5.68 (2H, s), 6.27 (IH, d, J=8Hz), 7.28 (IH, s), 7.60-7.64 (3H, m) , 7.69 (IH, dd, J=2, 8Hz) , 7.80 (IH, d, J=8Hz) , 7.92- 7.96 (4H, m) , 8.06 (IH, s) Example 76 The following compound described in (1) to (5) were prepared by a similar manner to that of Example 6. (1) 1- (6-Chloro-3, 4-methylenedioxybenzyl)-3-methoxyacetyl-2- propylindole-6-carboxamide (2) 1- (2-Chlorobenzyl) -3-ethoxyacetyl-2-propylindole-6- carboxamide NMR (DMSO-d 6 , δ) : 0.93 (3H, t, J=7Hz) , 1.18 (3H, t, J=7Hz), 1.46 (2H, sextet, J=7Hz) , 3.03 (3H, t, J=7Hz), 3.62 (2H, q, J=7Hz) , 4.74 (2H, s) , 5.63 (2H, s), 6.22 (IH, d, J=8Hz), 7.17 (IH, t, J=8Hz) , 7.30 (IH, s), 7.33 (IH, t, J=8Hz) , 7.58 (IH, d, J=8Hz), 7.80 (IH, d, J=8Hz) , 7.92 (IH, d, J=8Hz) , 7.94 (IH, s) , 8.00 (IH, s) (3) 1- (2-Chlorobenzyl)-3-isobutyryl-2-propylindol-6- ylacetamide mp : 146-148 β C IR (KBr) : 1715, 1650 cm "1 NMR (CDC1 3 , δ) : 1.01 (3H, t, J=7Hz) , 1.30 (6H, d, J=7Hz), 1.57-1.67 (2H, m) , 3.02-3.08 (2H, m) , 3.51- 3.60 (IH, m) , 3.66 (2H, s) , 5.45 (2H, s), 6.29 (IH, d, J=7.5Hz), 7.04-7.09 (2H, m) , 7.21 (2H, t, J=7.5Hz), 7.47 (IH, d, J=7.5Hz), 7.93 (IH, d, J=7.5Hz) MASS (m/z) : 411(M + +1), 74 (bp) (4) 1- ( 6-Chloro-3, 4-methylenedioxybenzyl) -3-isobutyryl-2- propylindole-6-ylacetamide mp : 136-138°C IR (KBr) : 1655, 1505 cm "1 NMR (CDC1 3 , δ) : 1.04 (3H, t, J=7Hz) , 1.29 (6H, d, J=7Hz), 1.55-1.67 (2H, m) , 3.01-3.07 (2H, m) , 3.50- 3.58 (IH, m) , 3.69 (2H, s) , 5.33 (2H, s) , 5.75 (IH, s), 5.90 (2H, s), 6.92 (IH, s) , 7.09 (IH, s) , 7.19 (IH, d, J=7.5Hz), 7.91 (IH, d, J=7.5Hz) MASS (m/z) : 455 (M + +l), 74 (bp) (5) 1- (2-Chlorobenzyl) -3-nitro-2-propylindole-6-carboxamide NMR (DMSO-d 6 , δ) : 0.95 (3H, t, J=7Hz) , 1.54 (2H, sextet, J=7Hz) , 3.13-3.17 (2H, m) , 5.72 (2H, s). 6.44 (IH, d, J=8Hz), 7.20 (IH, t, J=8Hz) , 7.36 (IH, t, J=8Hz), 7.42 (IH, s) , 7.60 (IH, d, J=8Hz) , 7.96 (IH, d, J=8Hz), 8.03 (IH, s) , 8.10 (IH, s), 8.22 (IH, d, J=8Hz) Example 77 The following compounds described in (1) to (13) were prepared in a similar manner to that of Example 26. (1) 1- (4-Chloro-2-fluorobenzyl) -3-methoxyacetyl-2- propylindole-6-carboxamide mp : 192-193°C NMR (DMSO-d 6 , δ) : 0.94 (3H, t, J=7Hz) , 1.44 (2H, sextet, J=7Hz), 3.09 (2H, t, J=7Hz) , 3.41 (3H, s), 4.69 (2H, s), 5.64 (2H, s), 6.50 (IH, t, J=8Hz) , 7.18 (IH, dd, J=2, 8Hz), 7.33 (IH, s) , 7.55 (IH, dd, J=2, 8Hz), 7.79 (IH, d, J=8Hz) , 7.89 (IH, d, J=8Hz), 7.92 (IH, s), 8.06 (IH, s) (2) 1- (2, 4-Dichlorobenzyl)-3-methoxyacetyl-2-propylindole-6- carboxamide mp : 203-205°C NMR (DMSO-d 6 , δ) : 0.94 (3H, t, J=7Hz) , 1.98 (2H, sextet, J=7Hz), 3.04 (2H, t, J=7Hz) , 3.42 (3H, s) , 4.71 (2H, s), 5.60 (2H, s), 6.20 (IH, d, J=8Hz) , 7.27 (IH, dd, J=2, 8Hz) , 7.32 (IH, s) , 7.77 (IH, d, J=2Hz), 7.82 (IH, d, J=8Hz) , 7.92 (IH, d, J=8Hz) , 7.94 (IH, s), 7.98 (IH, s) (3) 1- (4-Bromo-2-chlorobenzyl) -3-methoxyacetyl-2- propylindole-6-carboxamide mp : 178-180 β C NMR (DMSO-d 6 , δ) : 0.94 (3H, t, J=7Hz) , 1.48 (2H, sextet, J=7Hz), 3.04 (2H, t, J=7Hz) , 3.42 (3H, s) , 4.68 (2H, ε), 5.57 (2H, ε), 6.13 (IH, d, J=8Hz) , 7.30 (IH, s), 7.38 (IH, dd, J=2, 8Hz) , 7.80 (IH, d, J=8Hz), 7.86 (IH, d, J=2Hz) , 7.90 (IH, d, J=8Hz) , 7.93 (IH, s), 7.97 (IH, s) (4) 1- (4-Bromo-2-fluorobenzyl)-3-methoxyacetyl-2- propylindole-6-carboxamide mp : 197-199°C NMR (DMS0-d 6 , δ) : 0.94 (3H, t, J=7Hz) , 1.48 (2H, sextet, J=7Hz), 3.09 (2H, t, J=7Hz) , 3.40 (3H, s), 4.67 (2H, s), 5.62 (2H, s), 6.43 (IH, d, J=8Hz), 7.28 (IH, dd, J=2, 8Hz) , 7.65 (IH, dd, J=2, 8Hz), 7.78 (IH, d, J=8Hz), 7.90 (IH, d, J=8Hz) , 7.92 (IH, s), 8.05 (IH, s) (5) 1- (2-Chloro-4-fluorobenzyl)-3-methoxyacetyl-2- propylindole-6-carboxamide p : 174-176 β C NMR (DMSO-d 6 , δ) : 0.93 (3H, t, J=7Hz) , 1.48 (2H, sextet, J=7Hz), 3.04 (2H, t, J=7Hz) , 3.42 (3H, s), 4.70 (2H, s), 5.58 (2H, s) , 6.25 (IH, d, J=8Hz) , 7.06 (IH, dt, J=2, 8Hz), 7.32 (IH, s) , 7.50 (IH, dd, J=2, 8Hz), 7.80 (IH, d, J=8Hz) , 7.92 (IH, d, J=8Hz), 7.94 (IH, s), 8.00 (IH, s) (6) 1- (Benzo[b]thiophen-5-ylmethyl) -3-methoxyacetyl-2- propylindole-6-carboxamide mp : 197-199 β C (dec.) NMR (DMSO-d 6 , δ) : 0.92 (3H, t, J=7Hz) , 1.48 (2H, sextet, J=7Hz), 3.14 (2H, t, J=7Hz) , 3.42 (3H, s) , 4.72 (2H, s), 5.74 (2H, s) , 7.10 (IH, d, J=8Hz) , 7.28 (IH, s), 7.38 (IH, d, J=5Hz) , 7.44 (IH, s) , 7.75 (IH, d, J=5Hz), 7.78 (IH, d, J=8Hz) , 7.88 (IH, d, J=8Hz), 7.92 (IH, s), 7.96 (IH, d, J=8Hz), 8.12 (IH, s) (7) Methyl 1- (2, 4-dichlorobenzyl) -3-isobutyryl-2- propylindole-6-carboxylate NMR (CDC1 3 , δ) : 1.02 (3H, t, J=7Hz) , 1.31 (6H, d, J=7Hz), 1.60 (2H, sextet, J=7Hz) , 3.06 (2H, t, J=7Hz), 3.58 (2H, septet, J=7Hz), 3.93 (3H, s) , 5.46 (2H, s), 6.16 (IH, d, J=8Hz) , 7.04 (IH, d, J=8Hz), 7.50 (IH, s), 7.90 (IH, s) , 7.96 (2H, s) (8) Methyl 3-isobutyryl-2-propyl-l- (3-pyridylmethyl) indole- 6-carboxylate NMR (CDC1 3 , δ) : 1.02 (3H, t, J=7Hz) , 1.30 (6H, d, J=7Hz), 1.60 (2H, sextet, J=7Hz) , 3.12 (2H, t, J=7Hz), 3.56 (2H, septet, J=7Hz), 3.92 (3H, s), 5.48 (2H, s), 7.14-7.23 (2H, m) , 7.92-7.95 (2H, m) , 7.98 (IH, s), 8.42 (IH, d, J=2Hz) , 8.54 (IH, d, J=5Hz) (9) Methyl 3-isobutyryl-2-propyl-l- (1-naphthylmethyl) indole- 6-carboxylate NMR (CDC1 3 , δ) : 0.97 (3H, t, J=7Hz) , 1.34 (6H, d, J=7Hz), 1.64 (2H, sextet, J=7Hz) , 3.04-3.10 (2H, m) , 3.63 (IH, septet, J=7Hz) , 3.84 (3H, s), 5.92 (2H, s), 6.28 (IH, d, J=8Hz) , 7.22 (IH, t, J=8Hz) , 7.62 (IH, t, J=8Hz), 7.69 (IH, t, J=8Hz) , 7.77 (IH, d, J=8Hz), 7.77 (2H, s) , 7.92 (IH, s) (10) Methyl 3-iεobutyryl-2-propyl-l- (2-naphthylmethyl) indole- 6-carboxylate NMR (CDC1 3 , δ) : 1.00 (3H, t, J=7Hz) , 1.32 (6H, d, J=7Hz), 1.55-1.68 (2H, m) , 3.13-3.18 (2H, m) , 3.60 (IH, εeptet, J=7Hz) , 3.88 (3H, s) , 5.62 (2H, s) , 7.17 (IH, d, J=8Hz), 7.29 (2H, ε) , 7.42-7.48 (2H, m), 7.64-7.68 (IH, m) , 7.80 (2H, d, J=2Hz) , 7.96 (2H, s), 8.04 (IH, s) (11) Methyl 1- (6-chloro-3, -methylenedioxybenzyl) -3- methoxyacetyl-2-propylindole-6-carboxylate NMR (CDC1 3 ,- δ) : 1.04 (3H, t, J=7Hz) , 1.56-1.72 (2H, m) , 3.06-3.13 (2H, m) , 3.58 (3H, s) , 3.93 (3H, s) , 4.73 (2H, s), 5.40 (2H, s) , 5.70 (IH, s), 5.88 (2H, s), 6.92 (IH, s), 7.83 (IH, d, J=8Hz) , 7.96 (IH, s), 7.98 (IH, d, J=8Hz) (12) Methyl 1- (2-chlorobenzyl) -3-ethoxyacetyl-2-propylindole- 6-carboxylate NMR (CDC1 3 , δ) : 1.03 (3H, t, J=7Hz) , 1.34 (3H, , J=7Hz), 1.56-1.70 (2H, m) , 3.10 (3H, t, J=7Hz) , 3.77 (2H, q, J=7Hz) , 3.92 (3H, s) , 4.79 (2H, s), 5.52 (2H, s), 6.24 (IH, d, J=8Hz) , 7.03 (IH, t, J=8Hz), 7.22 (IH, t, J=8Hz) , 7.46 (IH, d, J=8Hz), 7.85 (IH, d, J=8Hz), 7.92 (IH, s) , 7.98 (IH, d, J=8Hz) (13) 1- (2-Chloro-4-methoxycarbonylbenzyl) -3-isobutyryl-2- propylindole-6-carboxamide NMR (CDC1 3 , δ) : 1.01 (3H, t, J=7Hz) , 1.32 (6H, d, J=7Hz), 1.60 (2H, sextet, J=7Hz) , 3.02-3.06 (2H, m) , 3.56 (IH, septet, J=7Hz), 3.90 (3H, s), 5.53 (2H, s), 6.28 (IH, d, J=8Hz), 7.63 (IH, d, J=8Hz) , 7.69 (IH, d, J=8Hz) , 7.82 (IH, s) , 7.98 (IH, d, J=8Hz), 8.14 (IH, s)

Claims: C L A I M S What we claim is A compound of the formula : wherein R 1 is hydrogen, halogen, nitro, carboxy, protected carboxy, acyl, cyano, hydroxyimino (lower) alkyl, lower alkenyl optionally subεtituted with oxo, or lower alkyl optionally εubεtituted with protected carboxy, carboxy or hydroxy; R^ lε hydrogen, halogen, lower alkenyl, acyl, or lower alkyl optionally substituted with protected carboxy, carboxy, lower alkoxy or hydroxy; R J is lower alkenyl or lower alkyl, both of which are optionally substituted with one or more substituent (s) selected from the group consisting of (1) oxo, (2) aryl optionally substituted with one or more substituent (s) selected from the group consisting of halogen, aryl, lower alkoxy, lower alkylenedioxy, cyano, nitro, carboxy, protected carboxy, acyl, and amino optionally substituted with acyl or protected carboxy, and (3) a heterocyclic group optionally substituted with halogen; and R 4 is carboxy, protected carboxy, acyl, cyano, halogen, a heterocyclic group, amino optionally substituted with acyl or protected carboxy, or lower alkyl optionally substituted with protected carboxy, carboxy or acyl; in addition to their significances above, R 1- 1 - and R2 together with the carbon atoms to which they are attached, represent a 4- to 7- membered carbocyclic ring optionally substituted with oxo, or its pharmaceutically acceptable salt. 2. A compound of claim 1, wherein R 1 is cyano, acyl, or lower alkyl optionally substituted with hydroxy, R^ is hydrogen, acyl, lower alkenyl, or lower alkyl optionally substituted with lower alkoxy or hydroxy, R J is methyl substituted with aryl or a heterocyclic group, wherein aryl iε optionally substituted with one or more substituent (s) selected from the group consisting of halogen, lower alkylenedioxy, protected carboxy and carboxy, and R 4 is acyl, cyano, or a heterocyclic group, in addition to their significanceε above, R 1 and R , together with the carbon atoms to which they are attached, represent a 4- to 7- membered carbocyclic ring optionally substituted with oxo. 3. A compound of claim 2, wherein R 1 is lower alkyl, or lower alkanoyl optionally substituted with hydroxy, lower alkoxy or aryl, R 2 is hydrogen, lower alkenyl, or lower alkyl optionally substituted with lower alkoxy, and R^ is benzyl optionally substituted with one or more substituent (s) selected from the group consisting of halogen and lower alkylenedioxy. 4. A compound of claim 3, wherein R^ is hydrogen, or lower alkyl, and R 6 is hydrogen, hydroxy, lower alkoxy, arylsulfonyl, a heterocyclic group, or lower alkyl optionally substituted with lower cycloalkyl or a heterocyclic group, in addition to their significances above, R^ and R , together with the nitrogen atom to which they are attached, may represent a heterocyclic group. 5. A compound of claim 4, wherein R 1 is lower alkanoyl optionally substituted with alkoxy, R 2 is lower alkyl, and R 4 is carbamoyl. 6. A proceεs for preparing a compound of the formula : wherein R 1 is hydrogen, halogen, nitro, carboxy, protected 79 - 186 - carboxy, acyl, cyano, hydroxyimino (lower) alkyl, lower alkenyl optionally substituted with oxo, or lower alkyl optionally substituted with protected carboxy, carboxy or hydroxy; R 2 is hydrogen, halogen, lower alkenyl, acyl, or lower alkyl optionally substituted with protected carboxy, carboxy, lower alkoxy or hydroxy; R^ is lower alkenyl or lower alkyl, both of which are optionally substituted with one or more substituent (s) selected from the group consisting of (1) oxo, (2) aryl optionally substituted with one or more substituent (s) selected from the group consisting of halogen, aryl, lower alkoxy, lower alkylenedioxy, cyano, nitro, carboxy, protected carboxy, acyl, and amino optionally substituted with acyl or protected carboxy, and (3) a heterocyclic group optionally substituted with halogen; and R- is carboxy, protected carboxy, acyl, cyano, halogen, a heterocyclic group, amino optionally substituted with acyl or protected carboxy, or lower alkyl optionally substituted with protected carboxy, carboxy or acyl; in addition to their significances above, R 1 and R , together with the carbon atoms to which they are attached, represent a 4- to 7- membered carbocyclic ring optionally εubstituted with oxo, or its pharmaceutically acceptable salt, which comprises, reacting a compound of the formula : wherein R , R 2 and R 4 are each as defined above, or its salt, with a compound of the formula : ,3 _ X- (III) 3 wherein R is the one as defined above, and X 1 is a leaving group, to give a compound of the formula : wherein R , R 2 , R 3 and R 4 are each as defined above, or its salt ; subjecting a compound of the formula wherein R 1 , R 2 and R are each as defined above, and R 4 is protected carboxy or lower alkyl substituted with protected carboxy, or its salt, to deesterification to give a compound of the formula wherein R , R^ and R J are each as defined above, and R^ is ccaarrbbooxxyy or lower alkyl substituted with carboxy, or its salt, iii) reacting a compound of the formula (1-2) defined above, or its reactive derivative at the carboxy group, or its salt, with a compound of the formula : ^ R 5 (IV) H" < R 6 wherein R 5 is hydrogen or lower alkyl, and R 6 is hydrogen, hydroxy, lower alkoxy, arylsulfonyl, a heterocyclic group, or lower alkyl optionally subεtituted with lower cycloalkyl or a heterocyclic group, in addition to their significances above, R 5 and R 6 , together with the nitrogen atom to which they are attached, may represent a heterocyclic group, or its reactive derivative at the amino group, or its εalt, to give a compound of the formula : wherein R 1 , R 2 , R 3 , R 5 and R^ are each as defined above, and or lower alkyl subεtituted with or its salt; iv) subjecting a compound of the formula wherein R 1 , R 2 and R 4 are each as defined above, and R~ is lower alkenyl or lower alkyl, both of which are optionally substituted with oxo and both of which are substituted with aryl which iε substituted with protected carboxy, or its salt, to deesterification to give a compound of the formula wherein R 1 , R 2 and R 4 are each as defined above, and R£ is lower alkenyl or lower alkyl, both of which are optionally substituted with oxo and both of which are substituted with aryl which is substituted with carboxy, or its salt; reacting a compound of the formula (1-5) defined above, or it reactive derivative at the carboxy group, or its salt, with the compound of the formula (IV) defined above, or its reactive derivative at the amino group, or its salt, to give a compound of the formula : (1-6) wherein R 1 , R 2 , R 3 , R^ and R° are each as defined above, and R 3 is lower alkenyl or lower alkyl, both of which are optionally substituted with oxo and both of which are substituted with aryl which is substituted with or its salt; reducing a compound of the formula wherein R , R 3 and R 4 are each as defined above, and R iε lower alkanoyl optionally substituted with protected carboxy or carboxy, or its salt, to give a compound of the formula : (1-8) wherein R 2 , R 3 and R 4 are each as defined above, and Rj 1 is lower alkyl optionally substituted with protected carboxy or carboxy, or its salt; vii) reacting a compound of the formula : wherein R 2 , R 3 and R 4 are each as defined above, or its salt, with a compound of the formula : R 1 - X 2 (V) wherein R^ is lower alkanoyl, aroyl, or lower alkanoyl optionally substituted with protected carboxy, carboxy, or aryl, X 2 is a leaving group, or its salt, to give a compound of the formula : wherein R 1 , R 2 , R 3 and R 4 are each as defined above, or its salt; viii) dehydrating a compound of the formula -i y wherein R , R"^ and R J are each as defined above, or its salt, to give a compound of the formula : wherein R 1 , R 2 and R are each as defined above, or its salt; ix) reacting a compound of the formula (1-12) defined above, or its salt, with azide compound, to give a compound of the formula : (1-13) wherein R 1 , R 2 and R 3 are each as defined above, or its salt; subjecting a compound of the formula : wherein R 3 and R 4 are each as defined above, and R 2 is lower alkyl substituted with protected carboxy, or its salt, to deesterification to give a compound of the formula : wherein R 3 and R 4 are each as defined above, and R 2 . is lower alkyl substituted with carboxy, or its salt; subjecting a compound of the formula (1-15) defined above, or its salt, to intramolecular acylation to give a compound of the formula : wherein R 3 and R 4 are each as defined above, and n is 1, 2, 3 or 4, or its salt; xii) reacting a compound of the formula : wherein R , R 3 and R 4 are each as defined above, and R^ j is chloroacetyl, or its salt, with a compound of the formula (IV) defined above, or its salt, to give a compound of the formula : (1-18) wherein R 2 , R 3 and R 4 are defined above, and R e 1S -COCH 2 N<[ 6 , or its salt; xiii) formylating a compound of the formula (1-9) defined above, or its salt, to give a compound of the formula wherein are each as defined above, or its salt; xiv) oxidizing a compound of the formula (1-19) defined above, or its salt, to give a compound of the formula wherein R 2 , R 3 and R 4 are each as defined above, or its salt; xv) subjecting a compound of the formula : ι 3 wherein R x , R and R are each as defined above, or its salt, to rearrangement reaction to give a compound of the formula : wherein R , R 2 , R 3 , R and R 6 are each as defined above, and is hydrogen, protected carboxy, or R 5 - C0 < D 6 ' or its salt; xvi) reacting a compound of the formula -i y 3 wherein R , R^ and R J are each as defined above, or its reactive derivative at the amino group, or its salt, with a compound of the formula : - x- (VI) wherein R°ιs acyl, and X J is leaving group, or its salt, or a compound of the formula l 9 -N=C=0 (VII) wherein R 9 is lower alkyl, to give a compound of the formula (1-24) wherein R 1 , R 2 , R 3 and R 8 are same as defined above, or its salt, xvii) reducing a compound of the formula : wherein R 1 , R 2 and R 4 are each as defined above, and R j is lower alkenyl or lower alkyl, both of which are optionally substituted with oxo and both of which are substituted with aryl which is substituted with nitro, or its salt, to give a compound of the formula : wherein R R 2 anc R4 are e cn as defined above, and R~ is lower alkenyl or lower alkyl, both of which are optionally subεtituted with oxo and both of which are substituted with aryl which is substituted with amino, or its salt; xviii) subjecting a compound of the formula wherein R 2 , R and R 4 are each as defined above, and Rf is lower alkanoyl substituted with lower alkoxy, or its salt, to dealkylation to give a compound of the formula : wherein R 2 , R 3 and R are each as defined above, and R 1 is lower alkanoyl substituted with hydroxy, or its salt; xix) oxidizing a compound of the formula wherein R 1 , R 3 and R 4 are each as defined above, and R 2 is 1-hydroxy(lower)alkyl, or its salt, to give a compound of the formula : wherein R 1 , R 3 and R 4 are each as defined above, and R R§ 2 } ii.s lower alkanoyl/ or its salt; xx) halogenating a compound of the formula (1-9) defined above, or its salt, to give a compound of the formula (1-31) wherein R 2 , R 3 and R 4 are each as defined above, and R j 1 is halogen, or its salt; xxi) subjecting a compound of the formula (1-9) defined above, or its salt, to nitration to give a compound of the formula : wherein R 2 , R 3 and R 4 are each as defined above, or its salt; xxii) reducing a compound of the formula (1-7) defined above, or its salt, to give a compound of the formula : wherein R 2 , R 3 and R 4 are each as defined above, and R^ is lower alkyl optionally substituted with protected carboxy or carboxy, cr its salt; xxiii) reacting a compound of the formula : y A wherein R , R J and R^ are each as defined above, and R 1 is lower alkanoyl, or its salt, with hydroxylamine or its salt, to give a compound of the formula : wherein R 2 , R 3 and R 4 are each as defined above, and Rj 1 is hydroxyimino(lower)alkyl, or its salt; or xxiv) reacting a compound of the formula : wherein R 1 , R 2 and R 4 are each as defined above, Rf is lower alkenyl or lower alkyl, both of which are optionally substituted with oxo and both of which are substituted with aryl which is subεtituted with amino, or its reactive derivative at the amino group, or its salt, with a compound of the formula (VI) defined above or its salt, or a compound of the formula (VII) defined above, to give a compound of the formula : wherein R 1 , R 2 and R 4 are each as defined above, and R 3 is lower alkenyl or lower alkyl, both of which are optionally substituted with oxo and both of which are substituted with aryl which is substituted with amino substituted with acyl, or its salt. 7. A pharmaceutical composition comprising the compound of claim 1, as an active ingredient, in association with a pharmaceutically acceptable, substantially non-toxic carrier or excipient. 8. A compound of claim 1 for use as a medicament. 9. A use of the compound of claim 1 for the manufacture of a medicament for inhibiting cGMP-PDE. 10. A use of the compound of claim 1 for the manufacture of a medicament for treating or preventing angina, hypertension, pulmonary hypertension, congestive heart failure, glomerular diseases, renal tuburo-intestinal diseases, renal failure, atherosclerosis, conditions of reduced blood vessel patency, peripheral vascular disease, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, urticaria, impotence, diabetic complication, glaucoma or diseases characterized by disorders of gut motility. 11. A method for treating or preventing angina, hypertension, pulmonary hypertension, congeεtive heart failure, glomerular diseases, renal tuburo-intestinal diseases, renal failure, atherosclerosis, conditions of reduced blood vesεel patency, peripheral vascular disease, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, urticaria, impotence, diabetic complication, glaucoma or diseaεes characterized by disorders of gut motility, by administering the compound of claim 1. 12. The use of a cyclic nucleotide-PDE inhibitorε, or itε pharmaceutical acceptable salt, for preventing or treating glomerular diseases, renal tubulo-interstitial diseases, chronic renal failure or diabetic complications. 13. The use of a cyclic nucleotide-PDE inhibitors, or its pharmaceutical acceptable salt, for manufacturing a medicament for preventing or treating glomerular diseases, renal tubulo-interstitial diseases, chronic renal failure or diabetic complications.

Inventors: HOSOGAI NAOMI, KOBAYASHI MASAKAZU, KURODA AKIO, NAGASHIMA AKIRA, NAKAJIMA YOSHIMITSU, NOMOTO ATSUSHI, OHNE KAZUHIKO, OKU TERUO, SAWADA KOZO, SOGABE KEIZO, TAMURA KOUICHI, HOSOGAI, NAOMI, KOBAYASHI, MASAKAZU, KURODA, AKIO, NAGASHIMA, AKIRA, NAKAJIMA, YOSHIMITSU, NOMOTO, ATSUSHI, OHNE, KAZUHIKO, OKU, TERUO, SAWADA, KOZO, SOGABE, KEIZO, TAMURA, KOUICHI
Applicants: FUJISAWA PHARMACEUTICAL CO, HOSOGAI NAOMI, KOBAYASHI MASAKAZU, KURODA AKIO, NAGASHIMA AKIRA, NAKAJIMA YOSHIMITSU, NOMOTO ATSUSHI, OHNE KAZUHIKO, OKU TERUO, SAWADA KOZO, SOGABE KEIZO, TAMURA KOUICHI, FUJISAWA PHARMACEUTICAL CO., LTD., HOSOGAI, NAOMI, KOBAYASHI, MASAKAZU, KURODA, AKIO, NAGASHIMA, AKIRA, NAKAJIMA, YOSHIMITSU, NOMOTO, ATSUSHI, OHNE, KAZUHIKO, OKU, TERUO, SAWADA, KOZO, SOGABE, KEIZO, TAMURA, KOUICHI
Application year: 1996
Main classification: C07D209
IPC codes: A61K31, A61P3, A61P9, A61P11, A61P13, A61P15, A61P27, A61P37, A61P43, C07D209, C07D401, C07D403, C07D405, C07D409, C07D417